Benzothia(di)azepine compounds and their use as bile acid modulators - Patents.com
Patent Information
- Application Number
- JP2023534086
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-12-04
- Filing Date
- 2021-12-03
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2041-12-03
AI Technical Summary
There is a need for bile acid modulating compounds with optimized profiles in terms of potency, selectivity, and bioavailability to effectively inhibit apical sodium-dependent bile acid transporter (ASBT) and hepatic bile acid transporter (LBAT) for the treatment of various diseases.
Development of certain 1,5-benzothiazepines and 1,2,5-benzothiadiazepine derivatives that act as potent inhibitors of ASBT and/or LBAT, providing pharmaceutical compositions for treating cardiovascular diseases, disorders of fatty acid metabolism, gastrointestinal diseases, and liver diseases.
These derivatives effectively reduce bile acid circulation, offering therapeutic benefits for a range of conditions including hypercholesterolemia, diabetes, constipation, liver diseases, and other metabolic disorders by minimizing bile acid reabsorption and associated complications.
Smart Images

Figure 2022117778000001 
Figure 2022117778000002
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to International Patent Application No. PCT / EP2020 / 084567, filed December 4, 2020, the disclosure of which is incorporated herein by reference in its entirety.
[0002] Technical Field The present invention relates to certain 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives as defined herein.These compounds are bile acid modulators with apical sodium-dependent bile acid transporter (ASBT) and / or hepatic bile acid transport (LBAT) inhibitory activity.The present invention also relates to pharmaceutical compositions comprising these compounds, and the use of these compounds in the treatment of cardiovascular disease, disorders of fatty acid metabolism and glucose utilization, gastrointestinal disease, and liver disease. [Background technology]
[0003] background Bile acids are physiological surfactants that play an important role in the intestinal absorption and transport of lipids, nutrients, and vitamins. They are also signaling agents that activate nuclear receptors and cell signaling pathways that regulate lipid, glucose, and energy metabolism. Bile acids are steroid acids that are synthesized from cholesterol in the liver and stored as mixed micelles in the gallbladder. During digestion, the duodenum triggers the release of hormones that contract the gallbladder, thereby releasing bile acids in the small intestine, where they allow the absorption of fat-soluble vitamins and cholesterol. When they reach the ileum, the bile acids are reabsorbed from the intestine and secreted into the portal blood and returned to the liver via the portal circulation. More than 90% of the bile acids are thus recycled and returned to the liver. These bile acids are then transported through the sinusoidal membrane of the hepatocytes and resecreted through the canalicular membrane into the bile. During this first pass, 75-90% of the bile acids are taken up by the hepatocytes, completing one enterohepatic circulation. The fraction of bile acids that avoid hepatic elimination enters the systemic circulation, where the free bile acids are filtered by the renal glomerulus and efficiently collected in the proximal tubules and excreted again into the systemic circulation. Interestingly, most of the bile acids secreted into the bile through the canalicular membrane originate from the recycling pool, with less than 10% arising from de novo hepatic synthesis. The small amount of bile acids that are not reabsorbed in the ileum reaches the colon. Within the intestinal tract, primary bile acids are converted into secondary bile acids under the action of intestinal bacteria, mainly by single or double dehydration of the steroid nucleus. Bile acids that avoid intestinal absorption are then excreted in the feces.
[0004] Overall, an efficient transport system helps maintain a constant bile acid pool, ensures a sufficiently high level of conjugated bile acids in the intestine, promotes lipid absorption, and reduces small intestinal bacterial load.This system also minimizes fecal and urinary bile acid loss, and protects the intestine and hepatobiliary compartments by eliminating potentially cytotoxic surfactants (as reviewed by Kosters and Karpen (Xenobiotica 2008, vol. 38, p.1043-1071); Chiang (J. Lipid Res. 2009, vol. 50, p.1955-1966); and Dawson (Handb. Exp. Pharmacol. 2011, vol. 201, p.169-203)).
[0005] The regulation of bile acid pool size has been found to play a crucial role in cholesterol homeostasis, with the hepatic conversion of cholesterol to bile acid being the main route for cholesterol elimination from the body.The liver plays an essential role in removing endogenous and xenobiotic compounds from the body.Normal hepatic biliary secretion and enterohepatic circulation are required for the elimination of endogenous compounds such as cholesterol and bilirubin and their metabolites from the body, thereby maintaining lipid and bile and bile acid homeostasis (Kosters and Karpen, Xenobiotica 2008, vol. 38, p.1043-1071).
[0006] The reabsorption of bile acids in the ileum can be inhibited by apical sodium-dependent bile acid transporter (ASBT) inhibitor compounds. It has been reported that the inhibition of bile acid reabsorption is useful for the treatment of several diseases, including dyslipidemia, diabetes, obesity, constipation, cholestatic liver disease, non-alcoholic steatohepatitis and other liver diseases. Many ASBT inhibitor compounds have been disclosed over the past several decades. For example, WO93 / 16055, WO94 / 18183, WO94 / 18184, WO96 / 05188, WO96 / 08484, WO96 / 16051, WO97 / 33882, WO98 / 03818, WO98 / 07449, WO98 / 40375, WO99 / 35135, WO99 / 64409, WO99 / 64410, WO00 / 47568, WO00 / 61568, WO00 / 38725, WO00 / 38726, WO00 / 38727, WO00 / 38728, WO00 / 38729, WO01 / 66533, WO No. 01 / 68096, No. WO02 / 32428, No. WO02 / 50051, No. WO03 / 020710, No. WO03 / 022286, No. WO03 / 022825, No. WO03 / 022830, WO03 / 061663, WO03 / 091232, WO03 / 106482, WO2004 / 006899, WO2004 / 076430, WO2007 / 009655, WO2007 / 009656, WO2011 / 137135, WO2019 / 234077, WO2020 / 161216, WO2020 / 161217, German Patent No. 1982580 4, EP 864582, EP 489423, EP 549967, EP 573848, EP 624593, EP 624594, EP 624595, EP 624596, EP 0864582, EP 1173205, EP 1535913 and EP 3210977. Summary of the Invention [Problem to be solved by the invention]
[0007] Despite the number of ASBT inhibitory compounds previously reported, there is a need for additional bile acid modulating compounds with optimized profiles in terms of potency, selectivity and bioavailability. [Means for solving the problem]
[0008] Detailed Description of the Invention It has been discovered that certain 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives are potent inhibitors of the apical sodium-dependent bile acid transporter (ASBT) and / or the hepatic bile acid transporter (LBAT) and may be useful in treating diseases in which inhibition of bile acid cycling is desirable. Thus, in a first aspect, the present invention provides compounds of formula (I): [ka] (Wherein, M and R 1 ~R 4 relates to a compound of the formula: [Table 1]
[0009] In certain embodiments, the compound of formula (I) is (E)-3-((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)acrylic acid; (S)-(E)-3-((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)acrylic acid; (R)-(E)-3-((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)acrylic acid; (E)-3-((3-butyl-7-(ethylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)acrylic acid; (S)-(E)-3-((3-butyl-7-(ethylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)acrylic acid; (R)-(E)-3-((3-butyl-7-(ethylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)acrylic acid; (E)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)acrylic acid; (S)-(E)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)acrylic acid; (R)-(E)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)acrylic acid; (Z)-3-((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylic acid; (S)-(Z)-3-((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylic acid; (R)-(Z)-3-((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylic acid; (Z)-3-((3-butyl-7-(ethylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylic acid; (S)-(Z)-3-((3-butyl-7-(ethylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylic acid; (R)-(Z)-3-((3-butyl-7-(ethylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylic acid; (Z)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylic acid; (S)-(Z)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylic acid; (R)-(Z)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylic acid; (Z)-3-((3-butyl-5-(4-fluorophenyl)-2-methyl-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylic acid; (S)-(Z)-3-((3-butyl-5-(4-fluorophenyl)-2-methyl-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylic acid; (R)-(Z)-3-((3-butyl-5-(4-fluorophenyl)-2-methyl-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylic acid; (S)-(Z)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-2-methyl-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylic acid; (R)-(Z)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-2-methyl-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylic acid; (Z)-3-((3-butyl-7-(ethylthio)-2-methyl-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylic acid; (S)-(Z)-3-((3-butyl-7-(ethylthio)-2-methyl-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylic acid; (R)-(Z)-3-((3-butyl-7-(ethylthio)-2-methyl-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylic acid; (Z)-3-((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylic acid; (S)-(Z)-3-((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylic acid; (R)-(Z)-3-((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylic acid; (E)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)acrylic acid; (S)-(E)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)acrylic acid; (R)-(E)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)acrylic acid; or a pharma- ceutically acceptable salt thereof.
[0010] As used herein, the term "pharmaceutical acceptable" refers to those compounds, materials, compositions and / or dosage forms that are suitable for human pharmaceutical use and are generally safe, non-toxic, and not biologically or otherwise objectionable.
[0011] The term "about" as used herein refers to a value or parameter herein, including (and describing) embodiments directed to the value or parameter itself. For example, a statement referring to "about 20" includes the statement "20." Numerical ranges include the numbers defining the range. Generally speaking, the term "about" refers to the stated value of the variable, and all values of the variable within experimental error of the stated value (e.g., within a 95% confidence interval of the mean), or within 10% of the stated value, whichever is greater.
[0012] The 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivative compounds of formula (I), or their pharma- ceutically acceptable salts, are inhibitors of the apical sodium-dependent bile acid transporter (ASBT inhibitors), inhibitors of the hepatic bile acid transporter (LBAT inhibitors), or inhibitors of both the apical sodium-dependent bile acid transporter and the hepatic bile acid transporter (ASBT / LBAT dual inhibitors).They are therefore useful in the treatment or prevention of diseases, disorders and conditions in which inhibition of bile acid circulation is desirable, such as cardiovascular diseases, disorders of fatty acid metabolism and glucose utilization, gastrointestinal diseases, and hepatic diseases.
[0013] Cardiovascular diseases and disorders of fatty acid metabolism and glucose utilization include, but are not limited to, hypercholesterolemia; disorders of fatty acid metabolism; type 1 and type 2 diabetes; complications of diabetes including cataracts, microvascular and macrovascular disease, retinopathy, neuropathy, nephropathy and delayed wound healing, tissue ischemia, diabetic foot, arteriosclerosis, myocardial infarction, acute coronary syndrome, unstable angina, stable angina, stroke, peripheral arterial occlusive disease, cardiomyopathy, heart failure, heart rhythm disorders and vascular restenosis; diabetes-related disorders such as insulin resistance (impaired glucose homeostasis), hyperglycemia, hyperinsulinemia, high levels of blood fatty acids or glycerol, obesity, dyslipidemia, hyperlipidemia including hypertriglyceridemia, metabolic syndrome (syndrome X), atherosclerosis and hypertension; and elevated high density lipoprotein levels.
[0014] Gastrointestinal diseases and disorders include constipation (such as chronic constipation, functional constipation, chronic idiopathic constipation (CIC), intermittent / sporadic constipation, constipation secondary to diabetes, constipation secondary to stroke, constipation secondary to chronic kidney disease, constipation secondary to multiple sclerosis, constipation secondary to Parkinson's disease, constipation secondary to systemic sclerosis, drug-induced constipation, constipation-predominant irritable bowel syndrome (IBS-C), mixed irritable bowel syndrome (IBS-M), pediatric functional constipation, and opioid-induced constipation); Crohn's disease; primary bile acid malabsorption; irritable bowel syndrome (IBS); inflammatory bowel disease (IBD); ileitis; and reflux disease and its complications, such as Barrett's esophagus, bile reflux esophagitis, and bile reflux gastritis.
[0015] As defined herein, liver disease is any disease in the liver and in organs related to the liver, such as pancreas, portal vein, liver parenchyma, intrahepatic bile duct system, extrahepatic bile duct system, and gallbladder.In some examples, liver disease is bile acid-dependent liver disease.Liver diseases and disorders include inherited metabolic disorders of the liver; congenital disorders of bile acid synthesis; congenital biliary abnormalities; biliary atresia; biliary atresia after Kasai operation; biliary atresia after liver transplantation; neonatal hepatitis; neonatal cholestasis; genetic forms of cholestasis; cerebrotendinous xanthomatosis; secondary defects in BA synthesis; Zellweger syndrome; cystic fibrosis-related liver disease; alpha-1 antitrypsin deficiency; Alagille syndrome (ALGS); Byler syndrome; primary defects in bile acid (BA) synthesis. deficiency; PFIC, including progressive familial intrahepatic cholestasis (PFIC)-1, PFIC-2, PFIC-3, and PFIC not otherwise specified, post-biliary diversion PFIC, and post-liver transplant PFIC; benign recurrent intrahepatic cholestasis (BRIC)-1, BRIC2, and BRIC not otherwise specified, post-biliary diversion BRIC, and post-liver transplant BRIC; autoimmune hepatitis; primary biliary cirrhosis (PBC); liver fibrosis; nonalcoholic fatty liver disease (NALHD) AFLD);Nonalcoholic steatohepatitis (NASH);Portal hypertension;Cholestasis;Down syndrome cholestasis;Drug-induced cholestasis;Intrahepatic cholestasis of pregnancy (jaundice of pregnancy);Intrahepatic cholestasis;Extrahepatic cholestasis;Parenteral nutrition-associated cholestasis (PNAC);Lymphoedematous cholestasis;Lymphoedematous cholestasis syndrome 1 (LSC1);Primary sclerosing cholangitis (PSC);Immunoglobulin G4-associated cholangitis;Primary biliary cholangitis inflammation;cholelithiasis (gallstones);choledocholithiasis;common choledocholithiasis;gallstone pancreatitis;Caroli's disease;malignant disease of the bile duct;malignant disease causing obstruction of the biliary system;biliary stenosis;AIDS cholangiopathy;ischemic cholangiopathy;pruritus due to cholestasis or jaundice;pancreatitis;chronic autoimmune liver disease resulting in progressive cholestasis;fatty liver;alcoholic hepatitis;acute fatty liver;fatty liver of pregnancy;drug-induced hepatitis;iron overload disorders;congenital bile acid synthesis defect type 1 (BAS1);drug-induced liver injury (DILI);hepatic fibrosis;congenital hepatic fibrosis;cirrhosis;Langerhans cell histiocytosis (LCH);neonatal ichthyosclerosing cholangitis (NISCH);erythroblastic protoporphyria (EPP);These include, but are not limited to, idiopathic adult cholangiopachyme (IAD); idiopathic neonatal hepatitis (INH); nonsyndromic intrahepatic cholangiopachyme (NS-PILBD); North American Indian childhood cirrhosis (NAIC); hepatic sarcoidosis; amyloidosis; necrotizing enterocolitis; toxicity caused by serum bile acids, including heart rhythm disturbances (e.g., atrial fibrillation) in the setting of abnormal serum bile acid profiles, cardiomyopathy associated with cirrhosis ("cholelithiasis"), and skeletal muscle fatigue associated with cholestatic liver disease; polycystic liver disease; viral hepatitis (such as hepatitis A, B, C, D, and E); hepatocellular carcinoma (hepatoma); cholangiocarcinoma; bile acid-associated gastrointestinal cancer; and cholestasis caused by tumors and neoplasms of the liver, bile duct, and pancreas.
[0016] Other diseases that can be treated or prevented by the compound of formula (I) or its pharma- ceutically acceptable salts include hyperabsorption syndromes (including abetalipoproteinemia, familial hypobetalipoproteinemia (FHBL), chylomicron retention disease (CRD) and sitosterolemia); hypervitaminosis and osteopetrosis; hypertension; glomerular hyperfiltration; polycystic kidney disease (PKD), including autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD); and pruritus of renal failure. The compounds are also useful in protecting against renal damage associated with liver disease or metabolic disease.
[0017] The transport of bile acids in the human body is mediated by members of the SLC10 family of solute carrier proteins, specifically Na(II)-Na(II) expressed in the sinusoidal membrane of hepatocytes. +It is regulated by the taurocholate cotransporting polypeptide (NTCP, also called hepatic bile acid transporter (LBAT); gene symbol SLC10A1) and by the apical sodium-dependent bile acid transporter (ASBT, also called ileal bile acid transporter (IBAT), ISBT, ABAT or NTCP2; gene symbol SLC10A2), which is expressed in the apical membrane of ileal enterocytes, proximal tubule cells, biliary epithelium, large cholangiocytes and gallbladder epithelial cells. In the liver, bile acids are efficiently extracted from portal blood by the hepatic bile acid transporter (LBAT) and resecreted across the canalicular membrane by the bile salt export pump (BSEP; gene symbol ABCB11). Reabsorption of bile acids in the ileum is handled by the apical sodium-dependent bile acid transporter (ASBT), commonly called the ileal bile acid transporter (IBAT). Both LBAT and ASBT transport more than two Na per solute molecule. + It functions as a voltage-activated sodium-solute cotransporter to move ions.
[0018] Xenobiotics and internal parasites, including bile acids, are taken up by the liver through the portal vein and secreted into bile by distinct transport proteins with individual substrate specificity. Glycine and taurine conjugated bile acids exist in anionic form and cannot cross the membrane by diffusion, thus completely relying on membrane transport proteins to enter or leave hepatocytes (Kosters and Karpen, Xenobiotica 2008, vol.38, p.1043-1071). ASBT and LBAT prefer glycine- and taurine-conjugated bile salts over their unconjugated counterparts, and show higher affinity for dihydroxy bile salts than trihydroxy bile salts. Non-bile acid substrates have yet to be identified for ASBT, but LBAT has also been found to transport various steroid sulfates, hormones and xenobiotics.
[0019] LBAT has not been as thoroughly characterized as ASBT in terms of drug inhibition requirements. Dong et al. identified FDA-approved drugs that inhibit human LBAT and compared the LBAT and ASBT inhibition requirements. A series of LBAT inhibition studies were performed using FDA-approved drugs in conjunction with iterative computational model development. Screening studies identified 27 drugs as novel LBATs, including irbesartan (Ki=11.9 μM) and ezetimibe (Ki=25.0 μM). General pharmacophore properties indicated that two hydrophobic substances and one hydrogen-bonding acceptor are important for the inhibition of LBAT. Of the 72 drugs screened in vitro, a total of 31 drugs inhibited LBAT, and 51 drugs (i.e., more than half) inhibited ASBT. Thus, although there is inhibitor overlap, ASBT is unexpectedly more tolerant to drug inhibition than LBAT, which may be related to LBAT possessing fewer pharmacophore features (Dong et al., Mol. Pharm. 2013, vol. 10, p.1008-1019).
[0020] Vaz et al. describe the identification of LBAT deficiency as a neonatal metabolic defect with a relatively mild clinical phenotype. The identification of LBAT deficiency demonstrates that this transporter is the main transport system of conjugated bile salts into the liver, but also suggests that auxiliary transporters may support enterohepatic circulation in the absence of this transporter (Vaz et al., Hepatology 2015, vol. 61, p.260-267). These findings support the hypothesis that LBAT inhibition is a safe mechanism of action, because hepatocytes still have the potential to take up the necessary amount of bile acids.
[0021] Liu et al. describe the identification of a new type of hyperbile acidemia associated with homozygosity for the p.Ser267Phe mutation in SLC10A1 (LBAT). The allele frequency of this mutation in the gene SLC10A1 varies in different populations, with the highest incidence occurring in Southern China (8% and 12% in Chinese Han and Dai, respectively) and Vietnam (11%). This "hidden" hyperbile acidemia was thought to affect 0.64% of Southern Chinese Han, 1.44% of Chinese Dai populations, and 1.21% of the Vietnamese population. An increase in conjugated and unconjugated serum BA levels in homozygous individuals was also observed. Liu et al. suggest that this finding is most likely due to reduced BA transport from the portal circulation into hepatocytes. This supports the hypothesis that the physiological function of the enterohepatic circulation is not only to recycle bile acids but also to remove them from the circulation to achieve homeostasis (Karpen and Dawson, Hepatology 2015, vol. 61, p.24-27). Alternatively, the liver may synthesize high levels of bile acids to compensate for reduced enterohepatic recycling in homozygous transporters. The increase in unconjugated bile acids in this study was not surprising, since LBAT also transports unconjugated bile acids (Liu et al., Scientific Reports 2017, 7: 9214, p.1-7).
[0022] LBAT has been found to be downregulated in multiple forms of cholestatic liver injury and cholestasis, while ASBT has been found to be downregulated in various gastrointestinal disorders such as Crohn's disease, primary bile acid malabsorption, inflammatory bowel disease, and ileal inflammation, but upregulated in cholestasis.LBAT also functions as a cellular receptor for viral entry of hepatitis B virus (HBV) and hepatitis D virus (HDV), which in turn is a major cause of liver disease and hepatocellular carcinoma.
[0023] ASBT inhibition has been studied for lowering plasma cholesterol levels and improving insulin resistance, as well as for alleviating hepatic bile acid load in cholestatic liver disease.In addition, ASBT inhibition has been found to restore insulin levels and normal blood glucose levels, thus establishing ASBT inhibition as a promising treatment for type 2 diabetes.ASBT inhibitors are also used to treat functional constipation.
[0024] Since ASBT is preferentially expressed in the ileum (often referred to as IBAT), ASBT inhibitors do not need to be systemically available. However, ASBT is also expressed in the proximal tubule cells of the kidney. A systemically available ASBT inhibitor may therefore also inhibit reuptake of bile acids in the kidney. This would lead to increased levels of bile acids in the urine, resulting in increased removal of bile acids from the body via the urine. A systemically available ASBT inhibitor that exerts its effect not only in the ileum but also in the kidney would therefore be predicted to result in greater levels of bile acid reduction than a non-systemically available ASBT inhibitor that exerts its effect only in the ileum.
[0025] Compounds with high ASBT inhibitory potency are particularly suitable for the treatment of liver diseases that cause cholestasis, such as progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, biliary atresia and non-alcoholic steatohepatitis (NASH).
[0026] Biliary atresia is a rare pediatric liver disease involving partial or total blockage (or even absence) of a large bile duct. This blockage or absence causes cholestasis, which results in the accumulation of bile acids that damage the liver. In some embodiments, the accumulation of bile acids occurs in the extrahepatic biliary system. In some embodiments, the accumulation of bile acids occurs in the intrahepatic biliary system. The current standard of care is the Kasai procedure, which is a surgery to remove the blocked bile duct and connect a portion of the small intestine directly to the liver. There are currently no approved drug treatments for this disorder.
[0027] Provided herein is a method for treating biliary atresia in a subject in need thereof, the method comprising administering a therapeutically effective amount of a compound of formula (I) or a pharma- ceutically acceptable salt thereof. In some embodiments, the subject undergoes a Kasai procedure prior to administration of the compound of formula (I) or a pharma- ceutically acceptable salt thereof. In some embodiments, the subject is administered a compound of formula (I) or a pharma- ceutically acceptable salt thereof prior to undergoing a Kasai procedure. In some embodiments, treating biliary atresia reduces serum bile acid levels in the subject. In some embodiments, serum bile acid levels are determined, for example, by an ELISA enzyme assay or an assay for measuring total bile acids as described in Danese et al., PLoS One. 2017, vol. 12(6):e0179200, incorporated herein by reference in its entirety. In some embodiments, serum bile acid levels can be reduced, for example, by 10% to 40%, 20% to 50%, 30% to 60%, 40% to 70%, 50% to 80%, or more than 90% of the serum bile acid levels prior to administration of the compound of Formula (I) or a pharma- ceutical acceptable salt thereof. In some embodiments, treatment of biliary atresia includes treatment of pruritus.
[0028] PFIC is a rare genetic disorder that affects an estimated 1 in 50,000-100,000 live births worldwide and causes progressive, life-threatening liver disease.
[0029] One symptom of PFIC is pruritus, which often leads to severe impairment of quality of life. In some cases, PFIC leads to cirrhosis and liver failure. Current treatments include partial bile diversion and liver transplantation, but these options carry substantial postoperative morbidity risks and potentially psychological and social problems.
[0030] Three additional genetic defects have been identified that correlate with three distinct PFIC subtypes, known as types 1, 2, and 3: PFIC, type 1, sometimes referred to as "Byler's disease," is caused by impaired bile secretion due to mutations in the ATP8B1 gene, which codes for a protein that helps maintain the proper balance of fats known as phospholipids in the cell membranes of the bile ducts. An imbalance of these phospholipids is associated with cholestasis and increased intrahepatic bile. Subjects affected with PFIC, type 1 typically develop cholestasis at one month of age and, unless surgically treated, progress to cirrhosis and end-stage liver disease by the end of the first decade of life. PFIC type 2, sometimes referred to as "Byler's syndrome," is caused by impaired bile salt secretion due to mutations in the ABCB11 gene, which codes for a protein known as the bile salt export pump, which moves bile acids out of the liver. Subjects with PFIC type 2 often develop liver failure within the first few years of life and are at high risk of developing a type of liver disease known as hepatocellular carcinoma. PFIC type 3 typically appears within the first few years of life in children with progressive cholestasis and is caused by mutations in the ABCB4 gene, which codes for a transporter that moves phospholipids across cell membranes.
[0031] In addition, mutations in the TJP2 gene, the NR1H4 gene, or the Myo5b gene have been proposed to be the cause of PFIC. In addition, some subjects with PFIC do not have mutations in any of the ATP8B1, ABCB11, ABCB4, TJP2, NR1H4, or Myo5b genes. In these cases, the cause of the disease is unknown.
[0032] Exemplary mutations of the ATP8B1 gene or resulting protein are listed in Tables 2 and 3 with numbering based on the human wild-type ATP8B1 protein (e.g., SEQ ID NO:1) or gene (SEQ ID NO:2). Exemplary mutations of the ABCB11 gene or resulting protein are listed in Tables 4 and 5 with numbering based on the human wild-type ABCB11 protein (e.g., SEQ ID NO:3) or gene (SEQ ID NO:4).
[0033] As can be understood by one of skill in the art, amino acid positions in a reference protein sequence that correspond to specific amino acid positions in SEQ ID NO:1 or 3 can be determined by aligning the reference protein sequence with SEQ ID NO:1 or 3 (e.g., using a software program such as ClustalW2). Changes to these residues (referred to herein as "mutations") can include one or more amino acid substitutions, insertions, and deletions within or adjacent to those sequences. As can be understood by one of skill in the art, nucleotide positions in a reference gene sequence that correspond to specific nucleotide positions in SEQ ID NO:2 or 4 can be determined by aligning the reference gene sequence with SEQ ID NO:2 or 4 (e.g., using a software program such as ClustalW2). Changes to these residues (referred to herein as "mutations") can include one or more nucleotide substitutions, insertions, and deletions within or adjacent to those sequences. See also Kooistra, et al., "KLIFS: A structural kinase-ligand interaction database," Nucleic Acids Res. 2016, vol. 44, no. D1, pp. D365-D371, which is incorporated by reference in its entirety.
[0034] Canonical protein sequence of ATP8B1 (SEQ ID NO:1) - Uniprot ID O43520 <h2 style=";text-align:left;direction:ltr">MSTERDSETT FDEDSQPNDE VVPYSDDETE DELDDQGSAV EPEQNRVNRE AEENREPFRK ECTWQVKAND RKYHEQPHFM NTKFLCIKES KYANNAIKTY KYNAFTFIPM NLFEQFKRAA NLYFLALLIL QAVPQISTLA WYTTLVPLLV VLGFTAIKDL VDDVARHKMD KEINNRTCEV IKDGRFKVAK WKEIQVGDVI RLKKNDFVPA DILLLSSSEP NSLCYVETAE LDGETNLKFK MSLEITDQYL QREDTLATFD GFIECEEPNN RLDKFTGTLF WRNTSFPLDA DKILLRGCVI RNTDFCHGLV IFAGADTKIM KNSGKTRFKR TKIDYLMNYM VYTIFVVLIL LSAGLAIGHA YWEAQVGNSS WYLYDGEDDT PSYRGFLIFW GYIIVLNTMV PISLYVSVEV IRLGQSHFIN WDLQMYYAEK DTPAKARTTT LNEQLGQIHY IFSDKTGTLT QNIMTFKKCC INGQIYGDHR DASQHNHNKI EQVDFSWNTY ADGKLAFYDH YLIEQIQSGK EPEVRQFFFL LAVCHTVMVD RTDGQLNYQA ASPDEGALVN AARNFGFAFL ARTQNTITIS ELGTERTYNV LAILDFNSDR KRMSIIVRTP EGNIKLYCKG ADTVIYERLH RMNPTKQETQ DALDIFANET LRTLCLCYKE IEEKEFTEWN KKFMAASVAS TNRDEALDKV YEEIEKDLIL LGATAIEDKL QDGVPETISK LAKADIKIWV LTGDKKETAE NIGFACELLT EDTTICYGED INSLLHARME NQRNRGGVYA KFAPPVQESF FPPGGNRALI ITGSWLNEIL LEKKTKRNKI LKLKFPRTEE ERRMRTQSKR RLEAKKEQRQ KNFVDLACEC SAVICCRVTP KQKAMVVDLV KRYKKAITLA IGDGANDVNM IKTAHIGVGISGQEGMQAVM SSDYSFAQFR YLQRLLLVHG RWSYIRMCKF LRYFFYKNFA FTLVHFWYSF FNGYSAQTAY EDWFITLYNV LYTSLPVLLM GLLDQDVSDK LSLRFPGLYI VGQRDLLFNY KRFFVSLLHG VLTSMILFFI PLGAYLQTVG QDGEAPSDYQ SFAVTIASAL VITVNFQIGL DTSYWTFVNA FSIFGSIALY FGIMFDFHSA GIHVLFPSAF QFTGTASNAL RQPYIWLTII LAVAVCLLPV VAIRFLSMTI WPSESDKIQK HRKRLKAEEQ WQRRQQVFRR GVSTRRSAYA FSHQRGYADL ISSGRSIRKK RSPLDAIVAD GTAEYRRTGD S
[0035] Canonical DNA sequence of ATP8B1 (SEQ ID NO:2) ATG AGT ACA GAA AGA GAC TCA GAA ACG ACA TTT GAC GAG GAT TCT CAG CCT AAT GAC GAA GTG GTT CCC TAC AGT GAT GAT GAA ACA GAA GAA CTT GAT GAC CAG GGG TCT GTT GTT GAA CCA GAAGAGAA AAC GAA GTC GTC CCA TTC AGA AAA GAA TGT ACA TGG CAA GTC AAA GCA AAC GAT CGC AAG TAC CAC GAA CAA CAC TTT ATG AAC ACA AAA TTC TTG TGT ATT AAG GAG AGT AAA TAT GCG AAT AAT GCA ATT AAA ACA TAC TAC AAG AAG ATTCAAC TTT GAG CAG TTT AAG AGA GCA GCC AAT TTA TAT TTC CTG GCT CTT CTT ATC TTA CAG GTT CCT CAA ATC TCT ACC CTG GCT TGG TAC ACC ACA CTA GTG CCC CTG CTT GGTG GTG CTG GGC GCTG ATC GAA GAA GACCA CGC CAT AAA ATG GAT AAG GAA ATC AAC AAT AGG ACG TGT GAA GTC ATT AAG GAT GGC AGG TTC AAA GTT GCT AAG TGG AAA ATT CAA GGA GAC GTC ATT CGT CGT AAA AAA AAT GAT GAT TTT GCT ACT CTT GTT CCA GAC GAC AAC AGC CTC TGC TAT GTG GAA ACA GCA GAA CTG GAT GGA GAA ACC AAT TTA AAA TTT AAG ATG TCA CTT GAA ATC ACA GAC CAG TAC CTCCAA AGA GAA GAT ACA TTG GCT ACA TTT GAT GGT TTT ATT GAA TGT GAA GAA CCC AAT AAC AGA CTA GAT AAG TTT ACA GGA ACA CTA TTT TGG AGA AAC ACA AGT TTT CCT TTG GAT GCT GAT AAA ATT TTG TTA CGT GGC TGT GTA ATT AGG AAC ACC GAT TTC TGC CAC GGC TTA GTC ATT TTT GCA GGT GCT GAC ACT AAA ATA ATG AAG AAT AGT GGG AAA ACC AGA TTT AAA AGA ACT AAA ATT GAT TAC TTG AAG TAC ATG GTT TAC ACG ATC TTT GTT GTT CTT ATT CTG CTT TCT GCT GGT CTT GCC ATC GGC CAT GCT TAT TGG GAA GCA CAG GTG GGC AAT TCC TCT TGG TAC CTC TAT GAT GGA GAA GCA GAT ACA CCC TCC TAC CGT GGA TTC CTC ATT TTC TGG GGC TAT ATC ATT GTT CTC AAC ACC ATG GTA CCC ATC TCT CTC TAT GTC AGC GTG GAA GTG ATT CGT CTT GGA CAG AGT CAC TTC ATC AAC TGG GAC CTG CAA ATG TAC TAT GCT GAG AAG GAC ACA CCC GCA AAA GCT AGA ACC ACC ACA CTC AAT GAA CAG CTC GGG CAG ATC CAT TAT ATC TTC TCT GAT AAG ACG GGG ACA CTC ACA CAA AAT ATC ATG ACC TTT AAA AAG TGC TGT ATC AAC GGG CAG ATA TAT GGG GAC CAT CGG GAT GCC TCT CAA CAC AAC CAC AAC AAA ATA GAG CAA GTT GAT TTT AGC TGG AAT ACA TATGCT GAT GGG AAG CTT GCA TTT TAT GAC CAC TAT CTT ATT GAG CAA ATC CAG TCA GGG AAA GAG CCA GAA GTA CGA CAG TTC TTC TTC TTG CTC GCA GTT TGC CAC ACA GTC ATG GTG GAT AGG ACT GAT GGT CAG CTC AAC TAC CAG GCA GCC TCT CCC GAT GAA GGT GCC CTG GTA AAC GCT GCC AGG AAC TTT GGC TTT GCC TTC CTC GCC AGG ACC CAG AAC ACC ATC ACC ATC AGT GAA CTG GGC ACT GAA AGG ACT TAC AAT GTT CTT GCC ATT TTG GAC TTC AAC AGT GAC CGG AAG CGA ATG TCT ATC ATT GTA AGA ACC CCA GAA GGC AAT ATC AAG CTT TAC TGT AAA GGT GCT GAC ACT GTT ATT TAT GAA CGG TTA CAT CGA ATG AAT CCT ACT AAG CAA GAA ACA CAG GAT GCC CTG GAT ATC TTT GCA AAT GAA ACT CTT AGA ACC CTA TGC CTT TGC TAC AAG GAA ATT GAA GAA AAA GAA TTT ACA GAA TGG AAT AAA AAG TTT ATG GCT GCC AGT GTG GCC TCC ACC AAC CGG GAC GAA GCT CTG GAT AAA GTA TAT GAG GAG ATT GAA AAA GAC TTA ATT CTC CTG GGA GCT ACA GCT ATT GAA GAC AAG CTA CAG GAT GGA GTT CCA GAA ACC ATT TCA AAA CTT GCA AAA GCT GAC ATT AAG ATC TGG GTG CTT ACT GGA GAC AAA AAG GAA ACT GCT GAA AAT ATA GGA TTT GCT TGT GAA CTT CTG ACTGAA GAC ACC ACC ATC TGC TAT GGG GAG GAT ATT AAT TCT CTT CTT CAT GCA AGG ATG GAA AAC CAG AGG AAT AGA GGT GGC GTC TAC GCA AAG TTT GCA CCT CCT GTG CAG GAA TCT TTT TTT CCA CCC GGT GGA AAC CGT GCC TTA ATC ATC ACT GGT TCT TGG TTG AAT GAA ATT CTT CTC GAG AAA AAG ACC AAG AGA AAT AAG ATT CTG AAG CTG AAG TTC CCA AGA ACA GAA GAA GAA AGA CGG ATG CGG ACC CAA AGT AAA AGG AGG CTA GAA GCT AAG AAA GAG CAG CGG CAG AAA AAC TTT GTG GAC CTG GCC TGC GAG TGC AGC GCA GTC ATC TGC TGC CGC GTC ACC CCC AAG CAG AAG GCC ATG GTG GTG GAC CTG GTG AAG AGG TAC AAG AAA GCC ATC ACG CTG GCC ATC GGA GAT GGG GCC AAT GAC GTG AAC ATG ATC AAA ACT GCC CAC ATT GGC GTT GGA ATA AGT GGA CAA GAA GGA ATG CAA GCT GTC ATG TCG AGT GAC TAT TCC TTT GCT CAG TTC CGA TAT CTG CAG AGG CTA CTG CTG GTG CAT GGC CGA TGG TCT TAC ATA AGG ATG TGC AAG TTC CTA CGA TAC TTC TTT TAC AAA AAC TTT GCC TTT ACT TTG GTT CAT TTC TGG TAC TCC TTC TTC AAT GGC TAC TCT GCG CAG ACT GCA TAC GAG GAT TGG TTC ATC ACC CTC TAC AAC GTG CTG TAC ACC AGC CTG CCC GTG CTC CTC ATGGGG CTG CTC GAC CAG GAT GTG AGT GAC AAA CTG AGC CTC CGA TTC CCT GGG TTA TAC ATA GTG GGA CAA AGA GAC TTA CTA TTC AAC TAT AAG AGA TTC TTT GTA AGC TTG TTG CAT GGG GTC CTA ACA TCG ATG ATC CTC TTC TTC ATA CCT CTT GGA GCT TAT CTG CAA ACC GTA GGG CAG GAT GGA GAG GCA CCT TCC GAC TAC CAG TCT TTT GCC GTC ACC ATT GCC TCT GCT CTT GTA ATA ACA GTC AAT TTC CAG ATT GGC TTG GAT ACT TCT TAT TGG ACT TTT GTG AAT GCT TTT TCA ATT TTT GGA AGC ATT GCA CTT TAT TTT GGC ATC ATG TTT GAC TTT CAT AGT GCT GGA ATA CAT GTT CTC TTT CCA TCT GCA TTT CAA TTT ACA GGC ACA GCT TCA AAC GCT CTG AGA CAG CCA TAC ATT TGG TTA ACT ATC ATC CTG GCT GTT GCT GTG TGC TTA CTA CCC GTC GTT GCC ATT CGA TTC CTG TCA ATG ACC ATC TGG CCA TCA GAA AGT GAT AAG ATC CAG AAG CAT CGC AAG CGG TTG AAG GCG GAG GAG CAG TGG CAG CGA CGG CAG CAG GTG TTC CGC CGG GGC GTG TCA ACG CGG CGC TCG GCC TAC GCC TTC TCG CAC CAG CGG GGC TAC GCG GAC CTC ATC TCC TCC GGG CGC AGC ATC CGC AAG AAG CGC TCG CCG CTT GAT GCC ATC GTG GCG GAT GGC ACC GCG GAG TAC AGG CGC ACC GGG GACAGC TGA [Table 2] TIFF2024500309000004.tif242161 TIFF2024500309000005.tif241162 TIFF2024500309000006.tif242161 TIFF2024500309000007.tif241160 TIFF2024500309000008.tif242162 TIFF2024500309000009.tif240162 TIFF2024500309000010.tif101160 [Table 3] TIFF2024500309000012.tif241161 TIFF2024500309000013.tif218162
[0036] References for Tables 2 and 3 1 Folmer et al., Hepatology. 2009, vol. 50(5), p. 1597-1605. 2 Hsu et al., Hepatol Res. 2009, vol. 39(6), p. 625-631. 3 Alvarez et al., Hum Mol Genet. 2004, vol. 13(20), p. 2451-2460. 4 Davit-Spraul et al., Hepatology 2010, vol. 51(5), p. 1645-1655. 5 Vitale et al., J Gastroenterol. 2018, vol. 53(8), p. 945-958. 6 Klomp et al., Hepatology 2004, vol. 40(1),p. 27-38. 7 Zarenezhad et al., Hepatitis Monthly: 2017, vol. 17(2); e43500. 8 Dixon et al., Scientific Reports 2017, vol. 7, 11823. 9 Painter et al., Eur J Hum Genet. 2005, vol. 13(4), p. 435-439. 10 Deng et al., World J Gastroenterol. 2012, vol. 18(44), p. 6504-6509. 11 Giovannoni et al., PLoS One. 2015, vol. 10(12): e0145021. 12 Li et al., Hepatology International 2017, vol. 11, No. 1, Supp. Supplement 1, pp. s180. Abstract Number: OP284. 13 Togawa et al., Journal of Pediatric Gastroenterology and Nutrition 2018, vol. 67, Supp. Supplement 1, pp. S363. Abstract Number: 615. 14Miloh et al., Gastroenterology 2006, vol. 130, No. 4, Suppl. 2, pp. A759-A760. Meeting Info.: Digestive Disease Week Meeting / 107th Annual Meeting of the American-Gastroenterological-Association. Los Angeles, CA, USA. May 19. 15 Droge et al., Zeitschrift fur Gastroenterologie 2015, vol. 53, No. 12. Abstract Number: A3-27. Meeting Info: 32. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber. Dusseldorf, Germany. 22 Jan 2016-23 Jan 2016 16 Mizuochi et al., Clin Chim Acta. 2012, vol. 413(15-16), p. 1301-1304. 17 Liu et al., Hepatology International 2009, vol. 3, No. 1, p. 184-185. Abstract Number: PE405. Meeting Info: 19th Conference of the Asian Pacific Association for the Study of the Liver. Hong Kong, China. 13 Feb 2009-16 Feb 2009 18 McKay et al., Version 2. F1000Res. 2013; 2: 32. DOI: 10.12688 / f1000research.2-32.v2 19Hasegawa et al., Orphanet J Rare Dis. 2014, vol. 9:89. 20 Stone et al., J Biol Chem. 2012, vol. 287(49),p. 41139-51. 21 Kang et al., J Pathol Transl Med. 2019 May 16. doi: 10.4132 / jptm.2019.05.03.(Epub ahead of print) 22 Sharma et al., BMC Gastroenterol. 2018, vol. 18(1), p. 107. 23 Uegaki et al., Intern Med. 2008, vol. 47(7),p. 599-602. 24 Goldschmidt et al., Hepatol Res. 2016, vol. 46(4), p. 306-311. 25 Liu et al., J Pediatr Gastroenterol Nutr. 2010, vol. 50(2),p. 179-183. 26 Jung et al., J Pediatr Gastroenterol Nutr. 2007, vol. 44(4),p. 453-458. 27 Bounford. University of Birmingham. Dissertation Abstracts International,(2016) Vol. 75, No. 1C. Order No.: AAI10588329. ProQuest Dissertations & Theses. 28 Stolz et al., Aliment Pharmacol Ther. 2019, vol. 49(9), p. 1195-1204. 29 Ivashkin et al., Hepatology International 2016, vol. 10, No. 1, Supp. SUPPL. 1, pp. s461. Abstract Number: LBO-38. Meeting Info: 25th Annual Conference of the Asian Pacific Association for the Study of the Liver, APASL 2016. Tokyo, Japan. 20 Feb 2016-24 Feb 2016 30 Blackmore et al., J Clin Exp Hepatol. 2013, vol. 3(2), p. 159-161. 31 Matte et al., J Pediatr Gastroenterol Nutr. 2010, vol. 51(4),p. 488-493. 32 Squires et al., J Pediatr Gastroenterol Nutr. 2017, vol. 64(3),p.425-430. 33 Hayshi et al., EBioMedicine. 2018, vol. 27, p.187-199. 34 Nagasaka et al., J Pediatr Gastroenterol Nutr. 2007, vol. 45(1),p.96-105. 35 Wang et al., PLoS One. 2016; vol. 11(4): e0153114. 36 Narchi et al., Saudi J Gastroenterol. 2017, vol. 23(5), p. 303-305. 37Alashkar et al., Blood 2015, vol. 126, No. 23. Meeting Info.: 57th Annual Meeting of the American-Society-of-Hematology. Orlando, FL, USA. December 05 -08, 2015. Amer Soc Hematol. 38 Ferreira et al., Pediatric Transplantation 2013, vol. 17, Supp. SUPPL. 1, pp. 99. Abstract Number: 239. Meeting Info: IPTA 7th Congress on Pediatric Transplantation. Warsaw, Poland. 13 Jul 2013-16 Jul 2013. 39 Pauli-Magnus et al., J Hepatol. 2005, vol. 43(2), p. 342-357. 40 Jericho et al., Journal of Pediatric Gastroenterology and Nutrition 2015, vol. 60(3),p. 368-374. 41 van der Woerd et al., PLoS One. 2013, vol. 8(11): e80553. 42 Copeland et al., J Gastroenterol Hepatol. 2013, vol. 28(3),p. 560-564. 43 Droge et al., J Hepatol. 2017, vol. 67(6),p. 1253-1264. 44 Chen et al., Journal of Pediatrics 2002, vol. 140(1), p. 119-124. 45Jirsa et al., Hepatol Res. 2004, vol. 30(1), p. 1-3. 46 van der Woerd et al., Hepatology 2015, vol. 61(4), p.1382-1391.
[0037] In some embodiments, the mutation in ATP8B1 is selected from L127P, G308V, T456M, D554N, F529del, I661T, E665X, R930X, R952X, R1014X, and G1040R.
[0038] Canonical protein sequence of ABCB11 (SEQ ID NO:3) - Uniprot ID O95342 MSDSVILRSI KKFGEENDGF ESDKSYNNDK KSRLQDEKKG DGVRVGFFQL FRFSSSTDIW LMFVGSLCAF LHGIAQPGVL LIFGTMTDVF IDYDVELQEL QIPGKACVNN TIVWTNSSLN QNMTNGTRCG LLNIESEMIK FASYYAGIAV AVLITGYIQI CFWVIAAARQ IQKMRKFYFR RIMRMEIGWF DCNSVGELNT RFSDDINKIN DAIADQMALF IQRMTSTICG FLLGFFRGWK LTLVIISVSP LIGIGAATIG LSVSKFTDYE LKAYAKAGVV ADEVISSMRT VAAFGGEKRE VERYEKNLVF AQRWGIRKGI VMGFFTGFVW CLIFLCYALA FWYGSTLVLD EGEYTPGTLV QIFLSVIVGA LNLGNASPCL EAFATGRAAA TSIFETIDRK PIIDCMSEDG YKLDRIKGEI EFHNVTFHYP SRPEVKILND LNMVIKPGEM TALVGPSGAG KSTALQLIQR FYDPCEGMVT VDGHDIRSLN IQWLRDQIGI VEQEPVLFST TIAENIRYGR EDATMEDIVQ AAKEANAYNF IMDLPQQFDT LVGEGGGQMS GGQKQRVAIA RALIRNPKIL LLDMATSALD NESEAMVQEV LSKIQHGHTI ISVAHRLSTV RAADTIIGFE HGTAVERGTH EELLERKGVY FTLVTLQSQG NQALNEEDIK DATEDDMLAR TFSRGSYQDS LRASIRQRSK SQLSYLVHEP PLAVVDHKST YEEDRKDKDI PVQEEVEPAP VRRILKFSAP EWPYMLVGSV GAAVNGTVTP LYAFLFSQIL GTFSIPDKEE QRSQINGVCL LFVAMGCVSL FTQFLQGYAF AKSGELLTKR LRKFGFRAML GQDIAWFDDL RNSPGALTTR LATTASQVQG AAGSQIGMIV NSFTNVTVAM IIAFSFSWKL SLVILCFFPFLALSGATQTR MLTGFASRDK QALEMVGQIT NEALSNIRTV AGIGKERRFI EALETELEKP FKTAIQKANI YGFCFAFAQC IMFIANSASY RYGGYLISNE GLHFSYVFRV ISAVVLSATA LGRAFSYTPS YAKAKISAAR FFQLLDRQPP ISVYNTAGEK WDNFQGKIDF VDCKFTYPSR PDSQVLNGLS VSISPGQTLA FVGSSGCGKS TSIQLLERFY DPDQGKVMID GHDSKKVNVQ FLRSNIGIVS QEPVLFACSI MDNIKYGDNT KEIPMERVIA AAKQAQLHDF VMSLPEKYET NVGSQGSQLS RGEKQRIAIA RAIVRDPKIL LLDEATSALD TESEKTVQVA LDKAREGRTC IVIAHRLSTI QNADIIAVMA QGVVIEKGTH EELMAQKGAY YKLVTTGSPI S
[0039] Canonical DNA sequence of ABCB11 (SEQ ID NO:4) ATG TCT GAC TCA GTA ATT CTT CGA AGT ATA AAG AAA TTT GGA GAG GAG AAT GAT GGT TTT GAG TCA GAT AAA TCA TAT AAT AAT GAT AAG AAA TCA AGG TTA CAA GAT GAG AAG AAA GGT GAT GGC GTT AGA GTT GGC TTC TTT CAA TTG TTT CGG TTT TCT TCA TCA ACT GAC ATT TGG CTG ATG TTT GTG GGA AGT TTG TGT GCA TTT CTC CAT GGA ATA GCC CAG CCA GGC GTG CTA CTC ATT TTT GGC ACA ATG ACA GAT GTT TTT ATT GAC TAC GAC GTT GAG TTA CAA GAA CTC CAG ATT CCA GGA AAA GCA TGT GTG AAT AAC ACC ATT GTA TGG ACT AAC AGT TCC CTC AAC CAG AAC ATG ACA AAT GGA ACA CGT TGT GGG TTG CTG AAC ATC GAG AGC GAA ATG ATC AAA TTT GCC AGT TAC TAT GCT GGA ATT GCT GTC GCA GTA CTT ATC ACA GGA TAT ATT CAA ATA TGC TTT TGG GTC ATT GCC GCA GCT CGT CAG ATA CAG AAA ATG AGA AAA TTT TAC TTT AGG AGA ATA ATG AGA ATG GAA ATA GGG TGG TTT GAC TGC AAT TCA GTG GGG GAG CTG AAT ACA AGA TTC TCT GAT GAT ATT AAT AAA ATC AAT GAT GCC ATA GCT GAC CAA ATG GCC CTT TTC ATT CAG CGC ATG ACC TCG ACC ATC TGT GGT TTC CTG TTG GGA TTT TTC AGG GGT TGG AAA CTG ACC TTG GTT ATT ATT TCT GTC AGC CCTCTC ATT GGG ATT GGA GCA GCC ACC ATT GGT CTG AGT GTG TCC AAG TTT ACG GAC TAT GAG CTG AAG GCC TAT GCC AAA GCA GGG GTG GTG GCT GAT GAA GTC ATT TCA TCA ATG AGA ACA GTG GCT GCT TTT GGT GGT GAG AAA AGA GAG GTT GAA AGG TAT GAG AAA AAT CTT GTG TTC GCC CAG CGT TGG GGA ATT AGA AAA GGA ATA GTG ATG GGA TTC TTT ACT GGA TTC GTG TGG TGT CTC ATC TTT TTG TGT TAT GCA CTG GCC TTC TGG TAC GGC TCC ACA CTT GTC CTG GAT GAA GGA GAA TAT ACA CCA GGA ACC CTT GTC CAG ATT TTC CTC AGT GTC ATA GTA GGA GCT TTA AAT CTT GGC AAT GCC TCT CCT TGT TTG GAA GCC TTT GCA ACT GGA CGT GCA GCA GCC ACC AGC ATT TTT GAG ACA ATA GAC AGG AAA CCC ATC ATT GAC TGC ATG TCA GAA GAT GGT TAC AAG TTG GAT CGA ATC AAG GGT GAA ATT GAA TTC CAT AAT GTG ACC TTC CAT TAT CCT TCC AGA CCA GAG GTG AAG ATT CTA AAT GAC CTC AAC ATG GTC ATT AAA CCA GGG GAA ATG ACA GCT CTG GTA GGA CCC AGT GGA GCT GGA AAA AGT ACA GCA CTG CAA CTC ATT CAG CGA TTC TAT GAC CCC TGT GAA GGA ATG GTG ACC GTG GAT GGC CAT GAC ATT CGC TCT CTT AAC ATT CAG TGG CTT AGA GAT CAG ATT GGG ATAGTG GAG CAA GAG CCA GTT CTG TTC TCT ACC ACC ATT GCA GAA AAT ATT CGC TAT GGC AGA GAA GAT GCA ACA ATG GAA GAC ATA GTC CAA GCT GCC AAG GAG GCC AAT GCC TAC AAC TTC ATC ATG GAC CTG CCA CAG CAA TTT GAC ACC CTT GTT GGA GAA GGA GGA GGC CAG ATG AGT GGT GGC CAG AAA CAA AGG GTA GCT ATC GCC AGA GCC CTC ATC CGA AAT CCC AAG ATT CTG CTT TTG GAC ATG GCC ACC TCA GCT CTG GAC AAT GAG AGT GAA GCC ATG GTG CAA GAA GTG CTG AGT AAG ATT CAG CAT GGG CAC ACA ATC ATT TCA GTT GCT CAT CGC TTG TCT ACG GTC AGA GCT GCA GAT ACC ATC ATT GGT TTT GAA CAT GGC ACT GCA GTG GAA AGA GGG ACC CAT GAA GAA TTA CTG GAA AGG AAA GGT GTT TAC TTC ACT CTA GTG ACT TTG CAA AGC CAG GGA AAT CAA GCT CTT AAT GAA GAG GAC ATA AAG GAT GCA ACT GAA GAT GAC ATG CTT GCG AGG ACC TTT AGC AGA GGG AGC TAC CAG GAT AGT TTA AGG GCT TCC ATC CGG CAA CGC TCC AAG TCT CAG CTT TCT TAC CTG GTG CAC GAA CCT CCA TTA GCT GTT GTA GAT CAT AAG TCT ACC TAT GAA GAA GAT AGA AAG GAC AAG GAC ATT CCT GTG CAG GAA GAA GTT GAA CCT GCC CCA GTT AGG AGG ATT CTG AAA TTC AGT GCT CCAGAA TGG CCC TAC ATG CTG GTA GGG TCT GTG GGT GCA GCT GTG AAC GGG ACA GTC ACA CCC TTG TAT GCC TTT TTA TTC AGC CAG ATT CTT GGG ACT TTT TCA ATT CCT GAT AAA GAG GAA CAA AGG TCA CAG ATC AAT GGT GTG TGC CTA CTT TTT GTA GCA ATG GGC TGT GTA TCT CTT TTC ACC CAA TTT CTA CAG GGA TAT GCC TTT GCT AAA TCT GGG GAG CTC CTA ACA AAA AGG CTA CGT AAA TTT GGT TTC AGG GCA ATG CTG GGG CAA GAT ATT GCC TGG TTT GAT GAC CTC AGA AAT AGC CCT GGA GCA TTG ACA ACA AGA CTT GCT ACA GAT GCT TCC CAA GTT CAA GGG GCT GCC GGC TCT CAG ATC GGG ATG ATA GTC AAT TCC TTC ACT AAC GTC ACT GTG GCC ATG ATC ATT GCC TTC TCC TTT AGC TGG AAG CTG AGC CTG GTC ATC TTG TGC TTC TTC CCC TTC TTG GCT TTA TCA GGA GCC ACA CAG ACC AGG ATG TTG ACA GGA TTT GCC TCT CGA GAT AAG CAG GCC CTG GAG ATG GTG GGA CAG ATT ACA AAT GAA GCC CTC AGT AAC ATC CGC ACT GTT GCT GGA ATT GGA AAG GAG AGG CGG TTC ATT GAA GCA CTT GAG ACT GAG CTG GAG AAG CCC TTC AAG ACA GCC ATT CAG AAA GCC AAT ATT TAC GGA TTC TGC TTT GCC TTT GCC CAG TGC ATC ATG TTT ATT GCG AAT TCT GCT TCC TACAGA TAT GGA GGT TAC TTA ATC TCC AAT GAG GGG CTC CAT TTC AGC TAT GTG TTC AGG GTG ATC TCT GCA GTT GTA CTG AGT GCA ACA GCT CTT GGA AGA GCC TTC TCT TAC ACC CCA AGT TAT GCA AAA GCT AAA ATA TCA GCT GCA CGC TTT TTT CAA CTG CTG GAC CGA CAA CCC CCA ATC AGT GTA TAC AAT ACT GCA GGT GAA AAA TGG GAC AAC TTC CAG GGG AAG ATT GAT TTT GTT GAT TGT AAA TTT ACA TAT CCT TCT CGA CCT GAC TCG CAA GTT CTG AAT GGT CTC TCA GTG TCG ATT AGT CCA GGG CAG ACA CTG GCG TTT GTT GGG AGC AGT GGA TGT GGC AAA AGC ACT AGC ATT CAG CTG TTG GAA CGT TTC TAT GAT CCT GAT CAA GGG AAG GTG ATG ATA GAT GGT CAT GAC AGC AAA AAA GTA AAT GTC CAG TTC CTC CGC TCA AAC ATT GGA ATT GTT TCC CAG GAA CCA GTG TTG TTT GCC TGT AGC ATA ATG GAC AAT ATC AAG TAT GGA GAC AAC ACC AAA GAA ATT CCC ATG GAA AGA GTC ATA GCA GCT GCA AAA CAG GCT CAG CTG CAT GAT TTT GTC ATG TCA CTC CCA GAG AAA TAT GAA ACT AAC GTT GGG TCC CAG GGG TCT CAA CTC TCT AGA GGG GAG AAA CAA CGC ATT GCT ATT GCT CGG GCC ATT GTA CGA GAT CCT AAA ATC TTG CTA CTA GAT GAA GCC ACT TCT GCC TTA GACACA GAA AGT GAA AAG ACG GTG CAG GTT GCT CTA GAC AAA GCC AGA GAG GGT CGG ACC TGC ATT GTC ATT GCC CAT CGC TTG TCC ACC ATC CAG AAC GCG GAT ATC ATT GCT GTC ATG GCA CAG GGG GTG GTG ATT GAA AAG GGG ACC CAT GAA GAA CTG ATG GCC CAA AAA GGA GCC TAC TAC AAA CTA GTC ACC ACT GGA TCC CCC ATC AGT TGA
Table 4
Table 5
[0040] Enter 4 and 35 1 Noah et al., J Hepatol. 2005, vol. 43(3), pp. 536-543. 2 Lam et al., Am J Physiol Cell Physiol. 2007, vol. 293(5), p.C1709-16. 3 Stindt et al., Life Int. 2013, vol. 33(10), pp. 1527-1735. 4 Gao et al., Shandong Year 2012, vol. 52(10), pp. 14-16. 5 Strautnieks et al., Gastroenterology. 2008, vol. 134(4), p.1203-1214. 6 Kagawa et al., Am J Physiol Gastrointest Liver Physiol. 2008, vol. 294(1), pp. G58-67. 7 Byrne et al., Hepatology. 2009, vol. 49(2), pp. 553-567. 8 Chen et al., J Pediatr. 2008, vol. 153(6), p. 825-8 9Davit-Spraul et al., Hepatology 2010, vol. 51(5),p. 1645-1655. 10 Droge et al., Sci Rep. 2016, vol. 6:24827. 11 Lang et al., Pharmacogenet Genomics. 2007, vol. 17(1), p.47-60. 12 Ellinger et al., World J Gastroenterol. 2017, vol. 23(29), p. :5295-5303. 13 Vitale et al., J Gastroenterol. 2018, vol. 53(8), p.945-958. 14 Knisely et al., Hepatology. 2006, vol. 44(2),p.478-86. 15 Ellis et al., Hepatology. 2018, vol. 67(4),p.1531-1545. 16 Lam et al., J Hepatol. 2006, vol. 44(1), p. 240-242. 17 Varma et al., Hepatology 2015, vol. 62(1),p.198-206. 18 Treepongkaruna et al., World J Gastroenterol. 2009, vol. 15(34),p.4339-4342. 19 Zarenezhad et al., Hepatitis Monthly: 2017, vol. 17(2); e43500. 20 Hayashi et al., Hepatol Res. 2016, vol. 46(2),p.192-200. 21 Guorui et al., Linchuang Erke Zazhi 2013, vol. 31(10), 905-909. 22 van Mil et al., Gastroenterology. 2004, vol. 127(2), p.379-384. 23 Anzivino et al., Dig Liver Dis. 2013, vol. 45(3), pp.226-232. 24 Park et al., World J Gastroenterol. 2016, vol. 22(20), p.4901-4907. 25 Imagawa et al., J Hum Genet. 2018, vol. 63(5),p.569-577. 26 Giovannoni et al., PLoS One. 2015, vol. 10(12): e0145021. 27 Hu et al., Mol Med Rep. 2014, vol. 10(3),p.1264-1274. 28 Lang et al,. Drug Metab Disposition. 2006, vol. 34(9), p.1582-1599. 29 Masahata et al., Transplant Proc. 2016, vol. 48(9), p.3156-3162. 30 Holz et al., Hepatol Commun. 2018, vol. 2(2),p.152-154. 31 Li et al., Hepatology International 2017, vol. 11, no. 1, Supp. Supplement 1, pp. S180. Abstract Number: OP284. 32 Francalanci et al., Laboratory Investigation 2011, vol. 91, Supp. SUPPL. 1, pp.360A. Abstract Number: 1526. 33 Francalanci et al., Digestive and Liver Disease 2010, vol. 42, Supp. SUPPL. 1, pp.S16. Abstract Number: T.N.5. 34 Shah et al., J Pediatr Genet. 2017, vol. 6(2),p.126-127. 35 Gao et al., Hepatitis Monthly 2017, vol. 17(10),e55087 / 1-e55087 / 6. 36 Evason et al., Am J Surg Pathol. 2011, vol. 35(5), p.687-696. 37 Davit-Spraul et al., Mol Genet Metab. 2014, vol. 113(3), p.225-229. 38 Maggiore et al., J Hepatol. 2010, vol. 53(5),p.981-6. 39 McKay et al., Version 2. F1000Res. 2013; 2: 32. DOI: 10.12688 / f1000research.2-32.v2 40 Liu et al., Pediatr Int. 2013, vol. 55(2),p.138-144. 41 Waisbourd-Zinman et al., Ann Hepatol. 2017, vol. 16(3), p.465-468. 42 Griffin, et al., Canadian Journal of Gastroenterology and Hepatology 2016, vol. 2016. Abstract Number: A200. Meeting Info: 2016 Canadian Digestive Diseases Week, CDDW 2016. Montreal, QC, United States. 26 Feb 2016-29 Feb 2016 43 Qiu et al., Hepatology 2017, vol. 65(5),p.1655-1669. 44 Imagawa et al., Sci Rep. 2017, 7:41806. 45 Kang et al., J Pathol Transl Med. 2019 May 16. doi: 10.4132 / jptm.2019.05.03.[Epub ahead of print] 46 Takahashi et al., Eur J Gastroenterol Hepatol. 2007, vol. 19(11),p.942-6. 47 Shimizu et al., Am J Transplant. 2011, vol. 11(2), p.394-398. 48 Krawczyk et al., Ann Hepatol. 2012, vol. 11(5),p.710-744. 49 Sharma et al., BMC Gastroenterol. 2018, vol. 18(1), p.107. 50Sattler et al., Journal of Hepatology 2017, vol. 66, No. 1, Suppl. S, pp.S177. Meeting Info.: International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver. Amsterdam, NETHERLANDS. April 19 -23, 2017. European Assoc Study Liver. 51 Jung et al., J Pediatr Gastroenterol Nutr. 2007, vol. 44(4),p.453-458. 52 Sciveres. Digestive and Liver Disease 2010, vol.42, Supp. SUPPL. 5, pp.S329. Abstract Number:CO18. Meeting Info:17th National Congress SIGENP. Pescara, Italy. 07 Oct 2010-09 Oct 2010 53 Sohn et al., Pediatr Gastroenterol Hepatol Nutr. 2019, vol. 22(2),p.201-206. 54 Ho et al., Pharmacogenet Genomics. 2010, vol. 20(1), p.45-57. 55 Wang et al., Hepatol Res. 2018, vol. 48(7),p.574-584. 56 Shaprio et al., J Hum Genet. 2010, vol. 55(5),p.308-313. 57Bounford. University of Birmingham. Dissertation Abstracts International,(2016) Vol. 75, No. 1C. Order No.: AAI10588329. ProQuest Dissertations & Theses. 58 Stolz et al., Aliment Pharmacol Ther. 2019, vol. 49(9), p.1195-1204. 59 Jankowska et al., J Pediatr Gastroenterol Nutr. 2014, vol. 58(1),p.92-95. 60 Kim. Journal of Pediatric Gastroenterology and Nutrition 2016, vol. 62, Supp. SUPPL. 1, pp.620. Abstract Number: H-P-045. Meeting Info: 49th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition, ESPGHAN 2016. Athens, Greece. 25 May 2016-28 May 2016. 61 Pauli-Magnus et al., Hepatology 2003, vol. 38, No. 4 Suppl. 1, pp.518A. print. Meeting Info.: 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA, USA. October 24-28, 2003. American Association for the Study of Liver Diseases. 62Li et al., Hepatology International 2017, vol. 11, No. 1, Supp. Supplement 1, pp.S362. Abstract Number: PP0347. Meeting Info: 26th Annual Conference of the Asian Pacific Association for the Study of the Liver, APASL 2017. Shanghai, China. 15 Feb 2017-19 Feb 2017. 63 Rumbo et al., Transplantation 2018, vol. 102, No. 7, Supp. Supplement 1, pp.S848. Abstract Number: P.752. Meeting Info: 27th International Congress of The Transplantation Society, TTS 2018. Madrid, Spain. 30 Jun 2018-05 Jul 2018. 64 Lee et al., Pediatr Gastroenterol Hepatol Nutr. 2017, vol. 20(2),p.114-123. 65 Sherrif et al., Liver international: official journal of the International Association for the Study of the Liver 2013, vol. 33, No. 8, pp.1266-1270. 66 Blackmore et al., J Clin Exp Hepatol. 2013, vol. 3(2), p.159-161. 67 Matte et al., J Pediatr Gastroenterol Nutr. 2010, vol. 51(4),p.488-493. 68 Lin et al., Zhongguo Dang Dai Er Ke Za Zhi. 2018, vol. 20(9),p.758-764. 69 Harmanci et al., Experimental and Clinical Transplantation 2015, vol. 13, Supp. SUPPL. 2, pp.76. Abstract Number: P62. Meeting Info: 1st Congress of the Turkic World Transplantation Society. Astana, Kazakhstan. 20 May 2015-22 May 2015. 70 Herbst et al., Mol Cell Probes. 2015, vol. 29(5), pp.291-298. 71 Moghadamrad et al., Hepatology. 2013, vol. 57(6), p.2539-2541. 72 Holz et al., Journal of Gastroenterology 2016, Vol. 54, No. 8. Abstract Number: KV275. Meeting Info: Visceral Medicine 2016, 71st Annual Meeting of the German Society for Gastroenterology, Digestive and Metabolic Diseases with Endoscopy Section - 10th Autumn Meeting of the German Society for General and Visceral Surgery. Hamburg, Germany. September 21, 2016–September 24, 2016. 73Wang et al., PLoS One. 2016; vol. 11(4): e0153114. 74 Hao et al., International Journal of Clinical and Experimental Pathology 2017, vol. 10(3), p.3480-3487. 75 Arnell et al., J Pediatr Gastroenterol Nutr. 2010, vol. 51(4),p.494-499. 76 Sharma et al., Indian Journal of Gastroenterology 2017, vol. 36, No. 1, Supp. Supplement 1, pp.A99. Abstract Number: M-20. Meeting Info: 58th Annual Conference of the Indian Society of Gastroenterology, ISGCON 2017. Bhubaneswar, India. 14 Dec 2017-17 Dec 2017. 77 Beausejour et al., Can J Gastroenterol. 2011, vol. 25(6), p.311-314. 78 Imagawa et al., Journal of Pediatric Gastroenterology and Nutrition 2016, vol. 63, Supp. Supplement 2, pp.S51. Abstract Number: 166. Meeting Info: World Congress of Pediatric Gastroenterology, Hepatology and Nutrition 2016. Montreal, QC, Canada. 05 Oct 2016-08 Oct 2016. 79Peng et al., Zhonghua er ke za zhi(Chinese journal of pediatrics) 2018, vol. 56, No. 6, pp.440-444. 80 Tibesar et al., Case Rep Pediatr. 2014, vol. 2014: 185923. 81 Ng et al., Journal of Pediatric Gastroenterology and Nutrition 2018, vol. 66, Supp. Supplement 2, pp.860. Abstract Number: H-P-127. Meeting Info: 51st Annual Meeting European Society for Paediatric Gastroenterology, Hepatology and Nutrition, ESPGHAN 2018. Geneva, Switzerland. 09 May 2018-12 May 2018. 82 Wong et al., Clin Chem. 2008, vol. 54(7),p.1141-1148. 83 Pauli-Magnus et al., J Hepatol. 2005, vol. 43(2), p.342-357. 84 Jericho et al., Journal of Pediatric Gastroenterology and Nutrition. 60, vol. 3, p.368-374. 85Scheimann et al., Gastroenterology 2007, vol. 132, No. 4, Suppl. 2, pp. A452. Meeting Info.: Digestive Disease Week Meeting / 108th Annual Meeting of the American-Gastroenterological-Association. Washington, DC, USA. May 19 -24, 2007. Amer Gastroenterol Assoc; Amer Assoc Study Liver Dis; Amer Soc Gastrointestinal Endoscopy; Soc Surg Alimentary Tract. 86 Jaquotot-Haerranz et al., Rev Esp Enferm Dig. 2013, vol. 105(1),p.52-54. 87 Khosla et al., American Journal of Gastroenterology 2015, vol. 110, No. Suppl. 1, pp. S397. Meeting Info.: 80th Annual Scientific Meeting of the American-College-of-Gastroenterology. Honolulu, HI, USA. October 16-21,2015. 88 Droge et al., J Hepatol. 2017, vol. 67(6),p.1253-1264. 89 Liu et al., Liver International 2010, vol. 30(6), p.809-815. 90 Chen et al., Journal of Pediatrics 2002, vol. 140(1), p.119-124. 91 U.S. Patent No. 9,295,677
[0041] In some embodiments, the ABCB11 mutation is selected from A167T, G238V, V284L, E297G, R470Q, R470X, D482G, R487H, A570T, N591S, A865V, G982R, R1153C, and R1268Q.
[0042] Provided is a method of treating PFIC (e.g., PFIC-1 and PFIC-2) in a subject, comprising performing an assay on a sample obtained from the subject to determine whether the subject has a mutation associated with PFIC (e.g., an ATP8B1, ABCB11, ABCB4, TJP2, NR1H4 or Myo5b mutation), and administering (e.g., specifically or selectively administering) a therapeutically effective amount of a compound of formula (I) or a pharma- ceutically acceptable salt thereof to the subject determined to have a mutation associated with PFIC. In some embodiments, the mutation is an ATP8B1 or ABCB11 mutation. For example, a mutation provided in any one of Tables 1-4. In some embodiments, the mutation in ATP8B1 is selected from L127P, G308V, T456M, D554N, F529del, I661T, E665X, R930X, R952X, R1014X, and G1040R. In some embodiments, the mutation in ABCB11 is selected from A167T, G238V, V284L, E297G, R470Q, R470X, D482G, R487H, A570T, N591S, A865V, G982R, R1153C, and R1268Q.
[0043] Also provided is a method for treating PFIC (e.g., PFIC-1 and PFIC-2) in a subject in need thereof, the method comprising: (a) detecting a mutation associated with PFIC in the subject (e.g., an ATP8B1, ABCB11, ABCB4, TJP2, NR1H4 or Myo5b mutation); and (b) administering to the subject a therapeutically effective amount of a compound of formula (I) or a pharma- ceutically acceptable salt thereof. In some embodiments, the method for treating PFIC may comprise administering to a subject having a mutation associated with PFIC (e.g., an ATP8B1, ABCB11, ABCB4, TJP2, NR1H4 or Myo5b mutation) a therapeutically effective amount of a compound of formula (I) or a pharma- ceutically acceptable salt thereof. In some embodiments, the mutation is an ATP8B1 or ABCB11 mutation. For example, a mutation provided in any one of Tables 1-4. In some embodiments, the mutation in ATP8B1 is selected from L127P, G308V, T456M, D554N, F529del, I661T, E665X, R930X, R952X, R1014X, and G1040R. In some embodiments, the mutation in ABCB11 is selected from A167T, G238V, V284L, E297G, R470Q, R470X, D482G, R487H, A570T, N591S, A865V, G982R, R1153C, and R1268Q.
[0044] In some embodiments, the subject is determined to have a mutation associated with PFIC in the subject or in a biopsy sample from the subject through the use of any art-recognized test, including next generation sequencing (NGS).In some embodiments, the subject is determined to have a mutation associated with PFIC by using a regulatory approved, for example FDA approved, test or assay to identify the subject or the biopsy sample from the subject to have a mutation associated with PFIC, or by carrying out any of the non-limiting examples of the assays described herein.Additional methods for diagnosing PFIC are described in Gunaydin, M. et al., Hepat Med. 2018, vol. 10, p.95-104, which is incorporated herein by reference in its entirety.
[0045] In some embodiments, treatment of PFIC (e.g., PFIC-1 and PFIC-2) reduces serum bile acid levels in a subject. In some embodiments, serum bile acid levels are determined, for example, by ELISA enzyme assay or assay for measuring total bile acid as described in Danese et al., PLoS One. 2017, vol. 12(6): e0179200, which is incorporated by reference in its entirety. In some embodiments, serum bile acid levels can be reduced, for example, by 10% to 40%, 20% to 50%, 30% to 60%, 40% to 70%, 50% to 80%, or more than 90% of serum bile acid levels prior to administration of a compound of formula (I) or a pharma- ceutically acceptable salt thereof. In some embodiments, treatment of PFIC includes treatment of pruritus.
[0046] Since LBAT is expressed on hepatocytes, LBAT and ASBT / LBAT dual inhibitors should have at least some bioavailability and free fraction in blood. Because LBAT inhibitor compounds only need to survive from the intestine to the liver, it is expected that relatively low systemic exposure of such compounds will be sufficient, thereby minimizing the potential risk of any side effects in the rest of the body. It is expected that the inhibition of LBAT and ASBT will have at least an additive effect in reducing intrahepatic bile acid concentration. It is also expected that ASBT / LBAT dual inhibitors may be able to reduce bile acid levels without inducing diarrhea, which can be observed with ASBT inhibitors.
[0047] Compounds with high LBAT inhibitory potency and sufficient bioavailability are predicted to be particularly suitable for the treatment of hepatitis. Compounds with dual ASBT / LBAT inhibitory potency and sufficient bioavailability are predicted to be particularly suitable for the treatment of non-alcoholic steatohepatitis (NASH).
[0048] NASH is a common and serious chronic liver disease that resembles alcoholic liver disease but occurs in people who consume little or no alcohol. In patients with NASH, fat accumulation in the liver, also known as nonalcoholic fatty liver disease (NAFLD) or steatosis, as well as other factors such as high LDL cholesterol and insulin resistance, can induce chronic inflammation in the liver, leading to progressive tissue scarring known as fibrosis and cirrhosis, and ultimately liver failure and death. Patients with NASH were found to have significantly higher total serum bile acid concentrations than healthy controls at all time points, both fasting (2.2-2.4-fold NASH increase) and postprandial (1.7-2.2-fold NASH increase). These are driven by increases in taurine- and glycine-conjugated primary and secondary bile acids. Patients with NASH exhibited greater variability in fasting and postprandial bile acid profiles. These results indicate that patients with NASH have higher fasting and postprandial exposure to bile acids, including the more hydrophobic and cytotoxic secondary species. Increased bile acid exposure may be involved in the liver injury and pathogenesis of NAFLD and NASH (Ferslew et al., Dig Dis Sci. 2015, vol. 60, p.3318-3328). Therefore, ASBT and / or LBAT inhibition may be beneficial for the treatment of NASH.
[0049] NAFLD is characterized by fatty liver without secondary causes of fatty liver, including excessive alcohol consumption, other known liver disease, or long-term use of lipogenic drugs (Chalasani et al., Hepatology 2018, vol. 67(1),p.328-357). NAFLD can be classified as nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH). According to Chalasani et al., NAFL is defined as the presence of 5% or more fatty liver without evidence of hepatocellular injury in the form of hepatocellular ballooning. NASH is defined as the presence of 5% or more fatty liver and inflammation with liver injury (e.g., ballooning) with or without any liver fibrosis. NASH is also commonly associated with liver inflammation and liver fibrosis, which can progress to cirrhosis, end-stage liver disease, and hepatocellular carcinoma. Liver fibrosis is not necessarily present in NASH, but the severity of fibrosis, if present, can lead to poor long-term outcomes.
[0050] There are many approaches that can be used to assess and evaluate the severity of disease, including whether a subject has NAFLD, and if so, whether the NAFLD is NAFL or NASH.In some embodiments, the severity of NAFLD can be assessed using NAS.In some embodiments, the treatment of NAFLD can be assessed using NAS.In some embodiments, NAS can be determined as described in Kleiner et al., Hepatology. 2005, 41(6):1313-1321, which is incorporated herein by reference in its entirety.See, for example, Table 6 for the simplified NAS scheme adapted from Kleiner. [Table 6]
[0051] In some embodiments, the NAS is determined non-invasively, for example, as described in U.S. Patent Application Publication No. 2018 / 0140219, which is incorporated herein by reference in its entirety. In some embodiments, the NAS is determined for a sample from a subject prior to administration of a compound of formula (I) or a pharma- ceutically acceptable salt thereof. In some embodiments, the NAS is determined during or after a period of administration of a compound of formula (I) or a pharma- ceutically acceptable salt thereof. In some embodiments, a lower NAS during or after a period of administration of a compound of formula (I) or a pharma- ceutically acceptable salt thereof compared to before administration of a compound of formula (I) or a pharma- ceutical acceptable salt thereof indicates treatment of NAFLD (e.g., NASH). For example, a reduction in NAS of 1, 2, 3, 4, 5, 6, or 7 indicates treatment of NAFLD (e.g., NASH). In some embodiments, the NAS following administration of a compound of formula (I) or a pharma- ceutical acceptable salt thereof is 7 or less. In some embodiments, the NAS during administration of a compound of formula (I) or a pharma- ceutically acceptable salt thereof is 5 or less, 4 or less, 3 or less, or 2 or less. In some embodiments, the NAS during administration of a compound of formula (I) or a pharma- ceutically acceptable salt thereof is 7 or less. In some embodiments, the NAS during administration of a compound of formula (I) or a pharma- ceutically acceptable salt thereof is 5 or less, 4 or less, 3 or less, or 2 or less. In some embodiments, the NAS after administration of a compound of formula (I) or a pharma- ceutically acceptable salt thereof is 7 or less. In some embodiments, the NAS after administration of a compound of formula (I) or a pharma- ceutically acceptable salt thereof is 5 or less, 4 or less, 3 or less, or 2 or less.
[0052] Additional approaches to assess and evaluate NASH in subjects include determining one or more biomarkers (e.g., serum markers and panels) that indicate one or more of fatty liver (e.g., fat accumulation in liver); liver inflammation; liver damage, liver inflammation, liver fibrosis, and / or liver cirrhosis.Further examples of physiological indicators of NASH can include liver morphology, liver stiffness, and the size or weight of the liver of the subject.In some embodiments, NASH in a subject is demonstrated by detecting biomarkers that indicate liver fat accumulation and liver damage.For example, elevated serum ferritin and low titer of serum autoantibodies can be common features of NASH.
[0053] In some embodiments, methods of assessing NASH include evaluating magnetic resonance imaging, either by spectroscopy or by proton density fat fraction (MRI-PDFF) to quantify steatosis, transient elastography (FIBROSCAN®), hepatic venous pressure gradient (HVPG), liver stiffness scale by MRE to diagnose significant liver fibrosis and / or cirrhosis, and histological features of liver biopsies. In some embodiments, magnetic resonance imaging is used to detect one or more of steatohepatitis (NASH-MRI), liver fibrosis (Fibro-MRI), and steatosis. See, e.g., U.S. Patent Application Publication Nos. 2016 / 146715 and 2005 / 0215882, each of which is incorporated herein by reference in its entirety.
[0054] In some embodiments, treatment of NASH can include a reduction in one or more symptoms associated with NASH in a subject following administration of one or more doses of a compound of Formula (I) or a pharmacologic acceptable salt thereof; a reduction in the amount of fatty liver; a reduction in NAS; a reduction in liver inflammation; a reduction in levels of biomarkers indicative of one or more of liver injury, inflammation, liver fibrosis, and / or cirrhosis; and a reduction in fibrosis and / or cirrhosis, a lack of further progression of fibrosis and / or cirrhosis, or a slowing of the progression of fibrosis and / or cirrhosis.
[0055] In some embodiments, treating NASH includes reducing one or more symptoms associated with NASH in a subject. Exemplary symptoms may include one or more of: liver enlargement, fatigue, right upper quadrant pain, abdominal swelling, enlargement of blood vessels just below the skin surface, male breast enlargement, spleen enlargement, palmar erythema, jaundice, and pruritus. In some embodiments, the subject is asymptomatic. In some embodiments, the subject's total body weight is not increased. In some embodiments, the subject's total body weight is decreased. In some embodiments, the subject's body mass index (BMI) is not increased. In some embodiments, the subject's body mass index (BMI) is decreased. In some embodiments, the subject's waist-to-hip (WTH) ratio is not increased. In some embodiments, the subject's waist-to-hip (WTH) ratio is decreased.
[0056] In some embodiments, the treatment of NASH can be assessed by measuring hepatic steatosis. In some embodiments, the treatment of NASH comprises reducing hepatic steatosis following administration of a compound of formula (I) or a pharma- ceutically acceptable salt thereof, as described herein. In some embodiments, hepatic steatosis is determined by one or more methods selected from the group consisting of ultrasonography, computed tomography (CT), magnetic resonance imaging, magnetic resonance spectroscopy (MRS), magnetic resonance elastography (MRE), transient elastography (TE) (e.g., FIBROSCAN®), measuring liver size or weight, or liver biopsy (e.g., Di Lascio et al., Ultrasound Med Biol. 2018, vol. 44(8), p.1585-1596; Lv et al., J Clin Transl Hepatol. 2018, vol. 6(2),p. 217-221; Reeder et al., J Magn Reson Imaging. 2011, vol. 34(4),spcone; and de Ledinghen V, et al., J Gastroenterol Hepatol. 2016, vol. 31(4), p.848-855). A subject diagnosed with NASH may have a fatty liver of greater than about 5%, for example, greater than about 5% to about 25%, about 25% to about 45%, about 45% to about 65%, or greater than about 65%. In some embodiments, a subject with a fatty liver of greater than about 5% to about 33% has stage 1 fatty liver, a subject with a fatty liver of about 33% to about 66% has stage 2 fatty liver, and a subject with a fatty liver of greater than about 66% has stage 3 fatty liver.
[0057] In some embodiments, the amount of fatty liver is determined before administration of the compound of formula (I) or a pharma- ceutically acceptable salt thereof. In some embodiments, the amount of fatty liver is determined during or after the administration period of the compound of formula (I) or a pharma- ceutically acceptable salt thereof. In some embodiments, a reduction in the amount of fatty liver during or after the administration period of the compound of formula (I) or a pharma- ceutically acceptable salt thereof compared to before administration of the compound of formula (I) or a pharma- ceutical acceptable salt thereof indicates treatment of NASH. For example, a reduction in the amount of fatty liver of about 1% to about 50%, about 25% to about 75%, or about 50% to about 100% indicates treatment of NASH. In some embodiments, a reduction in the amount of liver steatosis of about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, or about 95% indicates treatment of NASH.
[0058] In some embodiments, the presence of liver inflammation is determined by one or more methods selected from the group consisting of biomarkers indicative of liver inflammation and liver biopsy sample(s) from the subject. In some embodiments, the severity of liver inflammation is determined from liver biopsy sample(s) from the subject. For example, liver inflammation in liver biopsy samples can be assessed as described in Kleiner et al., Hepatology 2005, vol. 41(6), p.1313-1321 and Brunt et al., Am J Gastroenterol 1999, vol. 94, p.2467-2474, each of which is incorporated herein by reference in its entirety. In some embodiments, the severity of liver inflammation is determined before administration of the compound of formula (I) or a pharma- ceutically acceptable salt thereof. In some embodiments, the severity of liver inflammation is determined during or after administration of the compound of formula (I) or a pharma- ceutically acceptable salt thereof. In some embodiments, a reduction in the severity of liver inflammation during or after the administration period of the compound of formula (I) or a pharma- ceutically acceptable salt thereof, compared to before administration of the compound of formula (I) or a pharma- ceutically acceptable salt thereof, indicates treatment of NASH. For example, a reduction in the severity of liver inflammation of about 1% to about 50%, about 25% to about 75%, or about 50% to about 100% indicates treatment of NASH. In some embodiments, a reduction in the severity of liver inflammation of about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, or about 95% indicates treatment of NASH.
[0059] In some embodiments, the treatment of NASH includes treating fibrosis and / or cirrhosis, e.g., reducing the severity of fibrosis, lack of further progression of fibrosis and / or cirrhosis, or slowing the progression of fibrosis and / or cirrhosis. In some embodiments, the presence of fibrosis and / or cirrhosis is determined by one or more methods selected from the group consisting of transient elastography (FIBROSCAN®), non-invasive markers of liver fibrosis, and histological features of liver biopsy. In some embodiments, the severity (e.g., stage) of fibrosis is determined by one or more methods selected from the group consisting of transient elastography (FIBROSCAN®), fibrosis scoring systems, biomarkers of liver fibrosis (e.g., non-invasive biomarkers), and hepatic venous pressure gradient (HVPG). Non-limiting examples of fibrosis scoring systems include the NAFLD fibrosis scoring system (see, e.g., Angulo et al., Hepatology 2007, vol. 45(4), p.846-54), the fibrosis scoring system in Brunt et al., Am. J. Gastroenterol. 1999, vol. 94, p.2467-2474, the fibrosis scoring system in Kleiner et al., Hepatology 2005, vol. 41(6), p. 1313-1321, and the ISHAK fibrosis scoring system (see, Ishak et al., J. Hepatol. 1995, vol. 22, p.696-699), the contents of each of which are incorporated herein by reference in their entirety.
[0060] In some embodiments, the severity of fibrosis is determined before administration of the compound of formula (I) or a pharma- ceutically acceptable salt thereof. In some embodiments, the severity of fibrosis is determined during or after administration of the compound of formula (I) or a pharma- ceutically acceptable salt thereof. In some embodiments, a reduction in the severity of fibrosis during or after administration of the compound of formula (I) or a pharma- ceutically acceptable salt thereof compared to before administration of the compound of formula (I) or a pharma- cically acceptable salt thereof indicates treatment of NASH. In some embodiments, a reduction in the severity of fibrosis, a lack of further progression of fibrosis and / or cirrhosis, or a slowing of the progression of fibrosis and / or cirrhosis indicates treatment of NASH. In some embodiments, the severity of fibrosis is determined using a scoring system, such as any of the fibrosis scoring systems described herein, for example, the score can indicate the stage of fibrosis, for example, stage 0 (no fibrosis), stage 1, stage 2, stage 3, and stage 4 (cirrhosis) (see, e.g., Kleiner et al.). In some embodiments, the reduction in the stage of fibrosis is a reduction in the severity of fibrosis. For example, a reduction of 1, 2, 3, or 4 stages is a reduction in the severity of fibrosis. In some embodiments, a reduction in stage, for example, from stage 4 to stage 3, from stage 4 to stage 2, from stage 4 to stage 1, from stage 4 to stage 0, from stage 3 to stage 2, from stage 3 to stage 1, from stage 3 to stage 0, from stage 2 to stage 1, from stage 2 to stage 0, or from stage 1 to stage 0, indicates the treatment of NASH. In some embodiments, the stage of fibrosis is reduced from stage 4 to stage 3, from stage 4 to stage 2, from stage 4 to stage 1, from stage 4 to stage 0, from stage 3 to stage 2, from stage 3 to stage 1, from stage 3 to stage 0, from stage 2 to stage 1, from stage 2 to stage 0, or from stage 1 to stage 0 following administration of a compound of Formula (I) or a pharma- ceutical acceptable salt thereof, as compared to before administration of the compound of Formula (I) or a pharma- ceutical acceptable salt thereof.In some embodiments, the stage of fibrosis is reduced from stage 4 to stage 3, from stage 4 to stage 2, from stage 4 to stage 1, from stage 4 to stage 0, from stage 3 to stage 2, from stage 3 to stage 1, from stage 3 to stage 0, from stage 2 to stage 1, from stage 2 to stage 0, or from stage 1 to stage 0, during the period of administration of the compound of Formula (I) or a pharma- ceutical or pharma-ceutical acceptable salt thereof, as compared to before administration of the compound of Formula (I) or a pharma-ceutical or pharma-ceutical acceptable salt thereof. In some embodiments, the stage of fibrosis is reduced from stage 4 to stage 3, from stage 4 to stage 2, from stage 4 to stage 1, from stage 4 to stage 0, from stage 3 to stage 2, from stage 3 to stage 1, from stage 3 to stage 0, from stage 2 to stage 1, from stage 2 to stage 0, or from stage 1 to stage 0, during the period of administration of the compound of Formula (I) or a pharma-ceutical or pharma-ceutical acceptable salt thereof, as compared to before administration of the compound of Formula (I) or a pharma-ceutical or pharma-ceutical acceptable salt thereof.
[0061] In some embodiments, the presence of NASH is determined by one or more biomarkers that indicate one or more of liver damage, inflammation, liver fibrosis, and / or liver cirrhosis, or their scoring system.In some embodiments, the severity of NASH is determined by one or more biomarkers that indicate one or more of liver damage, inflammation, liver fibrosis, and / or liver cirrhosis, or their scoring system.The level of biomarker can be determined, for example, by measuring, quantifying, and monitoring the expression level of the gene or mRNA that codes for biomarker, and / or the peptide or protein of biomarker.Non-limiting examples of biomarkers indicative of one or more of liver injury, inflammation, liver fibrosis, and / or cirrhosis, and / or their scoring systems include the aspartate aminotransferase (AST) / platelet ratio index (APRI); aspartate aminotransferase (AST) / alanine aminotransferase (ALT) ratio (AAR); FIB-4 score based on APRI, alanine aminotransferase (ALT) level, and age of the subject (e.g., McPherson et al., Gut 2010, vol. 11, incorporated herein by reference in its entirety). 59(9), p.1265-9); hyaluronic acid; proinflammatory cytokines; a panel of biomarkers consisting of α2-macroglobulin, haptoglobin, apolipoprotein A1, bilirubin, gamma glutamyl transpeptidase (GGT) in combination with the age and sex of the subject to generate a measure of fibrotic and necroinflammatory activity in the liver (e.g., FIBROTEST®, FIBROSURE®); a panel of biomarkers consisting of bilirubin, gamma glutamyl transferase, hyaluronic acid, α2-macroglobulin in combination with the age and sex of the subject (e.g., HEPASCORE®; see, e.g., Adams et al., Clin. Chem. 2005, vol. 51(10), p.1867-1873)), and a panel of biomarkers consisting of tissue inhibitor of metalloproteinase-1, hyaluronic acid, and alpha2-macroglobulin (e.g., FIBROSPECT®); a panel of biomarkers consisting of tissue inhibitor of metalloproteinase-1 (TIMP-1), amino-terminal propeptide of type III procollagen (PIIINP), and hyaluronic acid (HA) (e.g., Enhanced Liver Fibrosis (ELF) Score, see, e.g., Lichtinghagen R, et al., J Hepatol. 2013 Aug;59(2):236-42, incorporated herein by reference in its entirety).In some embodiments, the presence of fibrosis is determined by a panel of biomarkers consisting of α2-macroglobulin, haptoglobin, apolipoprotein A1, bilirubin, gamma glutamyl transpeptidase (GGT) in combination with the subject's age and sex to generate a FIB-4 score, a measure of fibrosis and necroinflammatory activity in the liver (e.g., FIBROTEST®, FIBROSURE®); a panel of biomarkers consisting of bilirubin, gamma glutamyl transferase, hyaluronic acid, α2-macroglobulin in combination with the subject's age and sex (e.g., HEPASCORE®; see, e.g., Adams et al., Clin. Chem. 2005, vol. 51(10), p.1867-1873) and a panel of biomarkers consisting of tissue inhibitor of metalloprotease-1, hyaluronic acid, and α2-macroglobulin (e.g., FIBROSPECT®); and a panel of biomarkers consisting of TIMP-1, amino terminal propeptide of procollagen type III (PIIINP), and hyaluronic acid (HA) (e.g., Enhanced Liver Fibrosis (ELF) Score). In some embodiments, the level of aspartate aminotransferase (AST) is not elevated. In some embodiments, the level of aspartate aminotransferase (AST) is decreased. In some embodiments, the level of alanine aminotransferase (ALT) is not elevated. In some embodiments, the level of alanine aminotransferase (ALT) is decreased. In some embodiments, the "level" of an enzyme refers to the concentration of the enzyme, for example, in blood. For example, the level of AST or ALT can be expressed as units / L.
[0062] In some embodiments, the severity of fibrosis is assessed using a panel of biomarkers consisting of α2-macroglobulin, haptoglobin, apolipoprotein A1, bilirubin, gamma glutamyl transpeptidase (GGT) in combination with the subject's age and sex to generate a FIB-4 score, a measure of fibrosis and necroinflammatory activity in the liver (e.g., FIBROTEST®, FIBROSURE®); a panel of biomarkers consisting of bilirubin, gamma glutamyl transferase, hyaluronic acid, α2-macroglobulin in combination with the subject's age and sex (e.g., HEPASCORE®); see, e.g., Adams et al., Clin. Chem. 2005, vol. 11, incorporated herein by reference in its entirety. 51(10), p.1867-1873) and a panel of biomarkers consisting of tissue inhibitor of metalloproteinase-1, hyaluronic acid, and α2-macroglobulin (e.g., FIBROSPECT®); and a panel of biomarkers consisting of tissue inhibitor of metalloproteinase-1 (TIMP-1), amino-terminal propeptide of type III procollagen (PIIINP), and hyaluronic acid (HA) (e.g., Enhanced Liver Fibrosis (ELF) Score).
[0063] In some embodiments, liver inflammation is determined by liver inflammation biomarkers, such as the level of pro-inflammatory cytokines.Non-limiting examples of liver inflammation biomarkers include interleukin-(IL)6, interleukin-(IL)1β, tumor necrosis factor (TNF)-α, transforming growth factor (TGF)-β, monocyte chemotactic protein (MCP)-1, C-reactive protein (CRP), PAI-1, and collagen isoforms such as Col1a1, Col1a2, and Col4a1 (see, for example, Neuman, et al., Can. J. Gastroenterol. Hepatol. 2014, vol. 28(11), p.607-618 and U.S. Patent No. 9,872,844, each of which is incorporated herein by reference in its entirety).Liver inflammation can also be assessed by measuring changes in macrophage infiltration, such as changes in CD68 expression levels. In some embodiments, liver inflammation may be determined by measuring or monitoring serum or circulating levels of one or more of interleukin-(IL)6, interleukin-(IL)1β, tumor necrosis factor (TNF)-α, transforming growth factor (TGF)-β, monocyte chemotactic protein (MCP)-1, and C-reactive protein (CRP).
[0064] In some embodiments, the level of one or more biomarkers indicative of one or more of liver damage, inflammation, liver fibrosis, and / or liver cirrhosis is determined for a sample from a subject before administration of a compound of formula (I) or its pharma- ceutical acceptable salt.In some embodiments, the level of one or more biomarkers indicative of one or more of liver damage, inflammation, liver fibrosis, and / or liver cirrhosis is determined during or after administration of a compound of formula (I) or its pharma-ceutical acceptable salt.In some embodiments, a reduction in the level of one or more biomarkers indicative of one or more of liver damage, inflammation, liver fibrosis, and / or liver cirrhosis during or after administration of a compound of formula (I) or its pharma-ceutical acceptable salt compared to before administration of a compound of formula (I) or its pharma-ceutical acceptable salt indicates treatment of NASH. For example, a reduction in the level of one or more biomarkers indicative of one or more of liver damage, inflammation, liver fibrosis, and / or cirrhosis of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 99% indicates treatment of NASH. In some embodiments, the reduction in the level of one or more biomarkers indicative of one or more of liver injury, inflammation, liver fibrosis, and / or cirrhosis following administration of a compound of Formula (I) or a pharma- ceutical acceptable salt thereof is at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 99%.In some embodiments, the level of one or more biomarkers indicative of one or more of liver injury, inflammation, liver fibrosis, and / or cirrhosis during administration of a compound of Formula (I) or a pharma- ceutical acceptable salt thereof is at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 99%. In some embodiments, the level of one or more biomarkers indicative of one or more of liver damage, inflammation, liver fibrosis, and / or cirrhosis after a period of administration of a compound of Formula (I) or a pharma- ceutical acceptable salt thereof is at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 99%.
[0065] In some embodiments, the treatment of NASH reduces the level of serum bile acids in the subject. In some embodiments, the level of serum bile acids is determined, for example, by an ELISA enzyme assay or an assay for measuring total bile acids as described in Danese et al., PLoS One. 2017, vol. 12(6): e0179200, which is incorporated herein by reference in its entirety. In some embodiments, the serum bile acid level can be reduced, for example, by 10% to 40%, 20% to 50%, 30% to 60%, 40% to 70%, 50% to 80%, or more than 90% of the serum bile acid level before administration of the compound of formula (I) or a pharma- ceutical acceptable salt thereof. In some embodiments, the NASH is NASH with cholestasis. In cholestasis, the release of bile, including bile acids, from the liver is blocked. Bile acids may cause hepatocellular injury (see, e.g., Perez MJ, Briz O. World J. Gastroenterol. 2009, vol. 15(14), p.1677-1689), possibly leading to or increasing the progression of fibrosis and increasing the risk of hepatocellular carcinoma (see, e.g., Sorrentino P et al., Dig. Dis. Sci. 2005, vol. 50(6), p.1130-1135 and Satapathy SK and Sanyal AJ. Semin. Liver Dis. 2015, vol. 35(3), p.221-235, each of which is incorporated herein by reference in its entirety). In some embodiments, the treatment of NASH comprises treating pruritus. In some embodiments, the treatment of NASH with cholestasis comprises treating pruritus. In some embodiments, the subject with NASH with cholestasis has pruritus.
[0066] Exemplary biomarkers for NASH are provided in Table 7. [Table 7]
[0067] References for Table 7 1 McPherson et al., Gut. 2010, vol. 59(9), p.1265-1269. 2 Adams, et al. Clin Chem. 2005, vol. 51(10), p.1867-1873. 3 Lichtinghagen, et al. J Hepatol. 2013, vol. 59(2), p.236-242. 4 Neuman, et al. Can J Gastroenterol Hepatol. 2014, vol. 28(11), p.607-618. 5 U.S. Patent No. 9,872,844
[0068] Some compounds of formula (I) or their pharma- ceutically acceptable salts may show higher free fraction in plasma.In some embodiments, the free fraction is more than about 0.2%, such as more than about 0.4%, such as more than about 0.6%, such as more than about 0.8%, such as more than about 1.0%, such as more than about 1.25%, such as more than about 1.5%, such as more than about 1.75%, such as more than about 2.0%, such as more than about 2.5%, such as more than about 3%, such as more than about 4%, such as more than about 5%, such as more than about 7.5%, such as more than about 10%, or such as more than about 20%.
[0069] Some compounds of formula (I) or their pharma- ceutically acceptable salts may be excreted in urine. In some embodiments, the fraction of the compound excreted in urine is greater than about 0.2%, such as greater than about 0.4%, such as greater than about 0.6%, such as greater than about 0.8%, such as greater than about 1.0%, such as greater than about 2%, such as greater than about 3%, such as greater than about 5%, such as greater than about 7.5%, such as greater than about 10%, such as greater than about 20%, such as greater than about 30%, or such as greater than about 50%.
[0070] Following intestinal absorption, some compounds of formula (I) or their pharma- ceutical acceptable salts can circulate through enterohepatic circulation.In some embodiments, the fraction of compounds circulating through enterohepatic circulation is more than about 0.1%, such as more than about 0.2%, such as more than about 0.3%, such as more than about 0.5%, such as more than about 1.0%, such as more than about 1.5%, such as more than about 2%, such as more than about 3%, such as more than about 5%, such as more than about 7%, such as more than about 10%, such as more than about 15%, such as more than about 20%, such as more than about 30%, or such as more than about 50%.
[0071] Some compounds of formula (I) or pharma- ceutically acceptable salts thereof may cause renal excretion of bile salts. In some embodiments, the fraction of circulating bile acids excreted by the renal route is greater than about 1%, such as greater than about 2%, such as greater than about 5%, such as greater than about 7%, such as greater than about 10%, such as greater than about 15%, such as greater than about 20%, or greater than about 25%.
[0072] Some compounds of formula (I) or pharma- ceutically acceptable salts thereof may exhibit improved or optimal permeability. Permeability may be measured in Caco2 cells, and values are given as Papp (apparent permeability) values in cm / s. In some embodiments, the permeability is about 0.2×10 -6 cm / s, approximately 0.4 × 10 -6 cm / s, approximately 0.7×10 -6 cm / s, approximately 1.0×10 -6 cm / s, approximately 2×10 -6 cm / s, about 3×10 -6 cm / s, about 5×10 -6 cm / s, about 7×10 -6 cm / s, about 10×10 -6 cm / s, about 15×10 -6 At least about 0.1 × 10 cm / s -6 Exceeds cm / s.
[0073] Some compounds of formula (I) or pharma- ceutically acceptable salts thereof may exhibit improved or optimal bioavailability. In some embodiments, the oral bioavailability is greater than about 5%, such as greater than about 7%, such as greater than about 10%, such as greater than about 15%, such as greater than about 20%, such as greater than about 30%, such as greater than about 40%, such as greater than about 50%, such as greater than about 60%, such as greater than about 70%, or greater than about 80%. In other embodiments, the oral bioavailability is between about 10 and about 90%, such as between about 20 and about 80%, such as between about 30 and about 70%, or between about 40 and about 60%.
[0074] Some compounds of formula (I) or pharma- ceutically acceptable salts thereof may be substrates for relevant transporters in the kidney.
[0075] Certain compounds of formula (I) or pharma- ceutically acceptable salts thereof may increase concentrations of bile acids in the intestine, liver, and serum without causing adverse gastrointestinal effects.
[0076] Some compounds of formula (I) or pharma- ceutically acceptable salts thereof may reduce the concentration of bile acids in the liver without causing gastrointestinal disorders such as diarrhea.
[0077] As used herein, the terms "treatment", "treat" and "treating" refer to ameliorating, alleviating, delaying the onset of, or inhibiting the progression of a disease or disorder, or one or more symptoms thereof, as described herein. In some embodiments, treatment may be administered after one or more symptoms have developed. In other embodiments, treatment may be administered in the absence of symptoms. For example, treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and / or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example to prevent or delay recurrence.
[0078] Suitable pharma- ceutically acceptable salts of the compounds of the invention are, for example, base addition salts of compounds of the invention which are sufficiently acidic, such as alkali metal salts (e.g., sodium or potassium salts), alkaline earth metal salts (e.g., calcium or magnesium salts), ammonium salts, or salts with an organic base which provides a physiologically acceptable cation, e.g., a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.
[0079] Some compounds of formula (I) or pharma- ceutically acceptable salts thereof may have chiral centers and / or geometric isomeric centers (E- and Z-isomers). It should be understood that the present invention encompasses all such optical isomers, diastereoisomers and geometric isomers that possess ASBT and / or LBAT inhibitory activity. The present invention also encompasses all tautomeric forms of compounds of formula (I) or pharma- ceutically acceptable salts thereof that possess ASBT and / or LBAT inhibitory activity. Certain compounds of formula (I) or pharma- ceutically acceptable salts thereof may exist in unsolvated and solvated forms, such as hydrated forms. It should be understood that the present invention encompasses all such solvated forms that possess ASBT and / or LBAT inhibitory activity.
[0080] In another aspect, the present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) or a pharma-ceutically acceptable salt thereof and one or more pharma-ceutically acceptable excipients.The excipients may include, for example, fillers, binders, disintegrants, lubricants and glidants.In general, the pharmaceutical composition may be prepared in a conventional manner using conventional excipients.
[0081] Examples of suitable fillers include, but are not limited to, dicalcium phosphate dihydrate, calcium sulfate, lactose (such as lactose monohydrate), sucrose, mannitol, sorbitol, cellulose, microcrystalline cellulose, dry starch, hydrolyzed starch, and pregelatinized starch. In certain embodiments, the filler is mannitol and / or microcrystalline cellulose.
[0082] Examples of suitable binders include, but are not limited to, starch, pregelatinized starch, gelatin, sugars (such as sucrose, glucose, dextrose, lactose and sorbitol), polyethylene glycol, waxes, natural and synthetic gums (such as gum arabic and gum tragacanth), sodium alginate, cellulose derivatives (such as hydroxypropyl methylcellulose (or hypromellose), hydroxypropyl cellulose and ethyl cellulose), and synthetic polymers (such as acrylic and methacrylic acid copolymers, methacrylic acid copolymers, methyl methacrylate copolymers, aminoalkyl methacrylate copolymers, polyacrylic acid / polymethacrylic acid copolymers, and polyvinylpyrrolidone (povidone)). In certain embodiments, the binder is hydroxypropyl methylcellulose (hypromellose).
[0083] Examples of suitable disintegrants include, but are not limited to, dry starch, modified starch (such as (partially) pregelatinized starch, sodium starch glycolate and sodium carboxymethyl starch), alginic acid, cellulose derivatives (such as sodium carboxymethylcellulose, hydroxypropylcellulose and low-substituted hydroxypropylcellulose (L-HPC)), and crosslinked polymers (such as carmellose, croscarmellose sodium, carmellose calcium and crosslinked PVP (crospovidone)). In a particular embodiment, the disintegrant is croscarmellose sodium.
[0084] Examples of suitable lubricants and glidants include, but are not limited to, talc, magnesium stearate, calcium stearate, stearic acid, glyceryl behenate, colloidal silica, aqueous silicon dioxide, synthetic magnesium silicate, micronized silicon oxide, starch, sodium lauryl sulfate, boric acid, magnesium oxide, wax (such as carnauba wax), hydrogenated oil, polyethylene glycol, sodium benzoate, polyethylene glycol, and mineral oil.In certain embodiments, the lubricant or glidant is magnesium stearate or colloidal silica.
[0085] The pharmaceutical composition may be conventionally coated with one or more coating layers.An enteric coating layer or a coating layer for delayed or targeted release of the compound of formula (I) or its pharma-ceutically acceptable salt is also contemplated.The coating layer may comprise one or more coating agents, and may optionally comprise a plasticizer and / or a pigment (or dye).
[0086] Examples of suitable coating agents include, but are not limited to, cellulose-based polymers (such as ethyl cellulose, hydroxypropyl methylcellulose (or hypromellose), hydroxypropyl cellulose, cellulose acetate phthalate, cellulose acetate succinate, hydroxypropyl methylcellulose acetate succinate, and hydroxypropyl methylcellulose phthalate), vinyl-based polymers (such as polyvinyl alcohol), and polymers based on acrylic acid and its derivatives (such as acrylic acid and methacrylic acid copolymers, methacrylic acid copolymers, methyl methacrylate copolymers, aminoalkyl methacrylate copolymers, polyacrylic acid / polymethacrylic acid copolymers, etc.). In certain embodiments, the coating agent is hydroxypropyl methylcellulose. In other embodiments, the coating agent is polyvinyl alcohol.
[0087] Examples of suitable plasticizers include, but are not limited to, triethyl citrate, glyceryl triacetate, tributyl citrate, diethyl phthalate, acetyl tributyl citrate, dibutyl phthalate, dibutyl sebacate, and polyethylene glycol. In certain embodiments, the plasticizer is polyethylene glycol.
[0088] Examples of suitable pigments include, but are not limited to, titanium dioxide, iron oxide (such as yellow, brown, red or black iron oxide), and barium sulfate.
[0089] The pharmaceutical composition may be in a form suitable for oral administration, parenteral injection (including intravenous, subcutaneous, intramuscular and intravascular injection), topical administration, rectal administration. In a preferred embodiment, the pharmaceutical composition is in a form suitable for oral administration, such as a tablet or capsule.
[0090] The dosage required for therapeutic or prophylactic treatment will depend on the route of administration, the severity of the disease, the age and weight of the patient, and other factors normally considered by the attending physician in determining the appropriate regimen and dosage level for an individual patient.
[0091] The amount of compound administered varies depending on the patient being treated and may vary from about 1 μg / kg body weight to about 50 mg / kg body weight per day. A unit dose form such as a tablet or capsule usually contains about 1 to about 250 mg of active ingredient, such as about 2.5 mg, or about 5 mg, or about 10 mg, or about 15 mg, such as about 1 to about 100 mg, or about 1 to about 50 mg, or about 1 to about 20 mg. The daily dose may be administered as a single dose or may be divided into 1, 2, 3 or more unit doses. The daily orally administered dose of the bile acid modulator is preferably within about 1 to about 5 mg, more preferably within about 1 to about 10 mg, such as within about 1 to about 15 mg, or about 1 to about 20 mg, preferably within about 0.1 to about 250 mg, more preferably within about 1 to about 100 mg.
[0092] In another aspect, the present invention relates to a compound of formula (I) or a pharma- ceutically acceptable salt thereof for use as a medicament.The present invention also relates to the use of a compound of formula (I) or a pharma- ceutically acceptable salt thereof as a medicament.
[0093] In another aspect, the present invention relates to a compound of formula (I) or a pharma- ceutically acceptable salt thereof for use in the treatment or prevention of any of the diseases listed herein. The present invention also relates to the use of a compound of formula (I) or a pharma- ceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prevention of any of the diseases listed herein. The present invention also relates to a method of treating or preventing any of the diseases listed herein in a subject, such as a man, comprising administering a therapeutically effective amount of a compound of formula (I) or a pharma- ceutically acceptable salt thereof to a subject in need of such treatment or prevention.
[0094] Combination therapy In one embodiment of the present invention, the compound of formula (I) or its pharmaceutically acceptable salt is administered in combination with at least one other therapeutically active agent, such as one, two, three or more other therapeutically active agents.The compound of formula (I) or its pharmaceutically acceptable salt and at least one other therapeutically active agent may be administered simultaneously, sequentially or separately.The therapeutically active agent suitable for combination with the compound of formula (I) includes, but is not limited to, any of the known active agents useful for treating any of the above-mentioned diseases, disorders and disorders.
[0095] In one embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with another ASBT inhibitor.Suitable ASBT inhibitors are described in WO93 / 16055, WO94 / 18183, WO94 / 18184, WO96 / 05188, WO96 / 08484, WO96 / 16051, WO97 / 33882, WO98 / 03818, WO98 / 07449, WO98 / 40375, WO99 / 35135, WO99 / 64409, WO99 / 64410, WO00 / 47568, WO No. 00 / 61568, No. WO00 / 38725, No. WO00 / 38726, No. WO00 / 38727, No. WO00 / 38728, No. WO00 / 38729, No. WO01 / 66533, No. WO01 / 6809 No. 6, WO02 / 32428, WO02 / 50051, WO03 / 020710, WO03 / 022286, WO03 / 022825, WO03 / 022830, WO03 / 061663 , WO03 / 091232, WO03 / 106482, WO2004 / 006899, WO2004 / 076430, WO2007 / 009655, WO2007 / 009656, WO2011 / 137135, WO2019 / 234077, WO2020 / 161216, WO2020 / 161217, German Patent No. 19825804, European Patent No. 864582, European Patent No. 4 Nos. 89423, 549967, 573848, 624593, 624594, 624595, 624596, 0864582, 1173205, 1535913 and 3210977, all of which documents are incorporated herein by reference in their entirety.
[0096] In another embodiment, the compound of formula (I) or its pharma- ceutically acceptable salt is administered in combination with a bile acid binder (also called bile resealing agent or resin), such as colesevelam, cholestyramine or colestipol.In a preferred embodiment of such combination, the bile acid binder is formulated for colonic release.Examples of such formulations are disclosed, for example, in WO 2017 / 138877, WO2017 / 138878, WO2019 / 032026 and WO2019 / 032027, all of which are incorporated herein by reference in their entirety.
[0097] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a DPP-IV inhibitor, including the gliptins, such as sitagliptin, vildagliptin, saxagliptin, linagliptin, gemigliptin, anagliptin, tenegliptin, alogliptin, trelagliptin, omarigliptin, evogliptin, gosogliptin, and dutogliptin, or a pharma- ceutically acceptable salt thereof.
[0098] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with an HMG CoA reductase inhibitor, such as fluvastatin, lovastatin, pravastatin, simvastatin, atorvastatin, pitavastatin, cerivastatin, mevastatin, rosuvastatin, bervastatin or dalvastatin, or a pharma- ceutically acceptable salt thereof.
[0099] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a cholesterol absorption inhibitor, such as ezetimibe, or a pharma- ceutically acceptable salt thereof.
[0100] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a PPAR alpha agonist, including fibrates, such as clofibrate, bezafibrate, ciprofibrate, clinofibrate, clofibrate, fenofibrate, gemfilozil, lonifibrate, and simfribrate, or a pharma- ceutically acceptable salt thereof.
[0101] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a PPAR gamma agonist, including thiazolidinediones, such as pioglitazone, rosiglitazone and lobeglitazone, or a pharma- ceutically acceptable salt thereof.
[0102] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a PPAR alpha / gamma dual agonist, including the glitazars, such as saroglitazar, aleglitazar, muraglitazar or tesaglitazar, or a pharma- ceutically acceptable salt thereof.
[0103] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a PPAR alpha / delta dual agonist, such as elafibranor.
[0104] In yet another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a pan PPAR agonist (i.e., a PPAR agonist with activity across all subtypes alpha, gamma and delta), such as IVA337.
[0105] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a farnesoid X receptor (FXR) modulator, including an FXR agonist such as cafestol, chenodeoxycholic acid, 6α-ethyl-chenodeoxycholic acid (obeticholic acid: INT-747), fexaramine, tropifexor, cilofexor, and MET409.
[0106] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a TGR5 receptor modulator, including a TGR5 agonist such as 6α-ethyl-23(S)-methylcholic acid (INT-777).
[0107] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a FXR / TGR5 dual agonist, such as INT-767.
[0108] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with ursodeoxycholic acid (UDCA).In yet another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with nor-ursodeoxycholic acid (nor-UDCA).
[0109] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with an FGF19 modulator, such as NGM282.
[0110] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with an FGF21 agonist, such as BMS-986036.
[0111] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with an integrin inhibitor, such as PLN-74809 and PLN-1474.
[0112] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a CCR2 / CCR5 inhibitor, such as cenicriviroc.
[0113] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a caspase protease inhibitor, such as emricasan.
[0114] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a galectin-3 inhibitor, such as GR-MD-02.
[0115] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a stearoyl-CoA desaturase (SCD) inhibitor, such as aramchol (arachidylamide cholanic acid).
[0116] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with an apoptosis signal-regulating kinase 1 (ASK1) inhibitor, such as selonsertib.
[0117] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a LOXL2 inhibitor, such as simtuzumab.
[0118] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with an ACC inhibitor, such as GS-0976.
[0119] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a thyroid hormone receptor-β agonist, such as MGL3196.
[0120] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a GLP-1 agonist, such as liraglutide.
[0121] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a glucagon-like peptide / glucagon receptor dual agonist, such as SAR425899.
[0122] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a mitochondrial pyruvate carrier inhibitor, such as MSDC-0602K.
[0123] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with an antioxidant, such as vitamin E.
[0124] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with an SGLT1 inhibitor, an SGLT2 inhibitor, or a dual SGLT1 / SGLT2 inhibitor. Examples of such compounds are dapagliflozin, sotagliflozin, canagliflozin, empagliflozin, LIK066, and SGL5213.
[0125] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a diacylglycerol O-acyltransferase 2 (DGAT2) inhibitor, such as DGAT2RX and PF-06865571.
[0126] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a fatty acid synthase (FASN) inhibitor, such as TVB-2640.
[0127] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with an AMP-activated protein kinase (AMPK) activator, such as PXL-770.
[0128] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a glucocorticoid receptor antagonist (GR), a mineralocorticoid receptor antagonist (MR), or a GR / MR dual antagonist. Examples of such compounds are MT-3995 and CORT-118335.
[0129] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a cannabinoid receptor 1 (CB1) antagonist, such as IM102.
[0130] In another embodiment, the compound of formula (I) or a pharma- ceutical acceptable salt thereof is administered in combination with Klotho beta and a fibroblast growth factor receptor (FGFR) activator, such as MK-3655 (formerly known as NGM-313).
[0131] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a chemokine (cc motif) ligand 24 (CCL24) inhibitor, such as CM101.
[0132] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with an A3 antagonist such as PBF-1650.
[0133] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a P2x7 receptor antagonist, such as SGM1019.
[0134] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a P2Y13 receptor agonist, such as CER-209.
[0135] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a sulfated oxysterol, such as Dur-928.
[0136] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a leukotriene D4 (LTD4) receptor antagonist, such as MN-001.
[0137] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a type 1 natural killer T cell (NKT1) inhibitor, such as GRI-0621.
[0138] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with an anti-lipopolysaccharide (LPS) compound, such as IMM-124E.
[0139] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a VAP1 inhibitor, such as BI1467335.
[0140] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with an A3 adenosine receptor agonist, such as CF-102.
[0141] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a SIRT-1 activator, such as NS-20.
[0142] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a nicotinic acid receptor 1 agonist, such as ARI-3037MO.
[0143] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a TLR4 antagonist, such as JKB-121.
[0144] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a ketohexokinase inhibitor, such as PF-06835919.
[0145] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with an adiponectin receptor agonist, such as ADP-335.
[0146] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with an autotaxin inhibitor, such as PAT-505 and PF8380.
[0147] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a chemokine (cc motif) receptor 3 (CCR3) antagonist, such as bertilimumab.
[0148] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a chloride channel stimulator, such as cobiprostone and lubiprostone.
[0149] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a heat shock protein 47 (HSP47) inhibitor, such as ND-L02-s0201.
[0150] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a sterol regulatory element binding protein (SREBP) transcription factor inhibitor, such as CAT-2003 and MDV-4463.
[0151] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a biguanidine, such as metformin.
[0152] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with insulin.
[0153] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a glycogen phosphorylase inhibitor and / or a glucose-6-phosphatase inhibitor.
[0154] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a sulfonylurea, such as glipizide, glibenclamide and glimepiride.
[0155] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a meglitinide, such as repaglinide, nateglinide and ormiglitinide.
[0156] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a glucosidase inhibitor, such as acarbose or miglitol.
[0157] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a squalene synthase inhibitor, such as TAK-475.
[0158] In another embodiment, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered in combination with a PTPB1 inhibitor, such as trodasquemine, eltiprotafib, JTT-551 and claramine.
[0159] Preparation of compounds The compounds of the present invention can be prepared as free acids or pharma-ceutically acceptable salts thereof by the process described below. It is understood that throughout the following description of such processes, suitable protecting groups are added to and subsequently removed from various reactants and intermediates in a manner that is easily understood by those skilled in the art of organic synthesis, where appropriate. Conventional procedures for using such protecting groups, and examples of suitable protecting groups, are described, for example, in Greene's Protective Groups in Organic Synthesis by PGM Wutz and TW Greene, 4th Edition, John Wiley & Sons, Hoboken, 2006.
[0160] Common methods All solvents used were of analytical grade. Commercially available anhydrous solvents were routinely used for reactions. Starting materials were either obtained from proprietary sources or prepared according to literature procedures. Room temperature refers to 20-25°C. Compositions of solvent mixtures are given as volume percentages or volume ratios.
[0161] LCMS: Instrument name: Agilent 1290 infinity II Method A: Mobile phase A: 0.1% HCOOH in water:ACN (95:5), B:ACN; Flow rate: 1.5 mL / min; Column: ZORBAX XDB C-18 (50 x 4.6 mm) 3.5 μM Method B: Mobile phase A: 10 mM NH4HCO3 in water, B: ACN; Flow rate: 1.2 mL / min; Column: XBridge C8 (50 x 4.6 mm), 3.5 μM Method C: Mobile phase A: 0.1% HCOOH in water:ACN (95:5), B:ACN; Flow rate: 1.5 mL / min; Column: ATLANTIS dC18 (50 x 4.6 mm), 5 μM Method D: Mobile phase A: 10 mM NH4OAc in water, B: ACN; Flow rate: 1.2 mL / min; Column: Zorbax Extend C18 (50 x 4.6 mm) 5 μM Method E: Mobile phase A: 0.1% TFA in water: ACN (95:5), B: 0.1% TFA in ACN; Flow rate: 1.5 mL / min; Column: XBridge C8 (50 x 4.6 mm), 3.5 μM Method F: Mobile phase A: 0.1% TFA in water, B: 0.1% TFA in ACN; Flow rate: 0.8 mL / min; Column: ZORBAX ECLIPSE PLUS C18 (50×2.1 mm), 1.8 μm Method G: Mobile phase A: 0.1% TFA in water, B: 0.1% TFA in ACN; Flow rate: 0.8 mL / min; Column: Acquity UPLC BEH C18 (2.1 x 50 mm), 1.7 μm Method H: Mobile phase A: 10mM NH4OAc, B: 100% ACN; Flow rate: 0.8mL / min; Column: Acquity UPLC BEH C18(2.1×50)mm; 1.7μm Method I: Mobile phase A: 0.1% HCOOH in water:ACN (95:5), B:ACN; Flow rate: 0.8 mL / min; Column: ZORBAX ECLIPSE PLUS C18 (2.1 x 50) mm, 1.8 μm Method J: Mobile phase A: 0.1% TFA in water, B: ACN; Flow rate: 10 mL / min; Column: Zorbax Extend C18 (50 x 4.6 mm), 5 μM
[0162] UPLC: Equipment name:Waters Acquity I Class Method A: Mobile phase A: 0.1% HCOOH in water, B: 0.1% HCOOH in ACN; Flow rate: 0.8 mL / min; Column: Acquity UPLC HSS T3 (2.1 x 50) mm; 1.8 μm
[0163] HPLC: Instrument Name: Agilent 1260 Infinity II series instruments tracked using % with UV detection (Maxplot) Method A: Mobile phase A: 10 mM NH4HCO3 in water, B: ACN; Flow rate: 10 mL / min; Column: XBridge C8 (50 x 4.6 mm, 3.5 μm) Method B: Mobile phase A: 0.1% TFA in water, B: 0.1% TFA in ACN; Flow rate: 2.0 mL / min; Column: XBridge C8 (50×4.6 mm, 3.5 μm) Method C: Mobile phase A: 10 mM NH4OAc in Milli-q water, B: ACN; Flow rate: 10 mL / min; Column: Phenomenex Gemini C18 (150 x 4.6 mm, 3.0 μm) Method D: Mobile phase A: 0.1% TFA in water, B: ACN; Flow rate: 10 mL / min; Column: ATLANTIS dC18 (250 x 4.6 mm, 5.0 μm) Method E: Mobile phase A: 0.1% TFA in water, B: ACN, flow rate: 2.0 mL / min; column: X-Bridge C8 (50 x 4.6 mm, 3.5 μm)
[0164] Chiral SFC: Equipment name: PIC SFC 10 (Analysis) The ratio of CO2 to co-solvent ranges between 60:40 and 80:20 Method A: Mobile phase: 0.5% isopropylamine in IPA; Flow rate: 3 mL / min; Column: YMC Amylose-SA (250 x 4.6 mm, 5 μm) Method B: Mobile phase: 0.5% isopropylamine in IPA; Flow rate: 3 mL / min; Column: Chiralpak AD-H (250 x 4.6 mm, 5 μm) Method C: Mobile phase: 20 mM ammonia in methanol; Flow rate: 3 mL / min; Column: YMC Cellulose-SC (250 x 4.6 mm, 5 μm) Method D: Mobile phase: methanol; Flow rate: 3 mL / min; Column: Lux A1 (250 x 4.6 mm, 5 μm) Method E: Mobile phase: 0.5% isopropylamine in methanol; Flow rate: 5 mL / min; Column: Lux C4 Method F: Mobile phase: 0.5% isopropylamine in methanol; Flow rate: 3 mL / min; Column: YMC Cellulose-SC Method G: Mobile phase: 0.5% isopropylamine in methanol; Flow rate: 3 mL / min; Column: Lux A1 Method H: Mobile phase: 0.5% isopropylamine in IPA; Flow rate: 3 mL / min; Column: Lux A1 (250 x 4.6 mm, 5 μm) Method I: Mobile phase: 0.5% isopropylamine in methanol; Flow rate: 3 mL / min; Column: Chiral CCS (250 x 4.6 mm, 5 μm) Method J: Mobile phase: 0.5% isopropylamine in IPA; Flow rate: 5 mL / min; Column: YMC Cellulose-SC AD-H (250 x 4.6 mm, 5 μm) Method K: Mobile phase: 0.5% isopropylamine in methanol; Flow rate: 4 mL / min; Column: (R,R)-Whelk-01 (250 x 4.6 mm, 5 μm) Method L: Mobile phase: 0.5% isopropylamine in IPA; Flow rate: 3 mL / min; Column: Chiralcel OX-H (250 x 4.6 mm, 5 μm) Method M: Mobile phase: 0.5% isopropylamine in IPA; Flow rate: 5 mL / min; Column: YMC Cellulose-SC (250 x 4.6 mm, 5 μm) Method N: Mobile phase: methanol, flow rate: 5 mL / min; column: Chiralcel OX-H (250 x 4.6 mm, 5 μm) Method O: Mobile phase: 0.1% isopropylamine in IPA:methanol (1:1), flow rate: 3 mL / min; column: Chiralpak AS-H (250 x 4.6 mm, 5 μm) Method P: Mobile phase: 0.5% isopropylamine in methanol; Flow rate: 3 mL / min; Column: Chiralpak AS-H (250 x 4.6 mm, 5 μm) Method Q: Mobile phase: IPA, flow rate: 3 mL / min; Column: Lux A1 (250 x 4.6 mm, 5 μm) Method R: Mobile phase: 0.1% isopropylamine in IPA:methanol (1:1), flow rate: 3 mL / min; column: Lux A1 (250 x 4.6 mm, 5 μm) Method S: Mobile phase: 0.5% isopropylamine in methanol; flow rate: 3 mL / min; column: Chiralpak OX-H (250 x 4.6 mm, 5 μm) Method T: Mobile phase: 0.5% isopropylamine in IPA, flow rate: 4 mL / min; column: YMC Cellulose-SB (250 x 4.6 mm, 5 μm) Method U: Mobile phase: 0.5% isopropylamine in methanol; flow rate: 3 mL / min; column: Chiralcel OZ-H (250 x 4.6 mm, 5 μm)
[0165] Preparative HPLC: Instrument name: Agilent 1290 Infinity II Method A: Mobile phase A: 0.1% TFA in water; Mobile phase B: 0.1% TFA in ACN; Flow rate: 2.0 mL / min; Column: X-Bridge C8 (50×4.6 mm, 3.5 μm) Method B: Mobile phase A: 10 mM NH4OAc in water; B: ACN; Flow rate: 35 mL / min; Column: X select C18 (30 x 150 mm, 5 μm) Method C: Mobile phase A: 10 mM NH4HCO3 in water; B: ACN; Flow rate: 10 mL / min; Column: XBridge C8 (50 x 4.6 mm, 3.5 μm) Method D: Mobile phase A: 0.1% HCOOH in water; B: ACN; flow rate: 10 mL / min; column: X-select C18 (30 × 150 mm, 5 μm)
[0166] Chiral Prep SFC: Device name: PIC SFC 100 and PSC SFC 400 The ratio of CO2 to co-solvent ranges between 60:40 and 80:20 Method A: Mobile phase: 0.5% isopropylamine in IPA; Flow rate: 3 mL / min; Column: YMC Amylose-SA (250 x 30 mm, 5 μm) Method B: Mobile phase: 0.5% isopropylamine in IPA; Flow rate: 3 mL / min; Column: Chiralpak AD-H (250 x 30 mm, 5 μm) Method C: Mobile phase: 20 mM ammonia in methanol; Flow rate: 3 mL / min; Column: YMC Cellulose-SC (250 x 30 mm, 5 μm) Method D: Mobile phase: methanol; Flow rate: 3 mL / min; Column: Chiral CCS (250 x 30 mm, 5 μm) Method E: Mobile phase: methanol; Flow rate: 3 mL / min; Column: Lux A1 (250 x 30 mm, 5 μm) Method F: Mobile phase: 0.5% isopropylamine in IPA; Flow rate: 3 mL / min; Column: Lux A1 (250 x 30 mm, 5 μm) Method G: Mobile phase: 0.5% isopropylamine in methanol; Flow rate: 3 mL / min; Column: Chiral CCS (250 x 30 mm, 5 μm) Method H: Mobile phase: 0.5% isopropylamine in methanol; flow rate: 4 mL / min; column: (R,R)-Whelk-01 (250 x 30 mm, 5 μm) Method I: Mobile phase: 0.5% isopropylamine in IPA, flow rate: 5 mL / min; column: YMC Cellulose-SC (250 x 30 mm, 5 μm) Method J: Mobile phase: 0.5% isopropylamine in IPA, flow rate: 3 mL / min; column: Chiralcel OX-H (250 x 30 mm, 5 μm) Method K: Mobile phase: 0.5% isopropylamine in methanol; Flow rate: 5 mL / min; Column: YMC Cellulose-SC (250 x 30 mm, 5 μm) Method L: Mobile phase: methanol, flow rate: 5 mL / min; column: Chiralcel OX-H (250 x 30 mm, 5 μm) Method M: Mobile phase: 0.5% isopropylamine in methanol; Flow rate: 3 mL / min; Column: Chiralpak AS-H (250 x 4.6 mm, 5 μm) Method N: Mobile phase: 0.1% isopropylamine in IPA:MeOH (1:1), flow rate: 3 mL / min; column: Chiralpak AS-H (250 x 4.6 mm, 5 μm) Method O: Mobile phase: 0.5% isopropylamine in methanol; Flow rate: 4 mL / min; Column: Chiralpak OX-H (250 x 4.6 mm, 5 μm)
[0167] Abbreviation ACN Acetonitrile BOC tert-butoxycarbonyl DABCO 1,4-diazabicyclo[2.2.2]octane DCM Dichloromethane DMA Dimethylacetamide DMF Dimethylformamide IPA Isopropyl Alcohol LCMS Liquid Chromatography-Mass Spectrometry HPLC High Performance Liquid Chromatography PE Petroleum Ether SFC Supercritical Fluid Chromatography TFA Trifluoroacetic acid THF Tetrahydrofuran TLC Thin Layer Chromatography UPLC Ultra High Performance Liquid Chromatography
[0168] The invention will now be illustrated by the following non-limiting examples. All documents and references cited are incorporated by reference. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0169] Working Example Intermediate 1 tert-Butyl (1-((4-fluorophenyl)amino)-1-oxohexan-2-yl)carbamate [ka] To a stirred solution of 2-((tert-butoxycarbonyl)amino)hexanoic acid (93.0 g, 402 mmol) in DMF (930 mL) at 0° C., triethylamine (112 mL, 804 mmol) was added dropwise. 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide (307 g, 483 mmol) was then added and the reaction mixture was stirred at 0° C. for 10 min. 4-Fluoroaniline (44.7 g, 402 mmol) was then added dropwise and the reaction mixture was stirred at room temperature for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with ice-cold water (500 mL) and the solid product was precipitated. The resulting solid was filtered, washed with water (2×100 mL) and dried under vacuum to give the title compound. The obtained crude was carried onto the next step as is without any further purification. Yield: 69% (90 g, pale yellow solid). MCMS: (Method K)225.2 (M + +H-Boc), Rt.2.66 minutes, 99.41% (maximum).
[0170] Intermediate 2 2-Amino-N-(4-fluorophenyl)hexanamide [ka] To a stirred solution of tert-butyl (1-((4-fluorophenyl)amino)-1-oxohexan-2-yl)carbamate (Intermediate 1; 90 g, 277 mmol) in 1,4-dioxane (900 mL) was added HCl in dioxane (4 M in 1,4-dioxane, 360 mL, 1280 mmol) at 0° C., and the reaction mixture was stirred at room temperature for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was concentrated in vacuo, and the resulting residue was basified with 10% NaHCO3 solution (400 mL). The aqueous layer was extracted with EtOAc (2×500 mL), and the combined organic layers were washed with water (2×100 mL) and dried over anhydrous Na2SO4. The organic portion was concentrated under vacuum, and the resulting crude was carried on to the next step as is without any further purification. Yield: 91% (60 g, light brown liquid). LCMS:(Method K)225.1(M + +H), Rt.1.97 minutes, 94.23% (maximum).
[0171] Intermediate 3 N1-(4-fluorophenyl)hexane-1,2-diamine [ka] To a stirred solution of 2-amino-N-(4-fluorophenyl)hexanamide (Intermediate 2; 60 g, 268 mmol) in THF (300 mL) was added borane dimethylsulfide (1 M in THF, 401 mL, 401 mmol) at 0° C., and the reaction mixture was heated at 75° C. for 24 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with methanol (200 mL) at 0° C., and the reaction mixture was heated at 75° C. for 2 h. The reaction mixture was concentrated in vacuum, and the resulting residue was dissolved in DCM (500 mL). The organic layer was washed with water (2×200 mL), dried over anhydrous Na2SO4, and then concentrated under vacuum. The resulting crude was purified by Isolera column chromatography (eluent: 5-20% MeOH in DCM; silica gel: 230-400 mesh) to give the title compound. Yield: 87% (53 g, brown liquid). LCMS:(Method K)211.2(M + +H), Rt.1.97 minutes, 92.44% (maximum).
[0172] Intermediate 4 2,4-Dibromo-N-(1-((4-fluorophenyl)amino)hexan-2-yl)-5-methoxybenzenesulfonamide [ka] To a stirred solution of N1-(4-fluorophenyl)hexane-1,2-diamine (Intermediate 3; 20 g, 95 mmol) in THF (200 mL), 2,4-dibromo-5-methoxybenzenesulfonyl chloride (41.6 g, 114 mmol) and triethylamine (39.8 mL, 285 mmol) were added at 0° C., and the reaction mixture was stirred at room temperature for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with EtOAc (400 mL). The organic layer was washed with water (2×100 mL) and dried over anhydrous Na2SO4. The organic portion was concentrated under vacuum, and the resulting crude was purified by Isolera column chromatography (eluent: 15% EtOAc / PE; silica gel: 230-400 mesh) to give the title compound. Yield: 86% (45.5 g, brown solid). 1 H NMR (400MHz, DMSO-d6): δ8.02-7.90(m,2H),7.55(s,1H),6.82(m,2H),6.31-6.26(m,2H),5.45-5.30(m,1H),3.90(s,3H),3.30-3. 15(m,1H),3.05-2.82(m,2H),1.60-1.40(m,1H),1.40-1.30(m,1H),1.30-1.20(m,1H),1.15-0.98(m,3H),0.73(t,J=8.80Hz,3H). LCMS: (Method A) 538.9(M + +H), Rt.3.04 minutes, 85.57% (maximum).
[0173] Intermediate 5 7-Bromo-3-butyl-5-(4-fluorophenyl)-8-methoxy-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide [ka] To a stirred solution of 2,4-dibromo-N-(1-((4-fluorophenyl)amino)hexan-2-yl)-5-methoxybenzene-sulfonamide (Intermediate 4; 45 g, 84 mmol) in DMF (450 mL) was added potassium carbonate (23.11 g, 167 mmol) and copper iodide (1.59 g, 8.36 mmol) at room temperature. The reaction mixture was degassed with nitrogen for 15 minutes. Tris[2-(2-methoxyethoxy)ethyl]amine (5.41 g, 16.72 mmol) was then added at room temperature and the reaction mixture was heated at 130° C. for 16 hours. After completion of the reaction (monitored by TLC), the reaction mixture was filtered through a Celite pad and the Celite pad was washed with EtOAc (50 mL). A portion of the filtrate was concentrated under vacuum. The resulting residue was diluted with EtOAc (400 mL) and the organic layer was washed with water (2×100 mL). The organic portion was dried over anhydrous Na2SO4 and the resulting crude was purified by Isolera column chromatography (eluent: 12% EtOAc / PE; silica gel: 230-400 mesh) to give the title compound. Yield: 55% (22.0 g, white solid). 1 H NMR(400MHz,DMSO-d6):δ7.57(s,1H),7.50-7.42(d,J=6.6Hz,2H),7.02(t,J=9.0Hz,2H),6.70-6.50(m,2H) ,4.38-4.22(m,1H),3.95(s,3H),3.33(m,1H),2.95-2.80(m,1H),1.65-1.15(m,6H),0.89(t,J=9.2Hz,3H). LCMS: (Method A) 455.0(M + -H), Rt.2.71 minutes, 95.55% (maximum).
[0174] Intermediate 6 7-Bromo-3-butyl-5-(4-fluorophenyl)-8-methoxy-2-(4-methoxybenzyl)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide [ka] To a stirred solution of 7-bromo-3-butyl-5-(4-fluorophenyl)-8-methoxy-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide (Intermediate 5; 5 g, 10.93 mmol) in N-methyl-2-pyrrolidone (50 mL), Cs2CO3 (7.12 g, 21.86 mmol) was added and the reaction mixture was stirred at 0° C. for 30 min. Then 1-(bromomethyl)-4-methoxybenzene (3.30 g, 16.40 mmol) was added and the reaction mixture was stirred at room temperature for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was filtered through a Celite pad and the Celite pad was washed with EtOAc (2×20 mL). The filtrate was concentrated under vacuum and the crude was purified by Isolera column chromatography (eluent: 15-20% EtOAc / PE; silica gel: 230-400 mesh) to give the title compound. Yield: 73% (6 g, off-white solid). LCMS: (Method A) 578.1(M + +H), Rt.3.49 minutes, 75.44%.
[0175] Intermediate 7 3-Butyl-5-(4-fluorophenyl)-8-hydroxy-2-(4-methoxybenzyl)-7-(methylthio)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide [ka] To a stirred solution of 7-bromo-3-butyl-5-(4-fluorophenyl)-8-methoxy-2-(4-methoxybenzyl)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide (Intermediate 6; 1 g, 1.23 mmol) in DMF (20 mL) was added sodium thiomethoxide (0.43 g, 6.14 mmol) at room temperature, and the resulting mixture was stirred at 100° C. for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with water (50 mL) and the aqueous layer was extracted with EtOAc (2×50 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous Na2SO4, and concentrated under vacuum. The crude material obtained was purified by Isolera column chromatography (eluent: 10-15% EtOAc / PE; silica gel: 230-400 mesh) to give the title compound. Yield: 66% (500 g, off-white solid). LCMS: (Method B) 529.1(M + -H), Rt.3.20 minutes, 85.70% (maximum).
[0176] Intermediate 8 tert-Butyl (E)-3-((3-butyl-5-(4-fluorophenyl)-2-(4-methoxybenzyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)acrylate [ka] To a stirred solution of 3-butyl-5-(4-fluorophenyl)-8-hydroxy-2-(4-methoxybenzyl)-7-(methylthio)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide (Intermediate 7; 60 mg, 0.113 mmol) in anhydrous THF (2 mL), tert-butyl propiolate (21.40 mg, 0.17 mmol) and DABCO (6.34 mg, 0.06 mmol) were added and the reaction mixture was stirred at room temperature for 2 h. After completion of the reaction (monitored by TLC), the reaction mixture was concentrated under vacuum and the resulting residue was partitioned between water (5 mL) and EtOAc (5 mL). The aqueous layer was extracted with EtOAc (2×5 mL) and the combined organic layers were washed with brine (5 mL) and then dried over anhydrous Na2SO4. The organic portion was concentrated under vacuum and the resulting crude material was purified by Isolera column chromatography (eluent: 20% EtOAc / PE; silica gel: 230-400 mesh) to give the title compound. Yield: 81% (60 mg, colorless gum). LCMS: (Method A) 601.1(M + - t Bu+H), Rt.3.44 min, 94.98% (maximum).
[0177] Intermediate 9 tert-Butyl (E)-3-((3-butyl-7-(ethylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)acrylate [ka] To a stirred solution of 3-butyl-7-(ethylthio)-8-hydroxy-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothia-diazepine 1,1-dioxide (50 mg, 0.12 mmol) in THF (5 mL) was added tert-butyl propiolate (16 mg, 0.12 mmol) and DABCO (14 mg, 0.12 mmol) and the reaction mixture was stirred at room temperature for 1 h. After completion of the reaction (monitored by TLC), the reaction mixture was concentrated under vacuum and the resulting residue was partitioned between water (5 mL) and EtOAc (5 mL). The aqueous layer was extracted with EtOAc (2×5 mL) and the combined organic layers were washed with brine (5 mL) and dried over anhydrous Na2SO4. The organic portion was concentrated under vacuum and the resulting crude material was purified by Isolera column chromatography (eluent: 20% EtOAc / PE; silica gel: 230-400 mesh) to give the title compound. Yield: 30% (20 mg, off-white solid). LCMS: (Method E) 477.1(M + - t Bu+H), Rt.3.23 min, 99.30% (maximum).
[0178] Intermediate 10 3-Butyl-7-chloro-5-(4-fluorophenyl)-8-methoxy-2,3-dihydro-1,5-benzothiazepin-4(5H)-one [ka] To a stirred solution of 3-butyl-7-chloro-8-methoxy-2,3-dihydro-1,5-benzothiazepin-4(5H)-one (6 g, 20.01 mmol) in 1-bromo-4-fluorobenzene (88 g, 500 mmol), copper(I) iodide (0.38 g, 2.00 mmol) and K2CO3 (5.53 g, 40.0 mmol) were added and the solution was purged with nitrogen for 20 minutes to degas. Tris[2-(2-methoxyethoxy)ethyl]amine (1.30 g, 4.00 mmol) was then added under nitrogen atmosphere and the resulting reaction mixture was heated at 135° C. for 40 hours. After completion of the reaction (monitored by UPLC), the reaction mixture was filtered through Celite and the Celite pad was washed with EtOAc (100 mL). The filtrate was concentrated under vacuum and the resulting crude material was purified by Isolera column chromatography (eluent: 15-20% EtOAc / PE; silica gel: 230-400 mesh) to give the title compound. Yield: 64% (5.5 g, off-white solid). LCMS: (Method E) 394.0(M + +H), Rt.3.19 minutes, 91.57%.
[0179] Intermediate 11 3-Butyl-7-chloro-5-(4-fluorophenyl)-8-methoxy-2,3,4,5-tetrahydro-1,5-benzothiazepine [ka] To a stirred solution of 3-butyl-7-chloro-5-(4-fluorophenyl)-8-methoxy-2,3-dihydro-1,5-benzothiazepin-4(5H)-one (Intermediate 10; 5.5 g, 13.96 mmol) in THF (60 mL) at 0° C., borane dimethylsulfide (140 mL, 140 mmol) was added dropwise and the reaction mixture was refluxed at 75° C. for 40 h. After completion of the reaction (monitored by UPLC), the reaction mixture was cooled to 0° C. and quenched with methanol (100 mL). The resulting solution was heated at 65° C. for 2 h, then cooled to room temperature and concentrated under vacuum. The obtained crude material was purified by Isolera column chromatography (eluent: 15-20% EtOAc / PE; silica gel: 230-400 mesh) to give the title compound. Yield: 77% (4.5 g, colorless liquid). LCMS: (Method A) 380.0(M + ) Rt.3.61 min, 90.76% (max).
[0180] Intermediate 12 3-Butyl-7-chloro-5-(4-fluorophenyl)-8-methoxy-2,3,4,5-tetrahydro-1,5-benzothiazepine 1,1-dioxide [ka] To a stirred solution of 3-butyl-7-chloro-5-(4-fluorophenyl)-8-methoxy-2,3,4,5-tetrahydro-1,5-benzothiazepine (Intermediate 11; 4.5 g, 11.84 mmol) in THF (45 mL) and water (10 mL), oxone (36.4 g, 59.2 mmol) was added and the reaction mixture was stirred at room temperature for 24 h. After completion of the reaction (monitored by TLC), the reaction mixture was filtered through a Buchner funnel and the filtrate was extracted with EtOAc (2×200 mL). The combined organic layers were washed with water (50 mL) and brine (50 mL), dried over anhydrous Na2SO4, and concentrated under vacuum. The crude material was purified by Isolera column chromatography (eluent: 10-13% EtOAc / PE; silica gel: 230-400 mesh) to give the title compound. Yield: 84% (4.1 g, colorless solid). LCMS: (Method A) 412.1(M + +H), Rt.2.83 minutes, 96.78% (maximum).
[0181] Intermediate 13 3-Butyl-7-(ethylthio)-5-(4-fluorophenyl)-8-hydroxy-2,3,4,5-tetrahydro-1,5-benzothiazepine 1,1-dioxide [ka] To a stirred solution of 3-butyl-7-chloro-5-(4-fluorophenyl)-8-methoxy-2,3,4,5-tetrahydro-1,5-benzothiazepine 1,1-dioxide (Intermediate 12; 0.5 g, 1.21 mmol) in NMP (10 mL) was added sodium ethanethiolate (0.51 g, 6.07 mmol) and the reaction mixture was heated at 100° C. for 12 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with ice-cold water (10 mL) and the aqueous layer was extracted with EtOAc (2×15 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous Na2SO4 and concentrated under vacuum. The crude material was purified by Isolera column chromatography (eluent: 30% EtOAc / PE; silica gel: 230-400 mesh) to give the title compound. Yield: 78% (400 mg, off-white solid). LCMS: (Method A) 424.1(M + +H), Rt.3.10 minutes, 81.97% (maximum).
[0182] Intermediate 14 tert-Butyl (E)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)acrylate [ka] To a stirred solution of 3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-8-hydroxy-2,3,4,5-tetrahydro-1,5-benzothiazepine 1,1-dioxide (Intermediate 13; 0.1 g, 0.236 mmol) in anhydrous THF (4 mL), tert-butyl propiolate (44.67 mg, 0.35 mmol) and DABCO (13.24 mg, 0.12 mmol) were added and the reaction mixture was stirred at room temperature for 2 h. After completion of the reaction (monitored by TLC), the reaction mixture was concentrated under vacuum and the resulting residue was partitioned between water (5 mL) and EtOAc (5 mL). The aqueous layer was extracted with EtOAc (2×5 mL). The combined organic layers were then washed with brine (5 mL), dried over anhydrous Na2SO4, and concentrated under vacuum. The resulting crude material was purified by Isolera column chromatography (eluent: 10-20% EtOAc / PE; silica gel: 230-400 mesh) to give the title compound. Yield: 42% (63 mg, colorless solid). 1 H NMR (400MHz, DMSO-d6): δ7.70(d,J=12.4Hz,1H),7.58(s,1H),7.20(d,J=6.0Hz,1H),7. 05(t,J=8.8Hz,2H),6.72-6.69(m,2H),5.45(d,J=12.0Hz,1H),4.28-4.12(m,1H),3.55 -3.45(m,1H),3.35-3.00(m,1H),3.22-3.12(m,1H),2.95(q,J=7.20Hz,2H),2.30-2.18 (m,1H),1.45(s,9H),1.42-1.25(m,6H),1.19(t,J=7.20Hz,3H),0.90(t,J=7.2Hz,3H). LCMS: (Method B) 494.0(M + - t Bu+H), Rt.3.03 min, 86.92% (maximum).
[0183] Separation of Enantiomers: tert-Butyl (S)-(E)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)acrylate and tert-butyl (R)-(E)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)acrylate [ka] The two enantiomers of the racemate of tert-butyl (E)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)acrylate were separated by chiral SFC (Method T). The material was concentrated under vacuum at 45° C. The first eluting fraction corresponded to enantiomer 1 and the second eluting fraction to enantiomer 2. The absolute configurations of the two enantiomers are unknown.
[0184] Enantiomer 1: Yield: 44.3% (45 mg, white solid). LCMS: (Method B) 494.0(M + - t Bu+H), Rt. 3.03 min, 98.55% (max). Chiral SFC: (Method T): Rt. 2.95 min, 98.59% (max). Enantiomer 2: Yield: 45.6% (47 mg, white solid). LCMS: (Method A) 494.0(M + - t Bu+H), Rt. 3.27 min, 96.96% (max). Chiral SFC: (Method T) Peak 2: Rt. 4.64 min, 98.72% (max).
[0185] Intermediate 15 3-Butyl-5-(4-fluorophenyl)-8-hydroxy-7-(methylthio)-2,3,4,5-tetrahydro-1,5-benzothiazepine 1,1-dioxide [ka] To a stirred solution of 3-butyl-7-chloro-5-(4-fluorophenyl)-8-methoxy-2,3,4,5-tetrahydro-1,5-benzothiazepine 1,1-dioxide (Intermediate 12; 1 g, 2.42 mmol) in DMF (12 mL) was added sodium thiomethoxide (0.85 g, 12.14 mol) at room temperature, and the resulting mixture was stirred at 100° C. overnight. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with water (20 mL) and the aqueous layer was extracted with EtOAc (2×20 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous Na2SO4, and concentrated under vacuum. The obtained crude material was purified by Isolera column chromatography (eluent: 30-35% EtOAc / PE; silica gel: 230-400 mesh) to give the title compound. Yield: 30% (0.300 g, off-white solid). 1 H NMR (400MHz, CDCl3): δ7.66(s,1H),7.27(s,1H),6.94-6.94(m,2H),6.62-6.64(m,2H),4.14-4.16(m,1H),3.41-3.4 2(m,1H),2.96-2.96(m,1H),2.50(s,1H),2.40(s,3H),1.37-1.37(m,4H),1.29-1.30(m,4H),0.95(t,J=7.20Hz,3H). LCMS: (Method A) 408.2(M + -H), Rt.2.54 minutes, 98.39% (max).
[0186] Intermediate 16 Ethyl (Z)-3-((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylate [ka] To a stirred solution of 3-butyl-5-(4-fluorophenyl)-8-hydroxy-7-(methylthio)-2,3,4,5-tetrahydro-1,5-benzothiazepine 1,1-dioxide (Intermediate 15; 50 mg, 0.122 mmol) in DMA (1 mL) at 0° C., NaH (60%, 15.87 mg, 0.397 mmol) was added in small portions and the reaction mixture was stirred at room temperature for 30 min. A solution of ethyl 3-bromo-2,2-difluoropropanoate (66.2 mg, 0.305 mmol) in DMF (1 mL) was then added dropwise at 0° C. and the reaction mixture was stirred at 90° C. for 6 h. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature and quenched with dilute hydrochloric acid (1.5 N, pH approx. 4, 10 mL). The aqueous layer was extracted with EtOAc (2×15 mL). The combined organic layers were then washed with water (10 mL) and brine (15 mL) and dried over anhydrous Na2SO4. The organic portion was filtered and concentrated under vacuum, and the crude material obtained was purified by Isolera column chromatography (eluent: 10-15% EtOAc / PE; silica gel: 230-400 mesh) to give the title compound. Yield: 73.5% (50 mg, off-white solid). LCMS: (Method A) 526.0(M + +H), Rt.3.37 minutes, 94.37% (maximum).
[0187] Separation of Enantiomers: Ethyl (S)-(Z)-3-((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylate and ethyl (R)-(Z)-3-((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylate [ka] The two enantiomers of the racemate of ethyl (Z)-3-((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylate (0.2 g, 0.38 mmol) were separated by chiral SFC instrumentation (Method G). The material was concentrated under vacuum at 40° C. The first eluting fraction corresponded to enantiomer 1 and the second eluting fraction to enantiomer 2. The absolute configurations of the two enantiomers are unknown.
[0188] Enantiomer 1: Yield: 26.7% (60 mg, white solid). LCMS: (Method B) 526.2(M + +H), Rt. 2.82 min, 87.82% (max). HPLC: (Method B) Rt. 6.04 min, 89.00% (max). Chiral HPLC (Method G): Rt. 2.78 min, 99.51% (max). Enantiomer 2: Yield: 31.2% (70 mg, white solid). LCMS: (Method B) 526.0(M + +H), Rt. 2.83 min, 91.65% (max). HPLC: (Method B) Rt. 6.28 min, 89.73% (max). Chiral HPLC (Method G): Rt. 3.95 min, 99.27% (max).
[0189] Intermediate 17 3-Butyl-7-(ethylthio)-8-hydroxy-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepine 1,1-dioxide [ka] To a solution of 3-butyl-7-chloro-8-methoxy-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepine 1,1-dioxide (1 g, 2.54 mmol) in DMF (25 mL) was added sodium ethanethiolate (1.07 g, 12.69 mmol) and the reaction mixture was stirred at 120° C. for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with ice-cold water (25 mL) and extracted with EtOAc (2×50 mL). The combined organic layers were washed with ice-cold water (50 mL) and brine (50 mL) and dried over anhydrous Na2SO4. The organic portion was concentrated under vacuum and the crude material was purified by Isolera column chromatography (eluent: 30% EtOAc / PE; silica gel: 230-400 mesh) to give the title compound. Yield: 52% (0.56 g, off-white solid). LCMS: (Method A) 406.1(M + +H), Rt.3.11 minutes, 96.20% (maximum).
[0190] Intermediate 18 Ethyl (Z)-3-((3-butyl-7-(ethylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylate [ka] To a stirred solution of 3-butyl-7-(ethylthio)-8-hydroxy-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepine 1,1-dioxide (Intermediate 17; 0.1 g, 0.247 mmol) in DMF (3 mL) at 0° C., NaH (60%, 0.04 g, 0.86 mmol) was added in small portions and the reaction mixture was stirred at 0° C. for 1 h. A solution of ethyl 3-bromo-2,2-difluoropropanoate (0.16 g, 0.74 mmol) in DMF (1 mL) was then added and the reaction mixture was heated at 90° C. for 8 h. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to 0° C., quenched with dilute hydrochloric acid (1.5 N, pH approx. 4, 10 mL) and diluted with HO (20 mL). The aqueous layer was extracted with EtOAc (2×15 mL). The combined organic layers were then washed with water (10 mL) and brine (15 mL) and dried over anhydrous Na2SO4. The organic portion was filtered and concentrated under vacuum, and the crude material obtained was purified by Isolera column chromatography (eluent: 20% EtOAc / PE; silica gel: 230-400 mesh) to give the title compound. Yield: 46% (0.06 g, white solid). LCMS: (Method A) 522.0(M + +H), Rt.3.41 minutes, 99.41% (maximum).
[0191] Intermediate 19 Ethyl (Z)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylate [ka] To a stirred solution of 3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-8-hydroxy-2,3,4,5-tetrahydro-1,5-benzothiazepine 1,1-dioxide (Intermediate 13; 0.1 g, 0.24 mmol) in DMF (3 mL) at 0° C., NaH (60%, 0.03 g, 0.83 mmol) was added in small portions and the reaction mixture was stirred at room temperature for 1 h. A solution of ethyl 3-bromo-2,2-difluoropropanoate (0.15 g, 0.71 mmol) in DMF (1 mL) was then added dropwise at 0° C. and the reaction mixture was stirred at 90° C. for 8 h. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature and quenched with dilute hydrochloric acid (1.5 N, pH approx. 4, 10 mL). The aqueous layer was extracted with EtOAc (2×15 mL). The combined organic layers were washed with water (10 mL) and brine (15 mL), then dried over anhydrous Na2SO4. The organic portion was filtered and concentrated under vacuum, and the resulting crude material was purified by Isolera column chromatography (eluent: 10-15% EtOAc / PE; silica gel: 230-400 mesh) to give the title compound. Yield: 45.2% (0.06 g, colorless solid). LCMS: (Method E) 540.1(M + +H), Rt.2.86 minutes, 95.92% (maximum).
[0192] Intermediate 20 7-Bromo-3-butyl-5-(4-fluorophenyl)-8-methoxy-2-methyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide [ka] To a stirred solution of 7-bromo-3-butyl-5-(4-fluorophenyl)-8-methoxy-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide (Intermediate 5; 5.8 g, 12.68 mmol) in N-methyl-2-pyrrolidone (24 mL), Cs2CO3 (8.26 g, 25.4 mmol) was added at 0° C., and the reaction mixture was stirred for 15 min. Methyl iodide (1.58 mL, 25.4 mmol) was then added dropwise at 0° C., and the reaction mixture was stirred at room temperature for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with EtOAc (100 mL), and the organic layer was washed with water (50 mL). The organic portion was dried over anhydrous Na2SO4 and concentrated under vacuum. The obtained crude was purified by Isolera column chromatography (eluent: 15% EtOAc / PE; silica gel: 230-400 mesh) to give the title compound. Yield: 75% (5.1 g, white solid). 1 H NMR (400MHz, DMSO-d6): δ7.47(s,1H),7.41(s,1H),6.98-6.94(m,2H),6.72-6.69(m,2H),3.99-3.92 (m,5H),3.40-3.22(m,1H),2.63(s,3H),1.68-1.60(m,1H),1.50-1.35(m,5H),0.95(t,J=7.2Hz,3H). LCMS: (Method A) 471.0(M + +H), Rt.2.89 minutes, 88.26% (maximum).
[0193] Intermediate 21 3-Butyl-5-(4-fluorophenyl)-8-hydroxy-2-methyl-7-(methylthio)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide [ka] To a stirred solution of 7-bromo-3-butyl-5-(4-fluorophenyl)-8-methoxy-2-methyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide (Intermediate 20; 2.0 g, 4.24 mmol) in DMF (20 mL), sodium thiomethoxide (1.48 g, 21.21 mmol) was added at room temperature and the reaction mixture was stirred at 100° C. for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature and quenched with water (20 mL). The aqueous layer was extracted with EtOAc (2×30 mL). The combined organic layers were washed with brine (10 mL) and dried over anhydrous Na2SO4. The organic portion was concentrated under vacuum and the resulting crude was purified by Isolera column chromatography (eluent: 15-20% EtOAc / PE; silica gel: 230-400 mesh) to give the title compound. Yield: 81% (1.6 g, light yellow solid). 1 H NMR (400MHz, DMSO-d6): δ10.72(s,1H),7.27(s,1H),6.97(t,J=11.2Hz,3H),6.55-6.50(m,2H),3.98-3.86(m ,2H),3.30-3.05(m,1H),2.42(s,3H),2.34(s,3H),1.70-1.45(m,2H),1.40-1.25(m,4H),1.00-0.80(m,3H). LCMS: (Method A) 425.2(M + +H), Rt.2.56 minutes, 90.64% (maximum).
[0194] Intermediate 22 Ethyl (Z)-3-((3-butyl-5-(4-fluorophenyl)-2-methyl-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylate [ka] To a stirred solution of 3-butyl-5-(4-fluorophenyl)-8-hydroxy-2-methyl-7-(methylthio)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide (Intermediate 21; 0.1 g, 0.24 mmol) in DMF (3 mL) at 0° C., NaH (60%, 0.03 g, 0.82 mmol) was added portionwise and the reaction mixture was stirred for 1 h at 0° C. A solution of ethyl 3-bromo-2,2-difluoropropanoate (0.15 g, 0.71 mmol) in DMF (1 mL) was then added dropwise at 0° C. and the reaction mixture was stirred at 90° C. for 8 h. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature, quenched with dilute hydrochloric acid (1.5N, pH 4, 10 mL) and diluted with H2O (10 nL). The aqueous layer was extracted with EtOAc (2 x 15 mL). The combined organic layers were then washed with water (10 mL) and brine (15 mL) and dried over anhydrous Na2SO4. The organic portion was filtered and concentrated under vacuum, and the crude material obtained was purified by Isolera column chromatography (eluent: 20% EtOAc / PE; silica gel: 230-400 mesh) to give the title compound. Yield: 45% (0.06 g, white solid). LCMS: (Method A) 541.1(M + +H), Rt.3.31 minutes, 94.37% (maximum).
[0195] Intermediate 23 3-Butyl-7-(ethylthio)-5-(4-fluorophenyl)-8-hydroxy-2-methyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide [ka] To a stirred solution of 7-bromo-3-butyl-5-(4-fluorophenyl)-8-methoxy-2-methyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide (Intermediate 20; 1.0 g, 2.12 mmol) in DMF (5 mL), sodium ethanethiolate (0.89 g, 10.61 mmol) was added at room temperature and the reaction mixture was stirred at 100° C. for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature and quenched with water (10 mL). The aqueous layer was extracted with EtOAc (2×20 mL). The combined organic layers were washed with brine (10 mL) and dried over anhydrous Na2SO4. The organic portion was concentrated under vacuum and the resulting crude material was purified by Isolera column chromatography (eluent: 15% EtOAc / PE; silica gel: 230-400 mesh) to give the title compound. Yield: 74% (0.8 g, light yellow solid). 1 H NMR(400MHz,DMSO-d6):δ10.66(s,1H),7.28(s,1H),7.10-6.90(m,3H),6.62-6.40(m,2H),4.02-3.80(m,2H),3.00-3.10 (m,1H),3.00-2.78(m,2H),2.43(s,3H),1.70-1.45(m,2H),1.45-1.28(m,4H),1.20(t,J=9.60Hz,3H),0.98-0.82(m,3H). LCMS: (Method K) 439.1(M + +H), Rt.3.07 minutes, 85.59% (maximum).
[0196] Intermediate 24 Ethyl (Z)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-2-methyl-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylate [ka] To a stirred solution of 3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-8-hydroxy-2-methyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide (Intermediate 23; 0.2 g, 0.45 mmol) in DMF (3 mL) at 0° C., NaH (60%, 0.06 g, 1.59 mmol) was added in small portions and the reaction mixture was stirred at room temperature for 1 h. A solution of ethyl 3-bromo-2,2-difluoropropanoate (0.29 g, 1.37 mmol) in DMF (1 mL) was then added dropwise and the reaction mixture was stirred at 90° C. for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature and quenched with dilute hydrochloric acid (1.5 N, pH approx. 4, 10 mL) and then diluted with HO (5 mL). The aqueous layer was extracted with EtOAc (2×10 mL). The combined organic layers were washed with water (10 mL), brine (15 mL), and then dried over anhydrous Na2SO4. The organic portion was filtered and concentrated under vacuum, and the crude obtained was purified by Isolera column chromatography (eluent: 10-15% EtOAc / PE; silica gel: 230-400 mesh) to give the title compound. Yield: 65.6% (170 mg, brown sticky solid). 1 H NMR (400MHz, DMSO-d6): δ7.84-7.76(m,1H),7.58(s,1H),7.17(s,1H),7.04(m,2H),6.71-6.67(m,2H),4.28(q,J=9.6Hz,2H),3.82(d,J=7.2Hz,1H ),3.26(s,2H),2.95(q,J=9.6Hz,3H),2.51(s,3H),2.48-2.47(m,1H),1. 60-1.53(m,2H),1.42-1.25(m,3H),1.20-1.16(m,5H),0.93-0.88(m,3H).
[0197] Separation of Enantiomers: Ethyl (S)-(Z)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-2-methyl-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylate and ethyl (R)-(Z)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-2-methyl-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylate [ka] The two enantiomers of the racemate of ethyl (Z)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-2-methyl-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylate (0.17 g, 0.30 mmol) were separated by chiral SFC instrumentation (Method H). The material was concentrated under vacuum at 40° C. The first eluting fraction corresponded to enantiomer 1 and the second eluting fraction to enantiomer 2. The absolute configurations of the two enantiomers are unknown.
[0198] Enantiomer 1: Yield: 45.5% (80 mg, pale yellow gum). LCMS: (Method A) 555.0 (M + +H), Rt. 2.92 min, 96.79% (max). Chiral HPLC: (Method K) Rt. 3.76 min, 99.62% (max). Enantiomer 2: Yield: 39.9% (70 mg, pale yellow gummy solid). LCMS: (Method A) 555.0 (M + +H), Rt. 2.92 min, 97.00% (max). Chiral HPLC: (Method K) Rt. 4.35 min, 99.47% (max).
[0199] Intermediate 25 2-((tert-butoxycarbonyl)amino)hexanoic acid [ka] To a solution of 2-aminohexanoic acid (25 g, 0.19 mol) in water (250 mL) and THF (250 mL), NaHCO3 (48 g, 0.57 mol) and BOC anhydride (52.2 mL, 0.23 mol) were added and the reaction mixture was stirred at room temperature for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was cooled, quenched and acidified with 1.5 N HCl. The reaction mixture was extracted with EtOAc (2 x 150 mL). The combined organic layers were washed with ice-cold water (150 mL) and brine (150 mL), dried over anhydrous Na2SO4 and concentrated to give the title compound. Yield: 45.5 g (crude, white solid). 1 H NMR(400MHz,DMSO-d6):δ5.10-4.98(m,1H),4.33-4.30(m,1H),1.95-1.81(m,1 H),1.75-1.55(m,1H),1.46(s,10H),1.45-1.31(m,4H),0.93(t,J=7.2Hz,3H). LCMS: (Method E) 132.2(M + -Boc+H), Rt.2.36 minutes, 99.98% (maximum).
[0200] Intermediate 26 tert-Butyl (1-oxo-1-(phenylamino)hexan-2-yl)carbamate [ka] To a stirred solution of 2-((tert-butoxycarbonyl)amino)hexanoic acid (Intermediate 25; 45.5 g, 0.196 mol) in DMF (150 mL), triethylamine (54.83 mL, 0.39 mol) was added and the reaction mixture was cooled to 0° C. 1-Propanephosphonic anhydride solution (50% in EtOAc; 75.1 g, 0.23 mol) and aniline (18 g, 0.196 mol) were added and the reaction mixture was stirred at room temperature for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with ice-cold water (50 mL) and diluted with EtOAc (200 mL). The aqueous layer was washed with ice-cold water (200 mL) and brine (200 mL), then dried over anhydrous Na2SO4 and filtered off. The organic portion was concentrated under vacuum to give the title compound. Yield: 82% (49.7 g, white solid). 1 H NMR (400MHz, DMSO-d6): δ9.93(s,1H),7.60(d,J=7.6Hz,2H),7.30(t,J=8.0Hz,2H),7.06-6. 99(m,2H),4.07-4.02(m,1H),1.63-1.56(m,2H),1.46-1.28(m,13H),0.86(t,J=6.8Hz,3H). LCMS:(Method E)207.0(M + -Boc+H), Rt.2.69 minutes, 91.20% (maximum).
[0201] Intermediate 27 2-Amino-N-phenylhexanamide [ka] To a solution of tert-butyl (1-oxo-1-(phenylamino)hexan-2-yl)carbamate (Intermediate 26; 49.7 g, 0.162 mol) in 1,4-dioxane (500 mL) at 0° C. was added a solution of HCl in 1,4-dioxane (4 M, 199 mL), and the reaction mixture was stirred at room temperature for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was concentrated under vacuum, and the resulting residue was quenched with saturated NaHCO3 solution. The aqueous layer was extracted with EtOAc (2×200 mL). The combined organic layers were washed with brine (200 mL) and dried over anhydrous Na2SO4. The organic portion was filtered and concentrated under vacuum to give the title compound. Yield: 95% (32 g, colorless gum). 1 H NMR(400MHz,DMSO-d6):δ10.20-9.66(m,1H),7.64(dd,J=4.8,2.4Hz,2H),7.32-7.27(m,2H),7 .06-7.02(m,1H),3.29-3.26(m,1H),1.67-1.61(m,1H),1.46-1.27(m,5H),0.89-0.85(m,3H). LCMS: (Method B) 207.2(M + +H), Rt.2.03 minutes, 84.36% (maximum).
[0202] Intermediate 28 N1-Phenylhexane-1,2-diamine [ka] To a solution of 2-amino-N-phenylhexanamide (Intermediate 27; 32 g, 0.15 mol) in THF (320 mL) at 0° C., borane dimethylsulfide (2 M solution in THF, 117 mL, 0.23 mol) was added and the reaction mixture was heated at 75° C. for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to 0° C., quenched with methanol (150 mL), and then heated at 60° C. for 2 h. The reaction mixture was cooled to room temperature and concentrated under vacuum. The resulting residue was partitioned between water (50 mL) and EtOAc (50 mL). The aqueous layer was extracted with EtOAc (2×250 mL). The combined organic layers were washed with water (250 mL) and brine (250 mL). The organic portion was dried over anhydrous Na2SO4, filtered, and concentrated under vacuum. The crude material obtained was purified by Isolera column chromatography (eluent: 10% EtOAc / PE; silica gel: 230-400 mesh) to give the title compound. Yield: 93% (28 g, yellow oil). LCMS: (Method B) 193.3 (M + +H), Rt.1.98 minutes, 76.9% (maximum).
[0203] Intermediate 29 2,4-Dibromo-5-methoxy-N-(1-(phenylamino)hexan-2-yl)benzenesulfonamide [ka] To a solution of 2,4-dibromo-5-methoxybenzenesulfonyl chloride (3.2 g, 8.79 mmol) in THF (50 mL) at 0° C., N1-phenylhexane-1,2-diamine (Intermediate 28; 1.3 g, 6.76 mmol) and triethylamine (2.8 mL, 20.3 mmol) were added and the reaction mixture was stirred at room temperature for 4 h. After completion of the reaction (monitored by TLC), the reaction mixture was concentrated under vacuum and the resulting residue was dissolved in EtOAc (60 mL). The organic layer was washed with water (50 mL) and brine (50 mL), dried over anhydrous Na2SO4, and concentrated under vacuum. The obtained crude material was purified by Isolera column chromatography (eluent: 18% EtOAc / PE; silica gel: 230-400 mesh) to give the title compound. Yield: 97% (3.5 g, brown gum). LCMS: (Method E) 521.0(M + +H), Rt.3.14 minutes, 93.57% (maximum).
[0204] Intermediate 30 7-Bromo-3-butyl-8-methoxy-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide [ka] To a solution of 2,4-dibromo-5-methoxy-N-(1-(phenylamino)hexan-2-yl)benzenesulfonamide (Intermediate 29; 3.5 g, 6.72 mmol) in DMF (30 mL) was added K2CO3 (1.73 g, 12.5 mmol) and copper powder (0.42 g, 6.72 mmol). The reaction mixture was degassed under N2 atmosphere for 5 min, and the reaction mixture was then heated at 115 °C for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with ice-cold water (25 mL) and the aqueous layer was extracted with a 1:1 mixture of EtOAc and PE (2 x 50 mL). The combined organic layers were washed with brine (30 mL), dried over anhydrous Na2SO4, and concentrated under vacuum. The crude material obtained was purified by Isolera column chromatography (eluent: 25% EtOAc / PE; silica gel: 230-400 mesh) to give the title compound. Yield: 51% (1.5 g, brown gum). LCMS: (Method A) 439.0 (M + +H), Rt.2.83 minutes, 82.06% (maximum).
[0205] Intermediate 31 7-Bromo-3-butyl-8-methoxy-2-methyl-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide [ka] To a stirred solution of 7-bromo-3-butyl-8-methoxy-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothia-diazepine 1,1-dioxide (Intermediate 30; 4.5 g, 10.24 mmol) in N-methyl-2-pyrrolidone (20 mL), Cs2CO3 (6.7 g, 20.5 mmol) was added followed by iodomethane (3.2 mL, 51.2 mmol) and the reaction mixture was stirred at room temperature for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with water (25 mL) and the aqueous layer was extracted with a mixture of EtOAc and PE (30%, 2 x 75 mL). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na2SO4 and concentrated under vacuum. The crude material obtained was carried onto the next step as is without any further purification. Yield: 4.5 g (crude, light brown solid). LCMS: (Method E) 452.8(M + +H), Rt.3.19 minutes, 95.26% (maximum).
[0206] Intermediate 32 3-Butyl-7-(ethylthio)-8-hydroxy-2-methyl-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide [ka] To a solution of 7-bromo-3-butyl-8-methoxy-2-methyl-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide (Intermediate 31; 0.3 g, 0.66 mmol) in N-methyl-2-pyrrolidone (5 mL), sodium ethanethiolate (0.27 g, 3.31 mmol) was added and the reaction mixture was stirred at 100° C. for 12 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with ice-cold water (25 mL) and the aqueous layer was extracted with EtOAc (2×50 mL). The combined organic layers were washed with ice-cold water (50 mL) and brine (50 mL) and dried over anhydrous Na2SO4. The organic portion was concentrated under vacuum and the resulting crude material was purified by Isolera column chromatography (eluent: 30% EtOAc / PE; silica gel: 230-400 mesh) to give the title compound. Yield: 69% (0.2 g, off-white solid). 1 H NMR (400MHz, DMSO-d6): δ7.63(s,1H),7.42(s,1H),7.23-7.21(m,2H),6.83(t,J=7.6Hz,1H),6.68-6.64(m,3H),4.05-4.01(m, 2H),3.23-3.21(m,1H),2.80(q,J=7.2Hz,2H),2.60(s,3H),1.57-1.31(m,6H),1.27(t,J=7.20Hz,3H),0.96(t,J=7.20Hz,3H). LCMS:(Method E)421.0(M + +H), Rt.3.04 minutes, 95.23% (maximum).
[0207] Intermediate 33 Ethyl (Z)-3-((3-butyl-7-(ethylthio)-2-methyl-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylate [ka] To a stirred solution of 3-butyl-7-(ethylthio)-8-hydroxy-2-methyl-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide (Intermediate 32; 0.2 g, 0.47 mmol) in DMF (10 mL) at 0° C., NaH (60%, 0.06 g, 1.54 mmol) was added in small portions and the reaction mixture was stirred at 0° C. for 30 min. A solution of ethyl 3-bromo-2,2-difluoropropanoate (0.26 g, 1.19 mmol) in DMF (1 mL) was then added and the reaction mixture was heated at 100° C. for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to 0° C., quenched with dilute hydrochloric acid (1.5 N, pH approx. 4) and diluted with HO (5 mL). The aqueous layer was extracted with EtOAc (2×15 mL). The combined organic layers were washed with water (10 mL), brine (15 mL), and then dried over anhydrous Na2SO4. The organic layer was filtered and concentrated under vacuum, and the crude material obtained was purified by Isolera column chromatography (eluent: 20% EtOAc / PE; silica gel: 230-400 mesh) to give the title compound. Yield: 63% (0.17 g, white solid). LCMS: (Method A) 537.2(M + +H), Rt.2.88 minutes, 94.83% (maximum).
[0208] Intermediate 34 Ethyl (Z)-3-((3-butyl-5-(4-fluorophenyl)-2-(4-methoxybenzyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylate [ka] To a stirred solution of 3-butyl-5-(4-fluorophenyl)-8-hydroxy-2-(4-methoxybenzyl)-7-(methylthio)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide (Intermediate 7; 0.1 g, 0.19 mmol) in DMF (3 mL), NaH (60%, 0.03 g, 0.66 mmol) was added in small portions and the reaction mixture was stirred at room temperature for 30 min. A solution of ethyl 3-bromo-2,2-difluoropropanoate (0.123 g, 0.565 mmol) in DMF (1 mL) was then added dropwise at 0° C. and the reaction mixture was stirred at 100° C. for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature and quenched with dilute hydrochloric acid (1.5 N, pH approx. 4, 10 mL). The aqueous layer was extracted with EtOAc (2×10 mL). The combined organic layers were washed with water (10 mL), brine (10 mL) and dried over anhydrous Na2SO4. The organic portion was filtered and concentrated under vacuum, and the resulting fraction was purified by Isolera column chromatography (eluent: 10-15% EtOAc / PE; silica gel: 230-400 mesh) to give the title compound. Yield: 39% (60 mg, colorless solid). LCMS: (Method B) 646.8(M + +H), Rt.2.98 minutes, 79.20% (maximum).
[0209] Intermediate 35 (Z)-3-((3-butyl-5-(4-fluorophenyl)-2-(4-methoxybenzyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylic acid [ka] To a stirred solution of ethyl (Z)-3-((3-butyl-5-(4-fluorophenyl)-2-(4-methoxybenzyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylate (Intermediate 34; 60 mg, 0.09 mmol) in a mixture of 1,4-dioxane and water (3:1, 4 mL), lithium hydroxide (4.44 mg, 0.18 mmol) was added and the reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with dilute hydrochloric acid (1.5 N, pH approx. 4, 10 mL) and the aqueous layer was extracted with EtOAc (2×15 mL). The combined organic layers were washed with water (10 mL), brine (15 mL), and then dried over anhydrous Na2SO4. The organic portion was filtered and concentrated under vacuum, and the crude material obtained was purified by Isolera column chromatography (eluent: 5-10% methanol:DCM; silica gel: 230-400 mesh) to give the title compound. Yield: 60% (40 mg, white solid). LCMS: (Method A) 617.0(M + -H), Rt.2.75 minutes, 86.22% (maximum).
[0210] Intermediate 36 tert-Butyl (E)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-2-(4-methoxybenzyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)acrylate [ka] To a stirred solution of 3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-8-hydroxy-2-(4-methoxybenzyl)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide (100 mg, 0.18 mmol) in anhydrous THF (4 mL), tert-butyl propiolate (34.7 mg, 0.27 mmol) and DABCO (10.30 mg, 0.09 mmol) were added and the reaction mixture was stirred at room temperature for 2 h. After completion of the reaction (monitored by TLC), the reaction mixture was concentrated and the resulting residue was partitioned between water (5 mL) and EtOAc (5 mL). The aqueous layer was extracted with EtOAc (2×5 mL). The combined organic layers were then washed with water (5 mL) and brine (5 mL) and dried over anhydrous Na2SO4. The organic portion was concentrated under vacuum and the resulting crude material was purified by Isolera column chromatography (eluent: 10-20% EtOAc / PE; silica gel: 230-400 mesh) to give the title compound. Yield: 45.3% (60 mg, off-white solid). LCMS: (Method A) 549.1(M + -PMB-H), Rt.3.92 minutes, 93.06% (maximum).
[0211] Example 1 (E)-3-((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)acrylic acid [ka] To a stirred solution of tert-butyl (E)-3-((3-butyl-5-(4-fluorophenyl)-2-(4-methoxybenzyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)acrylate (Intermediate 8; 60 mg, 0.09 mmol) in toluene (3 mL) at 0° C., triphenylamine (67.2 mg, 0.27 mmol) and TFA (0.11 mL, 1.46 mmol) were added and the reaction mixture was stirred at room temperature for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with cold water (5 mL) and the aqueous layer was extracted with ethyl acetate (2×5 mL). The combined organic layers were washed with water (5 mL) and brine (5 mL) and dried over anhydrous Na2SO4. The organic portion was filtered and concentrated under vacuum. The resulting crude material was purified by preparative HPLC purification (Method D) to give the title compound. Yield: 50% (22 mg, off-white solid). 1 H NMR(400MHz,DMSO-d6)δ12.3(s,1H),7.73(d,J=12.0Hz,1H),7.51(s,1H),7 .41(d,J=9.2Hz,1H),7.15(s,1H),7.03(t,J=8.8Hz,2H),6.72-6.69(m,2H), 5.41(d,J=12.4Hz,1H),4.31(m,1H),3.27(m,1H),2.50(m,1H),2.33(s,3H), 1.57-1.56(m,1H),1.43-1.32(m,3H),1.29-1.24(m,2H),0.91-0.88(m,3H). LCMS:(Method A)479.0(M + -H), Rt.2.80 minutes, 95.41% (maximum). HPLC: (Method E) Rt. 5.30 min, 97.48% (max).
[0212] Examples 2 and 3 (S)-(E)-3-((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)acrylic acid and (R)-(E)-3-((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)acrylic acid [ka] The two enantiomers of the racemate (E)-3-((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)acrylic acid (Example 1; 0.24 g, 0.49 mmol) were separated by chiral SFC (Method K). The material was concentrated under vacuum at 40° C. The first eluting fraction corresponds to enantiomer 1 and the second eluting fraction corresponds to enantiomer 2. The absolute configurations of the two enantiomers are unknown.
[0213] Enantiomer 1: Yield: 37.1% (90 mg, off-white solid). 1 H NMR(400MHz,DMSO-d6):δ12.43(brs,1H),7.72(d,J=12.4Hz,1H),7.50(s,1H),7 .42-7.41(m,1H),7.14(s,1H),7.03(t,J=8.8Hz,2H),6.72-6.68(m,2H),5.45(d, J=12.4Hz,1H),4.34-4.30(m,1H),3.38-3.32(m,1H),2.99-2.94(m,1H),2.33(s, 3H), 1.58-1.56(m, 1H), 1.47-1.40(m, 3H), 1.38-1.24(m, 2H), 0.99-0.98(m, 3H). LCMS: (Method B) 480.8(M + +H), Rt. 1.97 min, 97.91% (max). HPLC: (Method B) Rt. 5.29 min, 98.98% (max). Chiral HPLC: (Method H) Rt. 2.48 min, 99.79% (max). Enantiomer 2: Yield: 37.2% (90 mg, off-white solid). 1 H NMR(400MHz,DMSO-d6):δ12.62(bs,1H),7.72(d,J=12.4Hz,1H),7.50(s,1H),7.41-7.39(m,1H), 7.15(s,1H),7.03(t,J=8.8Hz,2H),6.72-6.69(m,2H),5.45(d,J=12.4Hz,1H),4.34-4.31(m,1H), 3.38-3.32(m,1H),2.99-2.94(m,1H),2.33(s,3H),1.57-1.56(m,1H),1.47-1.40(m,3H),1.38-1.24(m,2H),0.99-0.98(m,3H). LCMS: (Method B) 481.0(M + +H), Rt. 1.977 min, 98.47% (max). HPLC: (Method B) Rt. 5.29 min, 98.98% (max). Chiral HPLC: (Method H) Rt. 3.13 min, 99.55% (max).
[0214] Example 4 (E)-3-((3-butyl-7-(ethylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)acrylic acid [ka] To a stirred solution of tert-butyl (E)-3-((3-butyl-7-(ethylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)acrylate (Intermediate 9; 40 mg, 0.07 mmol) in DCM (5 mL) at 0° C., TFA (0.11 mL, 1.50 mmol) was added and the reaction mixture was stirred at room temperature for 2 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with cold water (5 mL) and the aqueous layer was extracted with DCM (2×5 mL). The combined organic layers were washed with water (5 mL) and brine (5 mL) and dried over anhydrous Na2SO4. The organic portion was filtered and concentrated under vacuum. The resulting crude material was purified by preparative HPLC purification (Method A) to give the title compound. Yield: 56% (10 mg, off-white solid). 1 H NMR(400MHz,DMSO-d6):δ12.28(s,1H),7.74(d,J=12.0Hz,1H),7.53(s,1H),7.41(d,J =9.2Hz,1H),7.25(s,1H),7.19(t,J=8.4Hz,2H),6.75(t,J=7.2Hz,1H),6.67(d,J=8.4 Hz,2H),5.44(d,J=12.4Hz,1H),4.39-4.35(m,1H),3.45-3.35(m,2H),2.98-2.92(m,2 H),1.65-1.55(m,1H),1.50-1.25(m,5H),1.19(t,J=7.20Hz,3H),0.9(t,J=7.6Hz,3H). LCMS: (Method B) 474.9(M + -H), Rt.2.03 minutes, 94.04% (maximum). HPLC: (Method E) Rt. 5.36 min, 95.06% (max).
[0215] Examples 5 and 6 (S)-(E)-3-((3-butyl-7-(ethylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)acrylic acid and (R)-(E)-3-((3-butyl-7-(ethylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)acrylic acid [ka] The two enantiomers of the racemate (E)-3-((3-butyl-7-(ethylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)acrylic acid (Example 4; 0.04 mg, 0.07 mmol) were separated by SFC (Method H). The material was concentrated under vacuum at 40° C. The first eluting fraction corresponded to enantiomer 1 and the second eluting fraction to enantiomer 2. The absolute configurations of the two enantiomers are unknown.
[0216] Enantiomer 1: Yield: 14% (5 mg, white solid). 1 H NMR(400MHz,DMSO-d6):δ12.30(bs,1H),7.74(d,J=12.4Hz,1H),7.53(s,1H),7.42 (d,J=9.6Hz,1H),7.24(s,1H),7.19(t,J=8.0Hz,2H),6.75(t,J=7.6Hz,1H),6.68(d ,J=8.4Hz,2H),5.44(d,J=12.4Hz,1H),4.38-4.35(m,1H),3.42(s,2H),2.98-2.93( m, 2H), 1.59-1.47 (m, 1H), 1.42-1.35 (m, 5H), 1.28-1.17 (m, 3H), 0.92-0.86 (m, 3H). LCMS: (Method A) 475.0(M + -H), Rt. 2.94 min, 93.38% (max). HPLC: (Method B) Rt. 5.36 min, 93.65% (max). Chiral HPLC (Method S): Rt. 2.60 min, 98.59% (max). Enantiomer 2: Yield: 13.16% (5 mg, white solid).1 H NMR(400MHz,DMSO-d6):δ12.28(bs,1H),7.74(d,J=12.4Hz,1H),7.53(s,1H),7.41( d,J=10.0Hz,1H),7.24(s,1H),7.19(t,J=8.0Hz,2H),6.75(t,J=7.6Hz,1H),6.68(d ,J=8.4Hz,2H),5.44(d,J=12.4Hz,1H),4.39-4.35(m,1H),3.35(s,2H),2.98-2.93( m,2H),1.61-1.42(m,2H),1.61-1.42(m,4H),1.24-1.17(m,3H),0.92-0.90(m,3H). LCMS: (Method A) 475.0(M + -H), Rt. 2.92 min, 91.85% (max). HPLC: (Method B) Rt. 5.43 min, 92.13% (max). Chiral HPLC (Method S): Rt. 3.5 min, 97.83% (max).
[0217] Example 7 (E)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)acrylic acid [ka] To a stirred solution of tert-butyl (E)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)acrylate (Intermediate 14; 63 mg, 0.12 mmol) in DCM (5 mL) at 0° C., TFA (0.04 mL, 0.57 mmol) was added and the reaction mixture was stirred at room temperature for 2 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with cold water (5 mL) and the aqueous layer was extracted with DCM (2×5 mL). The combined organic layers were washed with water (5 mL) and brine (5 mL) and dried over anhydrous Na2SO4. The organic portion was filtered and concentrated under vacuum. The resulting crude material was purified by Isolera column chromatography (eluent: 40-45% EtOAc / PE; silica gel: 230-400 mesh) to give the title compound. Yield: 70% (40 mg, colorless solid). 1 H NMR(400MHz,DMSO-d6):δ12.29(s,1H),7.75(d,J=12.4Hz,1H),7.57(s,1H),7.21(s, 1H),7.04(t,J=8.8Hz,2H),6.85-6.55(m,2H),5.50(d,J=12.4Hz,1H),4.32-4.15(m, 1H),3.60-3.42(m,1H),3.38-3.30(m,1H),3.25-3.05(m,1H),2.96(q,J=7.20Hz,2H) ,2.30-2.18(m,1H),1.50-1.25(m,6H),1.19(t,J=7.20Hz,3H),0.9(t,J=7.2Hz,3H). LCMS: (Method A) 494.1(M + +H), Rt.2.58 minutes, 95.43% (maximum). HPLC: (Method E) Rt. 5.68 min, 99.06% (max).
[0218] Examples 8 and 9 (S)-(E)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)acrylic acid and (R)-(E)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)acrylic acid [ka] To a stirred solution of tert-butyl (E)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)acrylate enantiomer 1 (Intermediate 14; 40 mg, 0.07 mmol) in DCM (5 mL) at 0° C., TFA (0.2 mL, 2.60 mmol) was added dropwise and the reaction mixture was stirred at room temperature for 2 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with cold water (5 mL) and the aqueous layer was extracted with DCM (2×5 mL). The combined organic layers were washed with water (5 mL) and brine (5 mL) and dried over anhydrous Na2SO4. The organic portion was filtered and concentrated under vacuum, and the resulting crude material was purified by Isolera column chromatography (eluent: 30-35% EtOAc / PE; silica gel: 230-400 mesh) to give enantiomer 1 of the title compound.
[0219] Enantiomer 2 of the title compound was obtained following a similar procedure starting from 47 mg of enantiomer 2 of intermediate 61. The absolute configurations of the two enantiomers are not known.
[0220] Enantiomer 1: Yield: 43.5% (16 mg, white solid). 1H NMR(400MHz,DMSO-d6):δ12.31(bs,1H),7.75(d,J=12.00Hz,1H),7.56(s,1H),7.02(s,1H),7.04(t,J=8.80Hz,2H),6.70-6.68(m,2H),4.21 (d,J=14.40Hz,1H),3.50(m,1H),3.16(s,1H),2.96(q,J=7.2Hz,2H),2.23(s,1H),1.40-1.24(m,8H),1.21-1.17(m,3H),0.91-0.82(m,3H). LCMS: (Method B) 494.1(M + +H), Rt. 3.00 min, 97.33% (max). HPLC: (Method B) Rt. 5.54 min, 97.66% (max). Chiral SFC: (Method H) Rt. 3.36 min, 99.77% (max). Enantiomer 2: Yield: 34.4% (16 mg, colorless solid). 1 H NMR(400MHz,DMSO-d6):δ12.29(bs,1H),7.75(d,J=12.4Hz,1H),7.56(s,1H),7.20(s,1H),7.04(t,J=8.4Hz,2H),6.70-6.67(m,2H),4.22-4.21( m,1H),3.51-3.48(m,1H),3.19-3.13(m,1H),2.96(q,J=7.2Hz,2H),2.2 5-2.23(m,1H),1.43-1.28(m,8H),1.26-1.19(m,3H),0.91-0.88(m,3H). LCMS: (Method B) 492.1(M + -H), Rt. 2.06 min, 95.79% (max). HPLC: (Method B) Rt. 5.54 min, 96.75% (max). Chiral SFC: (Method H): Rt. 2.65 min, 100% (max).
[0221] Example 10 (Z)-3-((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylic acid [ka] To a stirred solution of ethyl (Z)-3-((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylate (Intermediate 16; 50 mg, 0.09 mmol) in a mixture of 1,4-dioxane and H2O (3:1, 4 mL), lithium hydroxide (4.56 mg, 0.19 mmol) was added and the reaction mixture was stirred at room temperature for 1 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with dilute hydrochloric acid (1.5 N, pH approx. 4, 10 mL). The aqueous layer was extracted with EtOAc (2 x 15 mL). The combined organic layers were then washed with water (10 mL) and brine (15 mL) and dried over anhydrous Na2SO4. The organic portion was filtered and concentrated under vacuum, and the resulting crude material was purified by preparative HPLC purification (Method A) to give the title compound. Yield: 15% (7 mg, white solid). 1 H NMR (400MHz, DMSO-d6): δ7.59-7.53(m,2H),7.15(s,1H),7.03(t,J=8.80Hz,2H),6.66-6.63(m,2H),4.22-4.18(m ,1H),3.61-3.51(m,1H),3.24-3.03(m,2H),2.42(s,3H),2.34-2.24(m,1H),1.38-1.27(m,6H),0.91-0.88(m,3H). LCMS: (Method A) 496(M + -H), Rt. 2.98 min, 97.26% (max) HPLC: (Method E) Rt. 5.51 min, 96.62% (max).
[0222] Examples 11 and 12 (S)-(Z)-3-((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylic acid and (R)-(Z)-3-((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylic acid [ka] To a stirred solution of enantiomer 1 of ethyl (Z)-3-((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylate (Intermediate 16; 0.06 g, 0.11 mmol) in a mixture of 1,4-dioxane and water (4:1, 5 mL) at 0° C., lithium hydroxide (5.47 mg, 0.23 mmol) was added and the reaction mixture was stirred at room temperature for 1 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with dilute hydrochloric acid (1.5 N, 10 mL). The aqueous layer was extracted with EtOAc (2×15 mL). The combined organic layers were washed with water (10 mL) and brine (10 mL) and dried over anhydrous Na2SO4. The organic portion was filtered and concentrated in vacuo, and the resulting crude material was purified by preparative purification (Method A) to give the title compound.
[0223] Enantiomer 2 of the title compound was obtained following a similar procedure starting from 0.07 g of enantiomer 2 of intermediate 62. The absolute configurations of the two enantiomers are unknown.
[0224] Enantiomer 1: Yield: 34.6% (57 mg, white solid). 1 H NMR(400MHz,DMSO-d6):δ13.66(bs,1H),7.67-7.62(m,2H),7.16(s,1H),7.03(t,J=8.80Hz,2H),6.67-6.64(m,2H),4. 19(m,1H),3.51-3.47(m,1H),3.16-3.09(m,1H),2.42(s,3H),2.35-2.25(m,2H),1.38-1.25(m,6H),0.92-0.88(m,3H). LCMS:(Method K)498.1(M + +H), Rt. 2.44 min, 99.56% (max). HPLC: (Method E) Rt. 5.39 min, 98.31 % (max). Chiral HPLC (Method H): Rt. 3.26 min, 100% (max). Enantiomer 2: Yield: 44% (30 mg, white solid). 1 H NMR(400MHz,DMSO-d6):δ13.66(bs,1H),7.65-7.62(m,2H),7.16(s,1H),7.03(t,J=8.80Hz,2H),6.67-6.64(m,2H),4. 19(m,1H),3.51-3.48(m,1H),3.16-3.12(m,1H),2.42(s,3H),2.35-2.25(m,2H),1.38-1.29(m,6H),0.92-0.88(m,3H). LCMS:(Method K)498.2(M + +H), Rt. 2.44 min, 98.08% (max). HPLC: (Method E) Rt. 5.49 min, 97.07% (max). Chiral HPLC (Method H): Rt. 5.23 min, 98.58% (max).
[0225] Example 13 (Z)-3-((3-butyl-7-(ethylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylic acid [ka] To a stirred solution of ethyl (Z)-3-((3-butyl-7-(ethylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylate (Intermediate 18; 0.06 g, 0.11 mmol) in a mixture of 1,4-dioxane and water (3:2, 5 mL), lithium hydroxide (5.51 mg, 0.23 mmol) was added and the reaction mixture was stirred at room temperature for 1 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with dilute hydrochloric acid (1.5 N, 10 mL) and diluted with ice-cold water (10 mL). The aqueous layer was extracted with EtOAc (2×15 mL). The combined organic layers were then washed with water (10 mL) and brine (15 mL) and dried over anhydrous Na2SO4. The organic portion was filtered and concentrated under vacuum, and the resulting crude material was purified by Isolera column chromatography (eluent: 10% EtOAc / PE; silica gel: 230-400 mesh) to give the title compound. Yield: 35% (20 mg, white solid). 1 H NMR(400MHz,DMSO-d6):13.64(bs,1H),7.69(s,1H),7.64(s,1H),7.24(s,1H),7.18(t ,J=7.6Hz,2H),6.74(t,J=7.2Hz,1H),6.64(d,J=8.4Hz,2H),4.26-4.22(m,1H),3.51-3 .48(m,1H),3.38-3.25(m,1H),3.10-3.07(m,1H),3.00-2.95(m,2H),2.29-2.27(s,1H) ,1.40-1.38(m,2H),1.35-1.30(m,4H),1.24-1.20(m,3H),0.91-0.90(t,J=3.2Hz,3H). LCMS: (Method A) 492.1(M + -H), Rt.3.09 minutes, 99.89% (maximum). HPLC: (Method B) Rt. 5.64 min, 99.15% (max).
[0226] Examples 14 and 15 (S)-(Z)-3-((3-butyl-7-(ethylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylic acid and (R)-(Z)-3-((3-butyl-7-(ethylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylic acid [ka] The two enantiomers of the racemate (Z)-3-((3-butyl-7-(ethylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylic acid (Example 13; 90 mg, 0.18 mmol) were separated by chiral SFC (Method O). The material was concentrated under vacuum at 45° C. The first eluting fraction corresponded to enantiomer 1 and the second eluting fraction to enantiomer 2. The absolute configurations of the two enantiomers are unknown.
[0227] Enantiomer 1: Yield: 30.6% (28 mg, pale yellow solid). 1 H NMR(400MHz,DMSO-d6):δ7.53(s,1H),7.38-7.32(m,1H),7.21-7.16(m,3H),6.72(t,J=7.2Hz,1H),6.63(d,J=8.4Hz,2H),4.28-4.19(m,1H),3.51- 3.45(m,1H),3.33-3.26(m,1H),3.25-3.00(m,1H),2.97-2.94(m,2H),2. 49-2.28(m,1H),1.39-1.31(m,6H),1.29-1.19(m,3H),0.92-0.86(m,3H). LCMS:(Method J)494.1(M + +H), Rt. 2.63 min, 98.75% (max). HPLC: (Method E) Rt. 5.652 min, 98.45% (max). Chiral HPLC: (Method S) Rt. 2.94 min, 100% (max). Enantiomer 2: Yield: 26.8% (25 mg, pale yellow solid). 1H NMR(400MHz,DMSO-d6):δ7.56(s,1H),7.41-7.35(m,1H),7.22-7.16(m,3H),6.73(t,J=7.2Hz,1H),6.63(d,J=8.0Hz,2H),4.29-4.24(m,1H),3.51- 3.46(m,1H),3.32-3.26(m,1H),3.25-3.00(m,1H),2.98-2.94(m,2H),2. 49-2.28(m,1H),1.39-1.31(m,6H),1.29-1.19(m,3H),0.92-0.86(m,3H). LCMS:(Method J)494.1(M + +H), Rt. 2.63 min, 96.93% (max). HPLC: (Method E) Rt. 5.65 min, 96.54% (max). Chiral HPLC: (Method S) Rt. 3.85 min, 99.64% (max).
[0228] Example 16 (Z)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylic acid [ka] To a stirred solution of ethyl (Z)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylate (Intermediate 19; 0.06 g, 0.11 mmol) in a mixture of 1,4-dioxane and water (3:1, 4 mL), lithium hydroxide (5.32 mg, 0.22 mmol) was added at 0° C., and the reaction mixture was stirred at room temperature for 2 hours. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with dilute hydrochloric acid (1.5 N, 5 mL), and the aqueous layer was extracted with EtOAc (2×10 mL). The combined organic layers were then washed with water (10 mL) and brine (5 mL), and dried over anhydrous Na2SO4. The organic portion was filtered and concentrated under vacuum, and the resulting crude material was purified by preparative purification (Method D) to give the title compound. Yield: 44% (30 mg, white solid). 1 H NMR(400MHz,DMSO-d6):13.70(bs,1H),7.61-7.57(m,2H),7.18(s,1H),7.04(t,J=8.8Hz,2H),6.67-6.64(m,2H),4.22-4.18(m,1H), 3.51-3.47(m,1H),3.29-3.25(m,1H),3.16-3.13(m,1H),2.99-2.94(m,2H),2.28-2.24(m,1H),1.37-1.18(m,9H),0.91-0.86(m,3H). LCMS: (Method A) 510.0(M + -H), Rt.3.06 minutes, 97.50% (maximum). HPLC: (Method B) Rt. 5.64 min, 97.90% (max).
[0229] Examples 17 and 18 (S)-(Z)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylic acid and (R)-(Z)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylic acid [ka] The two enantiomers of the racemate (Z)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylic acid (Example 16; 70 mg, 0.14 mmol) were separated by chiral SFC (Method H). The material was concentrated under vacuum at 40° C. The first eluting fraction corresponded to enantiomer 1 and the second eluting fraction to enantiomer 2. The absolute configurations of the two enantiomers are unknown.
[0230] Enantiomer 1: Yield: 28.1% (20 mg, white solid). 1 H NMR(400MHz,DMSO-d6):δ13.66(bs,1H),7.66-7.62(m,2H),7.18(s,1H),7.04(t,J=9.20Hz,2H),6.67(t,J=4.40Hz,2H),4.20(m,1H),3.50(m ,1H),3.30(s,1H),3.13(s,1H),2.99-2.94(m,2H),2.24(s,1H),1.37- 1.31(m,4H),1.30-0.24(m,2H),1.22-1.19(m,3H),0.91-0.88(m,3H). LCMS: (Method A) 512.1(M + +H), Rt. 3.09 min, 98.50% (max). HPLC: (Method B) Rt. 5.70 min, 99.93% (max). Chiral HPLC (Method U): Rt. 2.54 min, 99.10% (max). Enantiomer 2: Yield: 35.7% (25 mg, white solid). 1H NMR(400MHz,DMSO-d6):δ13.72(bs,1H),7.61-7.57(m,2H),7.18(s,1H),7.04(t,J=8.80Hz,2H),6.68-6.64(m,2H),4.20(m,1H),3.50(m,1 H),3.18(m,1H),3.13(m,1H),2.99-2.94(m,2H),2.23(m,1H),1.37-1.31(m,4H),1.30-1.24(m,2H),1.22-1.17(m,3H),0.91-0.88(m,3H). LCMS: (Method A) 510.0(M + -H), Rt. 2.68 min, 97.68% (max). HPLC: (Method B) Rt. 5.70 min, 99.94% (max). Chiral HPLC (Method U): Rt. 3.60 min, 99.77% (max).
[0231] Example 19 (Z)-3-((3-butyl-5-(4-fluorophenyl)-2-methyl-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylic acid [ka] To a stirred solution of ethyl (Z)-3-((3-butyl-5-(4-fluorophenyl)-2-methyl-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylate (Intermediate 22; 0.06 g, 0.11 mmol) in a mixture of 1,4-dioxane and water (3:2, 5 mL), lithium hydroxide (5.32 mg, 0.222 mmol) was added and the reaction mixture was stirred at room temperature for 1 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with dilute hydrochloric acid (1.5 N, 10 mL) and the aqueous layer was extracted with EtOAc (2×15 mL). The combined organic layers were washed with water (10 mL) and brine (15 mL) and dried over anhydrous Na2SO4. The organic portion was filtered and concentrated under vacuum, and the resulting crude material was purified by Isolera column chromatography (eluent: 10% EtOAc / PE; silica gel: 230-400 mesh) to give the title compound. Yield: 35% (20 mg, white solid). 1 H NMR(400MHz,DMSO-d6):δ13.65(bs,1H),7.68-7.63(m,1H),7.52(s,1H),7.13(s,1H),7.02(t,J=8.8Hz,2H),6.69-6.65(m,2H),4.04-4.00(m ,1H),3.84-3.82(m,1H),3.30(s,1H),2.51(s,3H),2.41(s,3H),1.62- 1.59 (m, 1H), 1.51-1.50 (m, 1H), 1.35-1.24 (m, 4H), 0.93-0.90 (m, 3H). LCMS: (Method A) 511.1(M + -H), Rt.2.98 minutes, 99.79% (maximum). HPLC: (Method B) Rt. 5.53 min, 99.15% (max).
[0232] Examples 20 and 21 (S)-(Z)-3-((3-butyl-5-(4-fluorophenyl)-2-methyl-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylic acid and (R)-(Z)-3-((3-butyl-5-(4-fluorophenyl)-2-methyl-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylic acid [ka] The two enantiomers of the racemate (Z)-3-((3-butyl-5-(4-fluorophenyl)-2-methyl-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylic acid (Example 19; 0.19 g, 0.37 mmol) were separated by SFC (Method S). The material was concentrated under vacuum at 40° C. The first eluting fraction corresponds to enantiomer 1 and the second eluting fraction corresponds to enantiomer 2. The absolute configurations of the two enantiomers are unknown.
[0233] Enantiomer 1: Yield: 31.5% (60 mg, white solid). 1 H NMR(400MHz,DMSO-d6):δ13.70(bs,1H),7.80(m,1H),7.61(s,1H),7.19(s,1H),7.08(t,J=8.80Hz,2H),6.75-6.72(m,2H), 4.08(m,1H),3.88(s,1H),3.34(s,1H),2.58(s,3H),2.39(s,3H),1.67-1.64(m,2H),1.40-1.22(m,4H),0.98-0.96(m,3H). LCMS: (Method A) 513.1(M + +H), Rt. 2.97 min, 99.31% (max). HPLC: (Method B). Rt. 5.64 min, 99.56% (max). Chiral HPLC (Method S): Rt. 3.03 min, 100% (max). Enantiomer 2: Yield: 34.2% (65 mg, white solid). 1H NMR(400MHz,DMSO-d6):δ13.64(bs,1H),7.74-7.70(m,1H),7.54(s,1H),7.14(s,1H),7.02(t,J=8.80Hz,2H),6.69-6.66(m,2H), 4.03(m,1H),3.84-3.82(m,1H),3.33(s,1H),2.55(s,3H),2.41(s,3H),1.62-1.58(m,2H),1.52-1.34(m,4H),0.92-0.91(m,3H). LCMS: (Method A) 513.1(M + +H), Rt. 2.55 min, 99.87% (max). HPLC: (Method B) Rt. 5.46 min, 97.79% (max). Chiral HPLC (Method S): Rt. 3.23 min, 99.60% (max).
[0234] Examples 22 and 23 (S)-(Z)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-2-methyl-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylic acid and (R)-(Z)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-2-methyl-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylic acid [ka] To a stirred solution of enantiomer 1 of ethyl (Z)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-2-methyl-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylate (Intermediate 24; 0.08 g, 0.14 mmol) in a mixture of 1,4-dioxane and water (3:1, 4 mL), lithium hydroxide (6.91 mg, 0.29 mmol) was added and the reaction mixture was stirred at room temperature for 3 hours. After completion of the reaction (monitored by TLC), the reaction mixture was acidified with dilute hydrochloric acid (1.5 N, pH approx. 4) and diluted with ice-cold water (5 mL). The aqueous layer was extracted with EtOAc (2×10 mL). The combined organic layers were washed with water (5 mL), then brine (5 mL) and dried over anhydrous Na2SO4. The organic portion was filtered and concentrated under vacuum, and the crude material obtained was purified by Isolera column chromatography (eluent: 5-10% MeOH / DCM; silica gel: 230-400 mesh) to give the title compound.
[0235] Enantiomer 2 of the title compound was obtained following a similar procedure starting from 0.07 g of enantiomer 2 of intermediate 66. The absolute configurations of the two enantiomers are unknown.
[0236] Enantiomer 1: Yield: 45.6% (35 mg, yellow solid). 1 H NMR (400MHz, DMSO-d6): δ7.45-7.39(m,2H),7.15(s,1H),7.03(t,J=8.8Hz,2H),6.68-6.65(m,2H),4.02(d,J=15.20Hz) ,1H),3.82(d,J=4.40Hz,1H),2.97-2.92(m,2H),2.51(s,3H),1.62-1.50(m,2H),1.39-1.24(m,8H),0.92-0.89(m,3H). LCMS:(Method J)527.1(M + +H), Rt. 2.63 min, 99.41% (Max). HPLC: (Method E) Rt. 5.83 min, 98.86% (Max). Chiral HPLC: (Method K) Rt. 3.40 min, 99.67% (Max). Enantiomer 2: Yield: 44.5% (30 mg, pale yellow solid). 1 H NMR(400MHz,DMSO-d6):δ13.61(bs,1H),7.73(d,J=18.80Hz,1H),7.55(s,1H),7.16(s,1H),7.03(t,J=8.40Hz,2H),6.70-6.67(m,2H),4.03(m,1H) ,3.82(d,J=4.40Hz,1H),3.35(s,1H),2.98-2.92(m,2H),2.51(s,3H),1. 62-1.59(m,2H),1.38-1.35(m,4H),1.34-1.33(m,3H),0.99-0.97(m,3H). LCMS:(Method J)527.1(M + +H), Rt. 2.63 min, 99.32% (max). HPLC: (Method E) Rt. 5.83 min, 98.56% (max). Chiral HPLC: (Method K) Rt. 3.67 min, 98.83% (max).
[0237] Example 24 (Z)-3-((3-butyl-7-(ethylthio)-2-methyl-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylic acid [ka] To a stirred solution of ethyl (Z)-3-((3-butyl-7-(ethylthio)-2-methyl-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylate (Intermediate 33; 0.17 g, 0.32 mmol) in a mixture of 1,4-dioxane and water (3:2, 5 mL), lithium hydroxide (0.02 g, 0.63 mmol) was added and the reaction mixture was stirred at room temperature for 1 h. After completion of the reaction (monitored by TLC), the reaction mixture was acidified with dilute hydrochloric acid (1.5 N, pH approx. 4) and diluted with ice-cold water (5 mL). The aqueous layer was extracted with EtOAc (2×15 mL). The combined organic layers were washed with water (10 mL) and brine (10 mL), then dried over anhydrous Na2SO4. The organic portion was filtered and concentrated under vacuum, and the resulting crude material was purified by Isolera column chromatography (eluent: 10% EtOAc / PE; silica gel: 230-400 mesh) to give the title compound. Yield: 55% (90 mg, white solid). 1 H NMR(400MHz,DMSO-d6):δ13.66(bs,1H),7.72-7.67(m,1H),7.55(s,1H),7.2 1-7.16(m,3H),6.75(t,J=7.2Hz,1H),6.66(d,J=8.4Hz,2H),4.08-4.04(m,1 H),3.89-3.86(m,1H),3.34-3.32(m,1H),3.00-2.94(m,2H),2.51(s,3H),1. 62-1.59(m,2H),1.35-1.34(m,4H),1.24-1.21(m,3H),0.92(t,J=6.8Hz,3H). LCMS: (Method B) 509.1(M + +H), Rt.2.10 minutes, 97.97% (maximum). HPLC: (Method B) Rt. 5.70 min, 97.98% (max).
[0238] Examples 25 and 26 (S)-(Z)-3-((3-butyl-7-(ethylthio)-2-methyl-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylic acid and (R)-(Z)-3-((3-butyl-7-(ethylthio)-2-methyl-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylic acid [ka] The two enantiomers of the racemate (Z)-3-((3-butyl-7-(ethylthio)-2-methyl-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylic acid (Example 24; 80 mg, 0.16 mmol) were separated by SFC (Method H). The material was concentrated under vacuum at 40° C. The first eluting fraction corresponds to enantiomer 1 and the second eluting fraction corresponds to enantiomer 2. The absolute configurations of the two enantiomers are unknown.
[0239] Enantiomer 1: Yield: 19% (15 mg, white solid). 1 H NMR (400MHz, DMSO-d6): δ13.63(bs,1H),7.75-7.72(m,1H),7.56(s,1H),7. 25-7.17(m,3H),6.75(t,J=7.2Hz,1H),6.67(d,J=8.0Hz,2H),4.06-4.04(m, 1H),3.86-3.81(m,1H),3.38-3.29(m,1H),2.98-2.96(m,2H),2.48(s,3H), 1.64-1.53(m,2H),1.36-1.24(m,4H),1.23-1.19(m,3H),0.93-0.86(m,3H). LCMS: (Method A) 509.0(M + +H), Rt. 2.63 min, 98.91% (max). HPLC: (Method B) Rt. 5.70 min, 99.69% (max). Chiral HPLC (Method H): Rt. 2.13 min, 99.56% (max). Enantiomer 2: Yield: 12.3% (10 mg, white solid). 1 H NMR (400MHz, DMSO-d6): δ13.63(bs,1H),7.70-7.65(m,1H),7.54(s,1H),7. 21-7.17(m,3H),6.76(t,J=7.2Hz,1H),6.67(d,J=8.4Hz,2H),4.08-3.99(m, 1H),3.88-3.25(m,1H),3.38-3.29(m,1H),2.98-2.96(m,2H),2.48(s,3H), 1.64-1.53(m,2H),1.39-1.30(m,4H),1.24-1.19(m,3H),0.93-0.86(m,3H). LCMS: (Method A) 509.0(M + +H), Rt. 2.63 min, 97.95% (max). HPLC: (Method B) Rt. 5.75 min, 97.95% (max). Chiral HPLC (Method A): Rt. 2.93 min, 99.09% (max).
[0240] Example 27 (Z)-3-((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylic acid [ka] To a stirred solution of (Z)-3-((3-butyl-5-(4-fluorophenyl)-2-(4-methoxybenzyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylic acid (Intermediate 35; 40 mg, 0.06 mmol) in toluene (5 mL) at 0° C., triphenylamine (7.59 mg, 0.03 mmol) and TFA (14 μL, 0.12 mmol) were added and the reaction mixture was stirred at room temperature for 2 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with cold water (5 mL) and the aqueous layer was extracted with EtOAc (2×15 mL). The combined organic layers were washed with water (10 mL) and brine (15 mL) and dried over anhydrous Na2SO4. The organic portion was filtered and concentrated under vacuum, and the resulting crude material was purified by preparative purification (Method A) to give the title compound. Yield: 31.8% (10 mg, white solid). 1 H NMR(400MHz,DMSO-d6):δ7.55(s,2H),7.40(d,J=8.80Hz,1H),7.12(s,1H),7.02(t,J=8.80Hz,2H),6.69-6.66(m,2H),4.34-4.30(m, 1H),3.51-3.29(m,1H),2.95-2.83(m,1H),2.40(s,3H),1.57-1.56(m,1H),1.45-1.39(m,3H),1.33-1.24(m,2H),0.92-0.88(m,3H). LCMS:(Method A)499.0(M + +H), Rt.2.40 minutes, 96.93% (maximum). HPLC: (Method E) Rt. 5.29 min, 98.18% (max).
[0241] Examples 28 and 29 (S)-(Z)-3-((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylic acid and (R)-(Z)-3-((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylic acid [ka] The two enantiomers of the racemate (Z)-3-((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylic acid (Example 27) were separated by chiral SFC. The material was concentrated under vacuum at 40° C. The first eluting fraction corresponds to enantiomer 1 and the second eluting fraction corresponds to enantiomer 2. The absolute configurations of the two enantiomers are unknown.
[0242] Example 30 (E)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)acrylic acid [ka] To a stirred solution of tert-butyl (E)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-2-(4-methoxybenzyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)acrylate (Intermediate 36; 30 mg, 0.05 mmol) in toluene (2 mL) at 0° C., triphenylamine (32.9 mg, 0.13 mmol) was added followed by TFA (55.1 μL, 0.72 mmol) and the reaction mixture was stirred at room temperature for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with cold water (5 mL) and the aqueous layer was extracted with DCM (2×5 mL). The combined organic layers were washed with water (5 mL) followed by brine (5 mL) and dried over anhydrous Na2SO4. The organic portion was filtered and concentrated under vacuum, and the crude material obtained was purified by Isolera column chromatography (eluent: 13-15% EtOAc / PE; silica gel: 230-400 mesh) to give the title compound. Yield: 53% (12 mg, off-white solid). 1 H NMR(400MHz,DMSO-d6):δ12.28(bs,1H),7.73(d,J=12.00Hz,1H),7.51(s,1H),7.44(d,J=9.20Hz, 1H),7.18(s,1H),7.04(t,J=8.40Hz,2H),6.73-6.69(m,2H),5.43(d,J=12.4Hz,1H),4.33(m,1H), 3.34(s,2H),2.93(q,J=7.2Hz,2H),1.57(m,1H),1.50-1.31(m,5H),1.26-1.20(m,3H),0.91-0.89(m,3H). LCMS:(Method A)493.0(M + -H), Rt.2.89 minutes, 97.67% (maximum). HPLC: (Method B) Rt. 5.37 min, 97.40% (max).
[0243] Examples 31 and 32 (S)-(E)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)acrylic acid and (R)-(E)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)acrylic acid [ka] The two enantiomers of the racemate of (E)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)acrylic acid (Example 30) were separated by chiral SFC (Method K). The material was concentrated under vacuum at 45° C. The first eluting fraction corresponds to Enantiomer 1 and the second eluting fraction corresponds to Enantiomer 2. The absolute configurations of the two enantiomers are unknown.
[0244] Enantiomer 1: Yield: 31% (28 mg, pale yellow solid). 1 H NMR(400MHz,DMSO-d6):δ12.41(bs,1H),7.71(d,J=12.0Hz,1H),7.51(s,1H),7.48-7.44(m,1H),7.18(s,1H),7.04(t,J=8.8Hz,2H),6.73-6.69( m,2H),5.43(d,J=12.4Hz,1H),4.35-4.33(m,1H),2.97-2.91(m,3H),1.5 7-1.56(m,1H),1.46-1.26(m,6H),1.19-1.18(m,3H),0.91-0.88(m,3H). LCMS: (Method A) 493.2 (M+_H), Rt. 2.92 min, 98.79% (max). HPLC: (Method B) Rt. 5.38 min, 98.11% (max). Chiral HPLC: (Method K) Rt. 2.24 min, 99.56% (max). Enantiomer 2: Yield: 27% (25 mg, pale yellow solid). 1H NMR (400MHz, DMSO-d6): δ12.29(bs,1H),7.72(d,J=12.0Hz,1H),7.51(s,1H),7.48-7.44(m,1H),7.18(s,1H),7.04(t,J=8.8Hz,2H),6.73-6.70( m,2H),5.43(d,J=12.4Hz,1H),4.35-4.31(m,1H),2.96-2.91(m,3H),1.5 7-1.56(m,1H),1.44-1.26(m,6H),1.24-1.16(m,3H),0.91-0.88(m,3H). LCMS: (Method A) 493.1 (M+_H), Rt. 2.93 min, 97.34% (max). HPLC: (Method B) Rt. 5.38 min, 96.08% (max). Kirar HPLC: (Method K) Rt. 2.73 min, 99.36% (max).
[0245] Biotechnology IBAT(h / m)アッセイプロトコル 10,000 cells (human or mouse IBAT overexpressing cells) were seeded in 96-well plates (Corning CLS3809) in 200 μL of MEM-alpha medium (Gibco 12571-063) supplemented with 10% FBS (Gibco 10438026) containing puromycin (Gibco A1113803) (10 mg / mL) and incubated for 48 hours at 37° C. in 5% CO2. After incubation, the medium was decanted from the wells and the cells were washed twice with 300 μL of MEM alpha basal medium (without FBS). After each decantation of the MEM alpha basal medium, the plate was tapped on a paper towel to ensure maximum removal of residual medium. Dilutions of test inhibitors prepared in DMSO (Sigma D2650) (maximum test concentration 10 μM, 3-fold serial dilutions, 10 points) were added to an incubation mix (maintaining a final DMSO concentration of 0.2%) containing 0.25 μM 3H-taurocholic acid (ARC ART-1368) and 5 μM cold taurocholic acid (Sigma T4009). 50 μL of incubation mix containing the test inhibitor was then added to the wells (in duplicate) and the plate was incubated for 20 min in a CO2 incubator at 37°C. After incubation, the reaction was stopped by keeping the plate on ice-water mix for 2-3 min, after which the incubation mix was completely aspirated from the wells. Wells were washed twice with 250 μL of cold unlabeled 1 mM taurocholate dissolved in HEPES (Gibco 15630080) buffered (10 mM) HBSS (Gibco 14175079), pH 7.4. Plates were tapped on paper towels after each wash to remove blocking buffer. Maximum removal of buffer was ensured.
[0246] 100 μL of MicroScint-20 (PerkinElmer 6013621) was added to the wells and kept at room temperature overnight, after which the plates were read on a PerkinElmer TopCount NXT™ Microplate Scintillation and Luminescence Counter following the 3H test protocol (set at a read time of 120 seconds per well).
[0247] LBAT(h / m) assay protocol 20,000 cells (human or mouse IBAT overexpressing cells) were seeded in 96-well plates (Corning CLS3809) in 100 μL of MEM-alpha medium (Gibco 12571-063) supplemented with 10% FBS (Gibco 10438026) containing Geneticin (Gibco 10131-027) (1 mg / mL) and incubated for 24 hours at 37° C. in 5% CO2. After incubation, the medium was decanted from the wells and the cells were washed twice with 300 μL of MEM alpha basal medium (without FBS). After each decantation of the MEM alpha basal medium, the plate was tapped on a paper towel to ensure maximum removal of residual medium.
[0248] For human LBAT, incubation mixes were prepared by adding test inhibitor dilutions (10-fold serial three-fold dilutions in DMSO (Sigma D2650)) in MEM alpha (without FBS) containing 0.3 μM 3H-taurocholic acid (ARC ART-1368) and 7.5 μM cold taurocholic acid (Sigma T4009) (maintaining a final DMSO concentration of 0.2%). For mouse LBAT, incubation mixes were prepared by adding test inhibitor dilutions (10-fold serial three-fold dilutions in DMSO) in MEM alpha (without FBS) containing 0.3 μM 3H-taurocholic acid and 25 μM cold taurocholic acid, maintaining a final DMSO concentration of 0.2%.
[0249] 50 μL of incubation mix containing the test inhibitor was then added to the wells (in duplicate) and the plate was incubated for 20 minutes in a CO2 incubator at 37°C. After incubation, the reaction was stopped by holding the plate on ice-water mix for 2-3 minutes, after which the incubation mix was completely aspirated from the wells. The wells were washed twice with 250 μL of chilled unlabeled 1 mM taurocholate dissolved in HEPES (Gibco 15630080) buffered (10 mM) HBSS (Gibco 14175079) (pH 7.4). The plate was tapped on a paper towel after each wash to ensure maximum removal of blocking buffer.
[0250] 100 μL of MicroScint-20 (PerkinElmer 6013621) was added to the wells and kept at room temperature overnight, after which the plates were read on a PerkinElmer TopCount NXT™ Microplate Scintillation and Luminescence Counter following the 3H test protocol (normal plate configuration, 120 second read time per well).
[0251] Bidirectional permeability assay (Caco-2 cells) Caco-2 cells (Evotec) were seeded at a density of 70,000 cells / well in Millicell® 24-well cell culture insert plates and maintained in an incubator (37° C., 5% CO2, 95% RH) for 21 days, with medium changed every other day.
[0252] Stock solutions (10 mM) of test compounds, atenolol (low permeability marker), propranolol (high permeability marker) and digoxin (substrate of P-gp transport pathway) were prepared in dimethyl sulfoxide (DMSO). Intermediate stock solutions (1 mM) were prepared by diluting 10 μL of 10 mM master stock solution with 90 μL of undiluted DMSO. Working stock solutions (10 μM) were prepared by diluting 50 μL of 1 mM solution with 4950 μL of FaSSIF buffer. After addition of compounds to FaSSIF, samples were subjected to sonication for 2 hours and centrifuged at 4000 RPM at 37° C. for 30 minutes. 4 mL of the resulting supernatant was used directly in the assay. The final DMSO concentration in the transport experiments was 1%.
[0253] On the day of the assay, Caco-2 monolayers were washed twice with transport buffer (HBSS, pH 7.4) and preincubated for 30 min in an incubator (37 °C, 5% CO2, 95% RH). The electrical resistance of the monolayers was measured with a Millicell®-ERS system. It was 350 ohm cm 2 Monolayers with larger transepithelial electrical resistance (TEER) values were selected for the assay.
[0254] The assay was performed in the absorptive (A2B) and secretory (B2A) directions. Transport experiments were initiated by adding compound-based transport assay buffer (FaSSIF buffer prepared in HBSS) to the donor compartments (upper chamber AB; basolateral chamber BA) in duplicate (n=2) wells. Drug-free HBSS buffer (pH 7.4) containing 1% bovine serum albumin (BSA) was introduced to the receiver (AB-basolateral; BA-upper) compartments. The volumes of the upper and basolateral compartments were 0.4 and 0.8 mL, respectively. After adding the dosing solution, the plate was incubated for 120 min at 37° C. in an incubator. After 120 min, donor and receiver samples were collected and matrix-matched with opposite buffer (1:1, 30 μL test sample + 30 μL blank buffer). Dose samples were matrix matched with reverse buffer (1:1, 30 μL test sample + 30 μL blank buffer). Samples were processed by adding acetonitrile containing internal standard (60 μL test sample + 200 μL acetonitrile containing internal standard (tolbutamide) 500 ng / ml). Samples were vortexed and centrifuged at 4000 rpm for 10 minutes. The resulting supernatant (100 μL) was diluted with 100 μL water and transferred to a new 96-well plate. Compound concentrations in samples were analyzed by liquid chromatography tandem mass spectrometry (LC-MS / MS) method using discovery grade bioanalytical methods, as appropriate.
[0255] The mean apparent permeability (P app ×10 -6 The velocity (cm / sec) was calculated as follows:
number
[0256] HepaRG-based assay protocol A cryopreserved vial of differentiated HepaRGs cells (Biopredic International HPR116080) was thawed in HepaRG Thawing / Plating / General Purpose Medium (Biopredic International ADD670C) supplemented with 200 mM Glutamax according to the protocol provided by Biopredic International. 70,000 cells per well were seeded in 96-well plates (Corning CLS3809) in 100 μL of HepaRG Thawing / Plating / General Purpose Medium supplemented with 200 mM Glutamax and incubated for 24 hours at 37°C in 5% CO2. After incubation, the seeding medium was replaced with HepaRG Maintenance / Metabolism Medium (Biopredic International ADD620C) and incubated for 6 days, replenishing with fresh HepaRG Maintenance / Metabolism Medium every 48 hours. After 7 days of incubation after seeding, the incubation medium was decanted from the wells and the cells were washed twice with 250 μL of William's Basal Medium E (Gibco 12551032). After each decantation of William's Basal Medium E, the plate was tapped on a paper towel to ensure maximum removal of residual medium. Incubation mix was prepared by adding test inhibitor dilutions (serial 3-fold dilutions in DMSO (Sigma D2650)) in William's Medium E (basal) containing 0.3 μM 3H-taurocholic acid (ARC ART-1368) and 7.5 μM cold taurocholic acid (Sigma T4009) (maintaining a final DMSO concentration of 0.2%). 50 μL of incubation mix containing the test inhibitor was then added to the wells (in duplicate) and the plate was incubated for 30 minutes in a 5% CO2 incubator at 37°C. After incubation, the reaction was stopped by keeping the plate on ice-water mix for 2-3 min, after which the incubation mix was completely aspirated from the wells.Wells were washed twice with 250 μL of cold unlabeled 1 mM taurocholate dissolved in HEPES (Gibco 15630080) buffered (10 mM) HBSS (Gibco 14175079), pH 7.4. Plates were tapped on paper towels after each wash to ensure maximum removal of blocking buffer.
[0257] 100 μL of MicroScint-20 (PerkinElmer 6013621) was added to the wells and kept at room temperature overnight, after which the plates were read on a PerkinElmer TopCount NXT™ Microplate Scintillation and Luminescence Counter following the 3H test protocol (set at 120 second read time per well in normal plate configuration).
[0258] Preparation of test compound dilutions All test compounds were provided in powder form at room temperature. 10 mM DMSO stock solutions of test compounds were prepared, aliquoted, and stored at -20°C. From the 10 mM DMSO stock solutions of compounds, 3-fold serial dilutions in DMSO were prepared to obtain a total of 10 dilutions of test compounds. 0.5 μL of this dilution in DMSO was added to 250 μL of FBS-free basal medium containing 3H-taurocholate and cold taurocholate to prepare the incubation mixture.
[0259] Bioavailability Test Male mice (C57BL / 6 or CD1) or Wistar rats aged 8-9 weeks were used. For each test compound, two groups of 3 animals each were used. One group received a single intravenous dose of 1 mg / kg (vehicle was 100% DMSO) through the tail vein, and the other group received a single oral dose of 10 mg / kg by gavage needle. The group that received the oral dose was fasted overnight. Blood samples were collected at 0.083, 0.25, 0.5, 1, 2, 4, 6, 8 and 24 hours following intravenous dosing, and at 0.25, 0.5, 1, 2, 4, 6, 8 and 24 hours following oral dosing. Blood samples were taken from the saphenous vein. 0.2% EDTA was used as an anticoagulant. Samples were analyzed using a discovery grade bioanalytical method developed for the estimation of test compounds in plasma, utilizing an LC-MS / MS system.
[0260] result Biological data for example compounds is shown in Table 8 below. [Table 8]
[0261] Effects of LBAT selective compounds on serum bile acid levels in OATP KO mice Male OATP KO mice (Oatp1a / 1b cluster knockout mice, Taconic, USA) aged 8-9 weeks were used in the study. After completion of the quarantine and acclimation period, animals were randomized into experimental groups based on body weight (n=4 mice per group). On the day of the experiment, baseline blood samples were collected, followed by oral administration of vehicle (0.5% CMC, 0.1% Tween80) or the compounds of Examples 3, 6, 13 or 15 at the indicated doses. Blood samples were then collected at various time points (indicated in each graph) after administration. Blood was allowed to clot and serum was collected by centrifugation at 3000g, 4°C for 15 minutes and stored at -80°C for further analysis. Total bile acid concentrations in each serum sample were determined by using the CELL BIOLABS Total Bile Acids kit (STA631) according to the manufacturer's instructions. Mean ± SEM, n=4.
[0262] The results are shown in Figures 1-4. Serum bile acid levels before dosing and during vehicle treatment ranged from 1-5 μmol / L. Oral administration of the compound of Example 13 increased serum bile acid in a dose-dependent manner. Within 1 hour after dosing, serum bile acid levels rose to approximately 100 μmol / L in response to 30 mg / kg of the compound of Example 13. The compounds of Examples 3, 6, and 15 also increased serum bile acid levels.
[0263] PD model: Evaluation of test compounds on total bile acid levels in male C57BL6 mice C57BL / 6N Tac mice aged 8-9 weeks are used to test the effect of bile acid modulators on bile acid levels. After completion of the quarantine and acclimation period, animals are randomized based on body weight into x experimental groups: (i) vehicle control, and (ii) test compound y mg / kg po, once daily. Animals are treated with test compound for 7 days. On study day 5, animals are housed individually in unused cages. On day 7, feces are collected from each cage, followed by blood collection from each animal via the retro-orbital route. Animals are euthanized and liver and terminal ileum are harvested from each animal for further analysis. Body weight and food consumption are measured twice weekly. Serum lipid profile is analyzed in serum samples on day 7. Total bile acids in serum are measured in serum samples on day 7. Fecal bile excretion is measured in fecal samples on day 7. Hepatic expression of CYP7A1 and SHP will be quantified in liver samples on day 7. Hepatic triglycerides and total cholesterol will be analyzed in liver samples on day 7.
[0264] Urinary bile acid model: Evaluation of test compounds on urinary bile acid levels in male C57BL / 6N mice C57BL / 6N Tac mice aged 8-9 weeks are used to test the effects of bile acid modulators on bile acid levels. After completion of the quarantine and acclimation period, animals are randomized based on body weight into x experimental groups: (i) vehicle control, and (ii) test compound y mg / kg po, once daily. Animals are treated with test compound for 7 days. On study day 6, animals are transferred to metabolic cages. On day 7, feces and urine are collected from each metabolic cage, followed by blood collection from each animal via the retro-orbital route. Animals are euthanized and kidneys are harvested from each animal for further analysis. Body weight is measured twice weekly. Total bile acids in serum are measured in the day 7 serum samples. Fecal bile excretion is measured in the day 7 fecal samples. Urinary excretion of bile acids is measured in the day 7 samples. Renal expression of ASBT, OSTa, OSTAb and MRP2 is quantified in day 7 samples.
Claims
1. Formula (I): 【Chemistry 1】 wherein M and R 1 ~R 4 See Table 1 below: 【Table 1】 or a pharma- ceutically acceptable salt thereof.
2. (E)-3-((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)acrylic acid; (S)-(E)-3-((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)acrylic acid; (R)-(E)-3-((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)acrylic acid; (E)-3-((3-butyl-7-(ethylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)acrylic acid; (S)-(E)-3-((3-butyl-7-(ethylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)acrylic acid; (R)-(E)-3-((3-butyl-7-(ethylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)acrylic acid; (E)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)acrylic acid; (S)-(E)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)acrylic acid; (R)-(E)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)acrylic acid; (Z)-3-((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylic acid; (S)-(Z)-3-((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylic acid; (R)-(Z)-3-((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylic acid; (Z)-3-((3-butyl-7-(ethylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylic acid; (S)-(Z)-3-((3-butyl-7-(ethylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylic acid; (R)-(Z)-3-((3-butyl-7-(ethylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylic acid; (Z)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylic acid; (S)-(Z)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylic acid; (R)-(Z)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylic acid; (Z)-3-((3-butyl-5-(4-fluorophenyl)-2-methyl-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylic acid; (S)-(Z)-3-((3-butyl-5-(4-fluorophenyl)-2-methyl-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylic acid; (R)-(Z)-3-((3-butyl-5-(4-fluorophenyl)-2-methyl-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylic acid; (S)-(Z)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-2-methyl-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylic acid; (R)-(Z)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-2-methyl-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylic acid; (Z)-3-((3-butyl-7-(ethylthio)-2-methyl-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylic acid; (S)-(Z)-3-((3-butyl-7-(ethylthio)-2-methyl-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylic acid; (R)-(Z)-3-((3-butyl-7-(ethylthio)-2-methyl-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylic acid; (Z)-3-((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylic acid; (S)-(Z)-3-((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylic acid; (R)-(Z)-3-((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-fluoroacrylic acid; (E)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)acrylic acid; (S)-(E)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)acrylic acid; (R)-(E)-3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)acrylic acid; or a pharma- ceutically acceptable salt thereof, 2. The compound of claim 1 selected from the group consisting of:
3. 10. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 or 2, and one or more pharma- ceutically acceptable excipients.
4. A pharmaceutical comprising a compound according to claim 1 or 2.
5. 5. The medicament according to claim 4, for use in the treatment or prevention of cardiovascular diseases or disorders of fatty acid metabolism or disorders of glucose utilisation, such as hypercholesterolemia; disorders of fatty acid metabolism; type 1 and type 2 diabetes; complications of diabetes including cataracts, microvascular and macrovascular disease, retinopathy, neuropathy, nephropathy and delayed wound healing, tissue ischemia, diabetic foot, arteriosclerosis, myocardial infarction, acute coronary syndrome, unstable angina, stable angina, stroke, peripheral arterial occlusive disease, cardiomyopathy, heart failure, heart rhythm disorders and vascular restenosis; diabetes-related diseases such as insulin resistance (disorders of glucose homeostasis), hyperglycemia, hyperinsulinemia, high levels of blood fatty acids or glycerol, obesity, dyslipidemia, hyperlipidemia including hypertriglyceridemia, metabolic syndrome (syndrome X), atherosclerosis and hypertension, and for increasing high density lipoprotein levels.
6. 5. The medicament according to claim 4, for use in the treatment or prevention of a gastrointestinal disease or disorder such as constipation (including chronic constipation, functional constipation, chronic idiopathic constipation (CIC), intermittent / sporadic constipation, constipation secondary to diabetes, constipation secondary to stroke, constipation secondary to chronic kidney disease, constipation secondary to multiple sclerosis, constipation secondary to Parkinson's disease, constipation secondary to systemic sclerosis, drug-induced constipation, constipation-predominant irritable bowel syndrome (IBS-C), mixed irritable bowel syndrome (IBS-M), paediatric functional constipation and opioid-induced constipation); Crohn's disease; primary bile acid malabsorption; irritable bowel syndrome (IBS); inflammatory bowel disease (IBD); ileitis; and reflux disease and its complications, such as Barrett's esophagus, bile reflux esophagitis and bile reflux gastritis.
7. Inherited metabolic disorders of the liver; Congenital disorders of bile acid synthesis; Congenital biliary abnormalities; Biliary atresia; Post-Kasai biliary atresia; Post-liver transplant biliary atresia; Neonatal hepatitis; Neonatal cholestasis; Genetic forms of cholestasis; Cerebrotendinous xanthomatosis; Secondary deficiency of BA synthesis; Zellweger syndrome; Cystic fibrosis-related liver disease; Alpha-1 antitrypsin deficiency; Alagille syndrome (ALGS); Byler syndrome; Biliary Primary deficiency of biliary acid (BA) synthesis; progressive familial intrahepatic cholestasis (PFIC), including PFIC-1, PFIC-2, PFIC-3, and PFIC not otherwise specified, post-biliary diversion PFIC, and post-liver transplant PFIC; benign recurrent intrahepatic cholestasis (BRIC), including BRIC-1, BRIC-2, and BRIC not otherwise specified, post-biliary diversion BRIC, and post-liver transplant BRIC; autoimmune hepatitis inflammation; primary biliary cirrhosis (PBC); liver fibrosis; nonalcoholic fatty liver disease (NAFLD); nonalcoholic steatohepatitis (NASH); portal hypertension; cholestasis; Down's syndrome cholestasis; drug-induced cholestasis; intrahepatic cholestasis of pregnancy (jaundice of pregnancy); intrahepatic cholestasis; extrahepatic cholestasis; parenteral nutrition-associated cholestasis (PNAC); hypophospholipid-associated cholestasis stenosis; lymphedematous cholestasis syndrome 1 (LSC1); primary sclerosing cholangitis (PSC); immunoglobulin G4-associated cholangitis; primary biliary cholangitis; cholelithiasis (gallstones); bile duct lithiasis; choledocholithiasis; gallstone pancreatitis; Caroli's disease; malignant disease of the bile duct; malignant disease causing obstruction of the biliary system; biliary stricture; AIDS cholangiopathy; ischemic cholangiopathy; pruritus due to cholestasis or jaundice; pancreatitis; Chronic autoimmune liver disease leading to progressive cholestasis; fatty liver; Alcoholic hepatitis; acute fatty liver; fatty liver of pregnancy; drug-induced hepatitis; iron overload disorders; congenital deficiency of bile acid synthesis type 1 (BAS type 1); drug-induced liver injury (DILI); hepatic fibrosis; congenital hepatic fibrosis; cirrhosis; Langerhans cell histiocytosis (LCH); neonatal ichthyosclerosing cholangitis (NISCH); erythroblastic protoporphyria (EPP); idiopathic adult cholangiocytosis (IAD); idiopathic neonatal hepatitis (INH); nonsyndromic intrahepatic cholangiocytosis (NS-PILBD); North American Indian childhood cirrhosis (NAIC); hepatic sarcoidosis; amyloidosis; necrotizing enterocolitis; heart rate disturbances in the setting of abnormal serum bile acid profiles.
5. The medicament according to claim 4, for use in the treatment or prevention of liver diseases or disorders such as toxicity caused by serum bile acids, including cardiomyopathy associated with chronic obstructive pulmonary disease (e.g. atrial fibrillation), cirrhosis ("cholelithiasis"), and skeletal muscle fatigue associated with cholestatic liver disease; polycystic liver disease; viral hepatitis (including hepatitis A, B, C, D and E); hepatocellular carcinoma (hepatoma); cholangiocarcinoma; bile acid-associated gastrointestinal cancer; and cholestasis caused by hepatic, biliary and pancreatic tumors and neoplasms, or for use in enhancing corticosteroid therapy in liver diseases.
8. The pharmaceutical composition of claim 4, for use in the treatment or prevention of hyperabsorption syndromes (including abetalipoproteinemia, familial hypobetalipoproteinemia (FHBL), chylomicron retention disease (CRD) and sitosterolemia); hypervitaminosis and osteopetrosis; hypertension; glomerular hyperfiltration; polycystic kidney disease (PKD), including autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD); and pruritus in renal failure, or for use in protecting against renal damage associated with liver disease or metabolic disease.
